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Scope & objectives 
The work presented in this thesis is framed within the larger ambition of the research group headed 
by Prof. Dr. Depicker to develop a seed-based platform for the production of recombinant proteins. 
Plants show distinct advantages over other systems for the production of recombinant proteins, 
which nowadays constitute one of the fastests growing groups of therapeutic products for human 
use. Plants are capable of complex protein production, lack human and animal pathogens and, for 
most systems, production is easily scalable and might also be very cheap. Previously, a cassette was 
developed in our research group for the high, seed-specific expression of a transgene based on 
regulatory elements that were derived from seed storage proteins of the common bean Phaseolus 
vulgaris. This cassette is used to transform the model organism Arabidopsis thaliana, whose small 
stature facilitates its cultivation in a greenhouse, and promote high seed-specific accumulation of 
heterologous proteins. The combination of both of these elements, i.e. the cassette and the 
Arabidopsis host, constitutes the seed-platform that is our system of choice and has successfully 
been used to express a multitude of recombinant proteins ranging from enzymes over single-chain 
variable fragments to entire antibodies. During this PhD work, two research projects were 
undertaken in parallel to amplify the capacity of the Arabidopsis seed-platform and these are 
detailed in the following paragraphs.  
A first project was aimed at extending the range of proteins produced in our system towards viral 
antigens, which are complex proteins that are often difficult to express. If their efficacious 
production could be managed in plants, this would allow plant-based platforms to consolidate a 
unique position among the conventional, cell-culture based systems. Several proteins of the porcine 
reproductive and respiratory virus, currently the most important pathogen of swine and for which 
novel vaccines are highly needed, were selected, extensively optimized and expressed in our system 
with the intention of evaluating the capacity of the seed-platform for subunit vaccine production. 
Despite all the advantages offered by plants for the production of heterologous proteins, they suffer 
from one drawback, namely that their N-glycosylation machinery differs from that of humans so that 
therapeutics produced in plants often carry immunogenic glycans, which is potentially very 
dangerous. This has sparked the development of a plethora of strategies to ‘humanize’ plant glycans 
and avoid immunogenic glycan residues. An additional problem associated with complex glycans in 
the context of therapeutic protein production is that these are heterogeneous and lead to the 
generation of different ‘glycoforms’ of the same protein that show different characteristics, which is 
highly undesireable from both a regulatory and commercial point of view. To avoid glycan 
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heterogeneity and immunogenicity, a straightforward method was conceived during the second 
project, circumventing extensive modifications of the plant glycosylation pathway, to glycoengineer 
the existing seed-platform so that therapeutic glycoproteins could be produced at high homogeneity 
while lacking immunogenic plant glycans. The objectives of each project are summarized below. 
 
Vaccine production in Arabidopsis seeds: 
• Optimization and expression of viral antigens in the platform 
• Assessment of the protective capacity of the seed-produced antigens via immunization trials 
 
Glycoengineering in Arabidopsis seeds: 
• Adapt the platform towards the production of glycoproteins lacking immunogenic plant 
glycans 
• Deliver proof-of-concept by expression of a reporter protein 
• Deliver proof-of-functionality by assessment of the immunogenicity of the reporter protein 
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Summary 
The discovery of vaccination, or the deliberate exposure to a pathogen or part thereof with the 
intention of creating long lasting protective immunity, has given mankind a powerful tool to combat 
infectious diseases. The advent of vaccination, together with widespread access to clean water, has 
drastically reduced the incidence of these diseases during the last century. Nowadays, recombinant 
technologies based on genetic engineering are readily at hand that allow the production of vaccines 
in an array of cell-culture systems based on bacteria, yeasts, insect or mammalian cells. Alternatively, 
also plants can be employed to make foreign proteins (on which vaccines are based), a concept called 
‘molecular farming’, and they have a unique mix of features that is useful for the latter. Plants are 
more evolved than bacteria and yeasts and as such are capable of producing complex proteins very 
similar (but not identical) to those of humans, they are considered safe because they do not harbor 
mammalian pathogens, production can easily be amplified by increasing the acreage of plants and no 
high-tech equipment is needed for their cultivation so protein production is potentially very cheap.  
In the research group of Prof. Dr. Depicker, a system was developed to stimulate the high 
accumulation of heterologous proteins (proteins that are foreign to the host in which they are 
introduced through genetic engineering) for various uses in the seeds of the model plant Arabidopsis 
thaliana, which is well suited for both lab and commercial scale production of these plant-made 
pharmaceuticals (PMPs). This system consists of gene elements of storage proteins that are present 
in very high quantities in the seeds of the common bean Phaseolus vulgaris, which are used to drive 
the expression of a foreign gene upon its introduction in Arabidopsis, resulting in high accumulation 
of the corresponding protein in the seeds. An advantage about the production of PMPs in seeds is 
that this does not interfere with the growth phase of the plant, the PMP is contained in a compact, 
desiccated volume and the seeds can be stored for later processing of the PMP. Throughout the 
years several different proteins have been successfully generated using this system such as enzymes 
and antibodies and, in collaboration with the research group of Prof. Dr. Nauwynck at the Faculty of 
Veterinary Medicine, we wanted to employ the benefits of the system for the production of a viral 
subunit vaccine (a vaccine consisting of specific proteins of a pathogen called antigens). Viral 
antigens often are complex proteins, which can be difficult to produce and plants might just be very 
suited for this. The porcine reproductive and respiratory virus (PRRSV) was selected as a target 
because it is currently the most important pathogen of swine and there is a continuous demand for 
new vaccines to combat it. 
PRRSV antigens had been made in plants before and turned out to be difficult to produce, only 
accumulating to very low levels in the plant tissues, so we selected glycoprotein 3, 4 and 5 (GP3, 4 
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and 5) and extensively optimized these with the intention of increasing their accumulation in the 
seeds of Arabidopsis. We removed their transmembrane domains that complicate production and 
coupled the antigens to stabilizing protein domains such as the green fluorescent protein (GFP) and 
immunoglobulin G ‘crystallizable fragments’ (Fc-domains). The resulting set of antigenic proteins, 17 
in total, was produced in the seeds and several antigens accumulated to high levels. These could be 
extracted and purified and when injected in mice, they generated antibodies, some of which had 
virus-neutralizing capacity, which is considered to be an important parameter for protective 
immunity against the PRRSV. However, these results could not be repeated during a pilot experiment 
where three piglets received an antigen cocktail. The exact reason for this is currently not clear and 
further investigation is required to clarify if the seed-produced antigens can protect piglets in vivo 
from the PRRSV. All in all, we showed expression of the PRRSV antigens to levels far above those 
achieved by other groups and this demonstrates the suitability, at least concerning accumulation and 
purification, of our seed-system for the production of viral antigens. However, to assemble an 
efficacious vaccine against the PRRSV, the seed-produced antigens also need to induce protective 
immunity and their capacity to do so, remains unclear. 
As mentioned before, plants show distinct advantages over other systems for the production of 
recombinant proteins. The technology has been adapted by major pharmaceutical companies and 
several products are in clinical trials on the way to be marketed. However, one major drawback is 
that plant and human N-glycans (sugar structures attached to proteins) differ and although the plant 
N-glycosylation pathway is to a large extent similar to that of humans, both pathways diverge during 
the later stages were complex glycans are formed. Complex plant glycans can bear groups that are 
absent (or present in other linkages) on human glycans and these are controversial because of their 
immunogenic potential (propensity to provoke a reaction from the immune system). A large fraction 
of the human population has antibodies in their blood directed against these groups. Although the 
implications of this observation are not entirely clear and are currently under debate, it is generally 
accepted that topical application of a PMP decorated with complex plant glycans is safe. However, 
this picture changes when a therapeutic protein intended for injection in the blood stream is 
envisaged. Here, binding of these antibodies to the glycans present on the protein might accelerate 
the clearance of the protein from the blood, but in the worst case scenario it might also cause a 
severe allergic reaction. Because of these potentially serious consequences a lot of research is 
dedicated to ‘humanizing’ plant glycans to avoid these immunogenic glycan groups.  
Another complication related to complex glycans in the context of therapeutic protein production is 
that these constitute a diverse group of structures. A glycoprotein decorated with these structures 
will thus exist as several ‘glycoforms’, having the same amino acid backbone but decorated with 
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different glycan structures. This heterogeneity is highly undesireable from both a commercial and 
regulatory point of view. To tackle these issues, i.e. glycan heterogeneity and immunogenicity, we 
devised a simple strategy in collaboration with the research group of Prof. Dr. Callewaert at the 
Faculty of Sciences to engineer our system so that glycoproteins (proteins decorated with glycans, 
which are sugar structures) could be produced at great uniformity without immunogenic plant 
glycans and while maintaining their native fold (normal structure). To achieve this, we introduced a 
fungal enzyme, the endoT, into the seeds of an Arabidopsis mutant, called the 
complex-glycan-deficient (cgl) mutant. This mutant only makes ‘high-mannose’ glycans and although 
these are non immunogenic by nature, they are still heterogenous and additionally, they can target a 
protein to mannose receptor bearing cells which, except for specific applications, is detrimental. 
However, these high-mannose glycans are also an excellent substrate for the endoT that cleaves 
these glycans from proteins leaving only a minimal glycan structure (a single N-acetylglucosamine 
(GlcNAc) residue) attached to the protein. Because this single GlcNAc is in direct contact with the 
protein it is important to maintain the overall structure of the protein that, at the same time, will 
display a completely homogenous glycan profile devoid of immunogenic plant glycans.  
We produced the endoT in the seeds of the cgl mutant were it is enzymatically active and introduced 
the activation-associated secretory protein 1 (ASP1), an antigenic protein from the parasitic 
nematode Ostertagia ostertagi, as a reporter protein. The ASP1 was purified from both wild type 
(unmodified) Arabidopsis seeds and endoT containing seeds, called wild type and GlycoDelete ASP1 
respectively, and extensively characterized.  This revealed that when the ASP1 is produced in our 
unmodified system it is indeed decorated with plant specific glycans that are potentially 
immunogenic, whereas in the endoT seeds these glycans are completely trimmed down to single 
GlcNAcs. When rabbits were immunized with both ASP1 glycosylation variants, most, but not all 
rabbits that had received the wild type ASP1 generated antibodies against the plant glycans thus 
confirming their immunogenic potential. On the contrary, no such antibodies were present among 
the rabbits that had received the GlycoDelete ASP1, thereby proving that our engineered system can 
effectively be used to produce glycosylation variants of therapeutic proteins lacking immunogenic 
glycans. The ASP1 apparently accumulated less in the endoT seeds than in the wild type seeds which 
could be due to the presence of the endoT gene, the enzyme itself or be related to the integration of 
the ASP1 gene in the Arabidopsis genome. This could, however, also be due to mere clonal variation 
and further investigation is required to shed light on this matter.  
In summary, we produced enzymatically active endoT in seeds of the cgl mutant. Upon introduction 
of the antigenic reporter protein ASP1 in the endoT seeds, its glycan were completely trimmed down 
to single GlcNAc residues that are in close contact with the protein. When rabbits were immunized 
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with purified ASP1, we showed that the ASP1 from endoT seeds did not provoke an antibody 
response against plant glycans, whereas the ASP1 from unmodified, wild type seeds did, thereby 
proving that the engineered seeds can effectively be used as a platform to produce PMPs with 
minimal glycans that lack immunogenic groups, which has great economic potential.  
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Samenvatting 
Met de ontdekking van vaccinatie, ofwel de bewuste blootstelling aan een pathogeen (of gedeelte) 
daarvan met de intentie om langdurige beschermende immuniteit op te wekken tegen dat 
pathogeen, heeft de mensheid een zeer doeltreffend middel in handen gekregen om besmettelijke 
ziekteverwekkers te bestrijden. Gedurende de twintigste eeuw heeft vaccinatie, samen met 
wijdverspreide toegang tot proper water, het voorkomen van deze ziektekiemen drastisch verlaagd. 
Tegenwoordig laten allerhande recombinante technologieën gebaseerd op genetische modificatie 
toe om vaccins aan te maken via verschillende systemen die beroep doen op bacteriële-, gist-, insect- 
en zoogdiercellen. Planten vormen een alternatief voor deze klassieke productieplatformen en zijn 
ook in staat eiwitten (waarop vaccins gebaseerd zijn) aan te maken, een concept dat men ‘molecular 
farming’ noemt. Daarenboven vertonen planten een unieke combinatie van eigenschappen die 
voordelig is voor de productie van eiwitten: ze zijn namelijk meer geëvolueerd dan bacteriën en 
gisten wat maakt dat zij in staat zijn om complexe eiwitten aan te maken sterk gelijkend (maar niet 
identiek, later meer daarover) op hoe deze in het menselijk lichaam aangemaakt worden. Verder is 
de productie flexibel, ze kan namelijk eenvoudig verhoogd worden door het areaal aan planten uit te 
breiden en is er voor de cultivatie van planten geen hoog-technologisch materiaal benodigd zodat de 
productie mogelijks ook zeer goedkoop is.  
In de onderzoeksgroep van Prof. Dr. Depicker is een systeem ontwikkeld om heterologe eiwitten 
(eiwitten die vreemd zijn aan het organisme waar ze via genetische manipulatie in geïntroduceerd 
worden), voor verscheidene doeleinden, aan te maken in de zaden van het modelorganisme 
Arabidopsis thaliana, dat geschikt is om plant-geproduceerde pharmaceutica (PPPs) aan te maken 
zowel op laboratorium- als op commerciële schaal. Dit systeem bestaat uit genelementen 
overgenomen van opslageiwitten die in grote hoeveelheden aanwezig zijn in de zaden van de 
gewone boon Phaseolus vulgaris en die gebruikt worden om de expressie van een vreemd gen te 
sturen wanneer dit binnengebracht wordt in Arabidopsis, zodaning dat het heterologe eiwit sterk 
accumuleert in de zaden. Voordelig aan de zaadspecifieke aanmaak van een PPP is dat dit de 
vegetatieve fase (groeifase) van de plant niet beïnvloed, daarenboven accumuleert het PPP in een 
droog en compact volume en kan het zaad opgeslagen worden zodat het PPP later verwerkt kan 
worden. Doorheen de jaren zijn verscheidene eiwitten zoals enzymes en antilichamen met succes via 
dit systeem tot expressie gebracht en wij wilden, in samenwerking met de onderzoeksgroep van Prof. 
Dr. Nauwynck aan de Faculteit Diergeneeskunde, de voordelen die het zaadplatform ons biedt 
aanwenden voor de productie van een vaccin. Meer bepaald een vaccin gebaseerd op virale eiwitten 
(virale antigenen). Virale eiwitten zijn complexe, vaak moeilijk aan te maken eiwitten en planten 
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zouden wel eens uitermate geschikt kunnen zijn voor hun productie. Het porcien reproductief en 
respiratoir syndroom virus (PRRSV) werd geselecteerd als doelorganisme, omdat dit momenteel de 
belangrijkste varkenspathogeen is en er een grote nood is aan nieuwe vaccins om het virus te 
bestrijden.  
PRRSV antigenen werden reeds aangemaakt in verschillende planten met slechts lage 
antigenopbrengsten als resultaat. De glycoproteinen (eiwitten waar suikerstructuren aan gekoppeld 
zijn) 3, 4 en 5 (GP3, 4, 5) werden door ons geselecteerd en uitgebreid geoptimaliseerd met als doel 
om hun accumulatie in de zaden te verhogen. De transmembraan domeinen van de antigenen, die 
productie bemoeilijken, werden verwijderd en  de antigenen werden gekoppeld aan stabiele 
eiwitdomeinen zoals het ‘groen fluorescerende eiwit’ en de ‘kristalliseerbare fragmenten’ van 
immunoglobulines. De set antigenische eiwitten die zo gevormd werd, 17 in totaal, werd aangemaakt 
in de zaden en verscheidene antigenen vertoonden een hoge opbrengst. Deze konden geëxtraheerd 
en opgezuiverd worden en na injectie in muizen waren deze in staat antilichamen op te wekken met 
de capaciteit om het virus te neutralizeren, wat verondersteld wordt een belangrijke parameter te 
zijn voor beschermende immuniteit tegen het PRRSV. Deze resultaten konden echter niet herhaald 
worden tijdens een pilootexperiment waarbij drie biggen een antigencocktail toegediend kregen. De 
precieze reden hiervoor blijft tot nu toe onduidelijk en verder onderzoek is nodig om uit te maken of 
de antigenen aangemaakt in Arabidopsis zaad in staat zijn om biggen effectief bescherming te bieden 
tegen het PRRSV. Alles bij elkaar genomen werd de productie van PRRSV antigenen in Arabidopsis 
zaden aangetoond en werden opbrengsten bereikt die vele male hoger liggen dan voordien ooit 
gerapporteerd werd, wat bewijst dat het zaadplatform geschikt is, wat betreft accumulatie en 
zuivering, voor de aanmaak van virale antigenen. Vooralsnog blijft het echter onduidelijk of de 
antigenen protectieve eigenschappen bezitten en effectief gebruikt kunnen worden om een 
doeltreffend vaccin tegen het PRRSV samen te stellen.  
Zoals eerder vermeld beschikken planten over specifieke voordelen ten opzichte van andere 
systemen wat betreft de aanmaak van recombinante eiwitten. Deze technologie werd ondertussen 
opgepikt door voorname pharmaceutische bedrijven en verscheidene PPPs bevinden zich in klinische 
proeven op weg naar commercialisatie. Eén nadeel is echter dat plant en menselijke N-glycanen 
(suikerstructuren vastgehecht aan eiwitten) verschillen en hoewel de plant N-glycosylatie machinerie 
sterk gelijkt op de menselijke, verschillen beide processes in de afwerking van de glycanen, zodanig 
dat complexe (afgewerkte) plant suikers structuren dragen die niet of anders voorkomen op 
menselijke glycanen. Deze plant-specifieke structuren zijn controversieel omwille van hun potentiële 
immunogeniciteit (hun intrinsieke vermogen om een reactie van het immuunsysteem uit te lokken).  
Inderdaad, een groot deel van de menselijke populatie draagt antilichamen die tegen deze structuren 
9 
 
zijn gericht. Alhoewel de implicaties van deze observatie momenteel nog onduidelijk zijn en een bron 
van discussie vormen, wordt algemeen aanvaard dat oppervlakkige behandeling met een PPP 
gedecoreerd met plant glycanen veilig is. Dit beeld verandert echter totaal wanneer een PPP bedoeld 
voor injectie in de bloedstroom beschouwd wordt. In dit geval zal de binding van antilichamen 
gericht tegen plant glycanen namelijk kunnen leiden tot een versnelde verwijdering van het PPP uit 
de bloedsomloop en in het slechtste geval, mogelijks een zeer ernstige allergische reactie teweeg 
brengen. Omwille van deze potentiële levensbedreigende gevolgen wordt er dan ook veel onderzoek 
verricht naar het ‘vermenselijken’ van plant glycanen met de intentie de immunogene structuren te 
vermijden. 
Een bijkomend probleem in de context van therapeutische proteinen is dat complexe glycanen een 
verzameling van heterogene structuren vormen. Dit zorgt ervoor dat een eiwit zal voorkomen als een 
set van ‘glycovormen’ (eenzelfde eiwit maar gedecoreerd met verschillende glycaanstructuren) die 
verschillende eigenschappen zullen vertonen en dus elk apart gekarakteriseerd moeten worden, 
hetgeen de commercialisatie en regularisatie van een therapeutisch glycoproteine verder 
bemoeilijkt. Om een mouw te passen aan deze heterogeniteit en de eerder vermeldde 
immunogeniciteit, werd in samenwerking met de onderzoeksgroep van Prof. Dr. Callewaert aan de 
Faculteit Wetenschappen een eenvoudige strategie uitgedacht om het zaadplatform aan te passen, 
zodanig dat glycoproteinen aangemaakt kunnen worden met een homogeen glycaanprofiel zonder 
immunogene plant glycanen en met behoudt van hun originele structuur. Om dit te bereiken werd 
een enzyme van de schimmel Trichoderma reesei, het endoT, geïntroduceerd in de zaden van de 
Arabidopsis complex-glycan-deficient (cgl) mutant die enkel ‘hoog-mannose’ glycanen aanmaakt. 
Hoewel deze glycanen van nature uit niet immunogeen zijn, is ook deze groep heterogeen. 
Daarenboven kunnen hoog-mannose glycanen door hun interactie met de mannose receptor een 
eiwit naar een specifieke set cellen sturen wat, op enkele gerichte applicaties na, liefst vermeden 
wordt. Deze hoog-mannose structuren zijn dus niet wenselijk. Het endoT is echter in staat deze 
glycanen af te splitsen van eiwitten waarbij slechts een minimale glycaanstructuur op het eiwit 
achterblijft die bestaat uit 1 enkele N-acetylglucosamine suikergroep (GlcNAc). Aangezien deze in 
direct contact staat met het eiwit is deze belangrijk om de structuur van het eiwit te behouden, maar 
door de glycaanstructuur te reduceren tot enkel en alleen deze GlcNAc groep wordt tegelijkertijd ook 
een compleet homogeen glycaanprofiel verkregen dat daarenboven ook nog eens geen immunogene 
plant glycanen draagt. 
Het endoT werd aangemaakt in de zaden van de cgl mutant waar werd aangetoond dat het enzyme 
actief is. Vervolgens werd het ‘activatie-geassocieerd secretorisch eiwit 1’ (ASP1), een antigeen eiwit 
van de parasitaire nematode Ostertagia ostertagi, ingebracht in de endoT zaden als reportereiwit. 
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Het ASP1 werd opgezuiverd uit zowel niet-gemodificeerd wild type Arabidopsis zaad als uit het endoT 
zaad, wild type en GlycoDelete ASP1 respectievelijk, en extensief gekarakteriseerd, wat aan het licht 
bracht dat het wild type ASP1 inderdaad potentieel immunogene plant glycanen draagt, daar waar 
de glycanen aanwezig op het GlycoDelete ASP1 volledig gereduceerd waren tot GlcNAc residus. Beide 
ASP1 varianten werden gebruikt om konijnen te immunizeren waarbij de meerderheid, maar niet alle 
konijnen die geïnjecteerd waren met het wild type ASP1 antilichamen aanmaakten specifiek gericht 
tegen plant glycanen, waardoor de immunogeniciteit van de plant glycanen nogmaals bevestigd 
werd. Deze antilichamen konden echter niet gedetecteerd worden in de sera van de konijnen die het 
GlycoDelete ASP1 hadden toegediend gekregen, waarbij we aantoonden dat het aangepaste 
zaadplatform effectief gebruikt kan worden voor de aanmaak van PPPs zonder immunogene plant 
glycanen. De opbrengst van het ASP1 eiwit in de endoT zaden bleek lager te liggen dan dit bereikt in 
de wild type zaden en dit is mogelijks toe te schrijven aan aanwezigheid van het endoT gen, het 
endoT enzyme zelf of dit is een artefact te wijten aan de integratie van het ASP1 gen in het genoom 
van de Arabidopsis cgl mutant. Het zou echter ook kunnen dat deze observatie aan louter toeval toe 
te schrijven is en verder onderzoek is nodig om deze kwestie verder uit te spitten.  
Om samen te vatten kunnen we stellen dat actief endoT werd aangemaakt in de zaden van de cgl 
mutant en dat dit in staat was om de glycanen van het antigenische reportereiwit ASP1 dat nadien 
geïntroduceerd werd in de endoT zaden volledig te trimmen tot enkel de GlcNAc residus die in direct 
contact staan met het eiwit. Toen konijnen geïnjecteerd werden met opgezuiverd ASP1 
geproduceerd in de endoT zaden, induceerden deze structuren geen antilichamen specifiek voor 
plant glycanen, daar waar de glycanen aanwezig op the ASP1 afkomstig uit de wild type zaden dat 
wel deden, waarbij bewezen werd dat de endoT zaden weldegelijk gebruikt kunnen worden als 
productieplatform voor de aanmaak van PPPs met minimale, niet-immunogene glycanen, wat een 
groot commercieel potentieel heeft.  
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Vaccination 
The early days  
Human history has been entangled with that of infectious diseases, outbreaks of which would 
periodically decimate or even topple entire societies. It is estimated that during the 14th century the 
plague, also known as “Black Death”, killed one out of three Europeans (Perry & Fetherston, 1997). 
Two centuries later the arrival of Europeans in Central America, carrying with them diseases that had 
been raging in Europe but were foreign to the Americas, initiated the demise of many great 
Mesoamerican civilizations. Disease spread rapidly, killing thousands, crippling societies and paving 
the way for the conquistadores that followed in its footsteps (Diamond, 1997). Mankind was left at 
the mercy of these infectious diseases and their devastating consequences until vaccination, the 
deliberate exposure to a pathogen or part of it to immunize against that pathogen, made its entry in 
human history. It was Jenner’s observation that milkmaids exposed to cowpox were protected from 
smallpox that sparked the first large scale vaccination program in 1798 (Bazin, 2011). This eventually 
culminated in the eradication of the smallpox in 1979 (Fenner et al., 1988). At the end of the 19th 
century the pioneer Louis Pasteur discovered that microorganism could be attenuated by exposure 
to environmental stresses (Plotkin, 2005). This initiated a new era during which vaccinology, the 
science behind vaccination, rapidly expanded. Pasteur’s principles of ‘isolate, inactivate and inject’ 
served as key concepts during this era and the initial discovery of attenuation was rapidly followed by 
the development of methods to inactivate whole microbes and the discovery of bacterial toxins and 
how these could be manipulated to produce toxoids, their harmless but immunogenic counterparts 
(Plotkin & Plotkin, 2011; Rappuoli, 2007; Rinaudo et al., 2009) . The importance of the work of these 
early scientists is reflected in the fact that the main vaccines in use nowadays are still based on the 
three concepts of attenuation, inactivation and administration of components (subunits) of 
pathogens to induce immunity. 
 
Attenuated, inactivated and subunit vaccines 
The purpose of vaccination is to induce long-lasting protective immunity from the exposure to 
pathogens or parts thereof, with the intention of preventing clinically relevant infectious diseases 
(Lambrecht et al., 2009). Until today, three major classes of vaccines have been in use to fight these 
infectious diseases, i.e. attenuated, killed and subunit vaccines (Buonaguro & Butler-Ransohoff, 
2010), each with its own merits and drawbacks. Attenuated vaccines consist of live pathogens (or 
infectious virions in the case of viruses) that have been weakened or adapted to growth in a non-host 
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organism prior to their inclusion in the vaccine (Plotkin, 2005). As a consequence of this, the 
pathogen will only be capable of suboptimal replication after injection and will cause a mild infection 
instead of the full-blown disease. As soon as an adaptive immune response is mounted, the pathogen 
is effectively eliminated from the host. The biggest advantage of this type of vaccines is that they 
tend to induce long lasting immunological memory, with the obvious downside being that the 
pathogen effectively replicates in the host organism and on occasion, this can cause serious disease. 
This is why, whenever feasible, inactivated vaccines or subunit vaccines, are preferred over 
attenuated vaccines. Neither inactivated vaccines, nor subunit vaccines contain infectious pathogen 
and hence are safe, but they both have their own drawbacks. The procedures used to inactivate 
pathogens can alter the structural elements that are important to mount an effective immune 
response. Additionally, the induced immune response will be weaker because of lack of replicating 
pathogen and the combination of these two factors causes inactivated vaccines to be less potent 
than their attenuated counterparts. Subunit vaccines on the other hand, contain only those elements 
of a pathogen that are known to be important to obtain protective immunity (Plotkin, 2005). 
However, without replicating pathogen or the co-stimulatory molecules that are still present in killed 
pathogens, the antigens used in subunit vaccines are generally very weak immunogens and need to 
be administered with strong immune stimulating substances called adjuvants (Granell et al., 2010; 
Lambrecht et al., 2009). Which type of vaccine is used against a specific pathogens depends on the 
intrinsic characteristics of the pathogen but, given that they are sufficiently potent to induce lasting 
immunological memory, the tendency is towards inactivated and subunit vaccines, with the latter 
being favored by the technologies nowadays at hand for recombinant protein production. 
 
Recombinant vaccines 
The advent of molecular biology and genetic engineering in the 1980s revolutionized the production 
of vaccines and especially that of subunit vaccines. Whereas previously tedious procedures had to be 
followed to isolate specific components from pathogens, obviously with the risk of contamination by 
live pathogen, genetic engineering now allowed the production of selected antigenic proteins in 
bacteria, yeasts, animal and insect cells (Plotkin & Plotkin, 2011). One of the first successes of this 
new technology was a hepatitis B vaccine based on a recombinant hepatitis B surface antigen 
produced in yeast which substituted purification of the surface antigen from plasma of infected 
individuals (Mcaleer et al., 1984). Another famous example attained through genetic engineering are 
the human papilloma virus vaccines to protect against cervical cancer (Frazer, 2004). Here the major 
capsid protein of the virus auto-assembles into highly immunogenic virus like particles when it is 
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produced in eukaryotic cells (Kirnbauer et al., 1992). By now numerous vaccines against a whole 
range of pathogens have been developed and their distribution, together with widespread access to 
purified water, have reduced the incidence of infectious diseases causing mortality among children 
by 97 to 99% (Rappuoli et al., 2002). The world health organization estimates that vaccines avert two 
to three million deaths a year making it the single most cost-effective tool to combat infectious 
diseases. In this respect vaccination should be considered no less than one of the major 
achievements of mankind.  
 
Transgenic plants as biofactories 
The demonstration in 1983 by Herrera-estrella et al. (1983) that a foreign resistance gene could be 
inserted into tobacco plants by agrobacterium-mediated transformation and that these subsequently 
made functional protein, opened up a whole new field for the production of therapeutic proteins. 
Hopes were high as plants have some distinct features as compared to the more conventional 
systems based on cultured bacteria, yeast or mammalian cells. Plants were considered to be safe as 
they are not susceptible to human or animal pathogens and to be capable of complex protein 
production, given that they correctly perform post-translational modification such as disulfide bond 
formation and N-glycosylation (Gomord & Faye, 2004), a presumption that was soon confirmed when 
Hiatt et al. (1989) showed the correct production of a recombinant antibody in tobacco plants. 
Additionally it was expected that plants represented a cheaper system, given that less high-tech 
equipment would be needed for their cultivation. Rapidly a future was envisaged in which plants 
would both feed and heal mankind. Edible vaccines such as bananas or tomatoes with curative 
properties would be grown cheaply were they were needed most, obviously with great benefit to the 
poor and sick in the world (Ma et al., 2003; Penney et al., 2011). The field of ‘molecular farming’, or 
the production of plant-made-pharmaceuticals (PMPs), expanded quickly and many of the proteins 
previously produced in conventional cell culture systems were introduced into plants. Antigens from 
major pathogens such as rabies, Yersinia pestis, the hepatitis B virus, human papilloma virus and 
human immunodeficiency virus (HIV) were all produced in plants and complex structures such as 
bacterial toxins, virus-like particles (VLPs) and antibodies were shown to assemble correctly (Alvarez 
& Cardineau, 2010; Giorgi et al., 2010; Shchelkunov & Shchelkunova, 2010).  Proof-of-concept of the 
immunogenicity of several plant-produced antigens was also delivered in animal models and when 
Thanavala et al. (2005) demonstrated that human immunity against hepatitis B virus could be 
boosted by feeding transgenic potatoes, the dream of edible vaccines for the poor became almost 
tangible. However, this initial enthusiasm was tempered by practical constraints and the same study 
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also highlights these shortcomings. Yields of antigen were low, a recurring issue for many PMPs 
(Nagels et al., 2012b; Pelosi et al., 2012), requiring the human volunteers to consume quite large 
volumes of potato pointing towards a second drawback, namely that of dose-standardization (Paul & 
Ma, 2010). To receive the correct vaccine dose patients should ingest a defined quantity of 
transgenic material, a prerequisite that would be difficult to implement outside of a laboratory 
setting. This eventually led to the consensus that plant-produced-vaccines (PPVs) need to be 
processed into a convenient formulation containing a standardized dose so they can be easily 
administered (Rybicki, 2009).  
Currently, different types of vaccines against a range of pathogens are being investigated and 
developed. Oral (mucosal) vaccines are still a major research focus and formulations have been 
devised with excellent thermo stable properties that allow the storage of the vaccine at ambient 
temperature for prolonged periods of time (Penney et al., 2011). A property that has led to the 
replacement of the term ‘edible vaccine’ with the more appropriate ‘heat stable oral vaccine’ 
(Rybicki, 2010). Another major research focus is on purified vaccines for parenteral delivery since 
injection remains the most effective route of vaccination to date (Pelosi et al., 2012). Full purification 
of a PPV provides the greatest control over the administered product and the immune response that 
is induced is generally stronger so less antigen is needed (Paul & Ma, 2010; Salyaev et al., 2010). The 
decades of research carried out ever since the conception of PMPs also tackled the initially recurring 
issue of low protein yield. Although the optimal conditions for a given PMP still need to be identified 
on a case-by-case basis, different transformation systems are now available for a whole range of 
plant species and a variety of regulatory elements allow for tissue specific and subcellular targeted 
accumulation of the PMP. This has led to reported record yields of up to 80% of total soluble protein 
(TSP) for a transient viral based system (Marillonnet et al., 2004), 51% of TSP after stable chloroplast 
transformation (Lentz et al., 2010) and 37% of TSP for a seed-produced PMP obtained via stable 
genomic transformation (De Jaeger et al., 2002). 
 In 2006, the first PPV was allowed onto the market. The United States Department of Agriculture 
granted market approval to Dow Agro Science for their veterinary vaccine against the Newcastle 
disease affecting poultry1. Dow Agro Science never commercialized the vaccine but used it as proof-
of-concept for the suitability of their tobacco suspension cell system for vaccine production. 
Together with several dedicated plant biotech companies most big pharmaceutical companies now 
also have a division working on PMPs as exemplified by the acquirement of ICON genetics by Bayer. 
                                                            
1
 http://www.aphis.usda.gov/animal_health/vet_biologics/publications/notice_06_10.pdf 
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Recently, the Israelian company Protalix was allowed to market its PMP Elelyso2 under an expanded 
orphan disease program. Elelyso is the brand name of the human enzyme glucocerebrosidase 
produced in carrot cell culture and it is used in enzyme replacement therapy to treat Gaucher’s 
disease, a genetic lysosomal storage disease (Aviezer et al., 2009). With this milestone approval of a 
non-topical PMP for parenteral use in humans and several PPVs in different stages of clinical trials, 
both for oral as parenteral delivery, it is expected that PPVs are on the verge of breaking through as 
valuable and useful alternatives for the current expensive and limited production of vaccines via the 
classical bacteria, yeast and mammalian cell based culture systems (Penney et al., 2011).  
  
                                                            
2
 http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm302549.htm 
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Seed production of PMPs 
Over the years, many different platforms have been used for recombinant protein production. These 
include leafy crops, cereal and legume seeds, oilseeds, fruits and vegetables, vegetative tissue of 
higher plants, cell cultures, algae, mossess and aquatic plants (Ma et al., 2003; Obembe et al., 2011). 
All these systems have their advantages and disadvantages, but seeds are of particular interest 
because they have evolved to stockpile proteins for extended periods of time in a stable 
environment (Stoger et al., 2005). Indeed, when recombinant antibodies and formats derived thereof 
were produced in seeds they accumulated to high levels, were stable at room temperature for 
extended periods and retained their binding capacity (reviewed in Virdi and Depicker (2013)).  
Several factors drive these desirable traits. The abundance of chaperones and disulfide isomerases 
during seed formation ensures that proteins reach their correct conformation, proteases are little 
abundant and the compacted, dessicated nature of seeds stabilizes proteins (Muntz, 1998). Seed 
water content is generally below 10% which is in stark contrast with leaves that in most cases contain 
more than 90% of water (Boothe et al., 2010). The long term, stable storage of proteins in a small 
volume eliminates the need for immediate processing of the harvested material. This decoupling of 
the cultivation phase and further downstream processing gives seeds a marked advantage over other 
more watery tissues, that need to be processed by freeze-drying upon harvesting or from which the 
PMP has to be purified immediately. Downstream processing is further facilitated by the fact that the 
seed proteome is relatively simple and that secondary metabolites known to interfere with 
purification, such as alkaloids, are only present in small amounts (De Jaeger et al., 2002; Stoger et al., 
2005). Finally, seed-specific production of a PMP does not intervene with the vegetative phase of 
plant growth. 
A range of seeds are being employed for commercial PMP production, each with its own 
characteristics. Maize has the highest seed biomass but has the undesirable trait of outcrossing, 
increasing the risk for transgene spread. Barley and rice are both self-pollinating and have relative 
high seed yields. Oilseeds such as safflower and rapeseed allow the PMP to be specifically purified by 
targeting to the oil bodies that are then easily separated from the crude seed extract and the PMP 
released, a technique used by the former Canadian company SemBioSys Genetic Inc. Although not 
being used on a commercial scale, the legumes pea and soybean also have a high potential for PMP 
production because of their massive protein content that can amount up to 40% of seed weight 
(Boothe et al., 2010; Stoger et al., 2005). 
Another interesting species, Arabidopsis thaliana, has some distinct features beneficial for PMP 
production that are not encountered with the seed crops mentioned before. As a model organism 
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protocols for transformation and optimal growth are widely available. It is self-pollinating and its 
small stature facilitates growing in greenhouses, thus reducing biosafety issues. It has a short life 
cycle of three months that considerably reduces the timeline between transformation and PMP. 
Methods for automatic sowing and harvesting of the seeds are under development and until today, 
some the highest seed yields of PMP have been obtained in Arabidopsis (De Jaeger et al., 2002; Loos 
et al., 2011a).  
 
The Arabidopsis seed platform 
To take full advantage of the favorable capacities of Arabidopsis for the production of PMPs, an 
expression cassette was developed in our group designed for high seed-specific expression of 
recombinant proteins. It was hypothesized that the regulatory elements that are responsible for the 
massive accumulation of the endogenous seed storage proteins of the dicotyledonous plant 
Phaseolus vulgaris would bestow the same characteristic onto a heterologous protein if placed under 
control of these elements. Initially it was proven that the arcelin seed storage protein from the 
common bean (Phaseolus vulgaris) also accumulated to high levels (15% of TSP) when it was 
introduced in Arabidopsis (Goossens et al., 1999). This spurred the development of an expression 
cassette based on the promoter and terminator from the arcelin5-I gene and indeed when 
Arabidopsis was transformed with a murine single-chain variable fragment (scFv) cloned into this 
cassette, the scFv accumulated up to 12.5% of TSP in the seeds of homozygous offspring (De Jaeger 
et al., 2002). The cassette was further optimized by changing the promoter of the arcelin5-I gene for 
that of the gene encoding β-phaseolin, another important seed storage protein from Phaseolus 
vulgaris, and substituting the 5’-untranslated region (5’-UTR) of the arcelin5-I gene by that of the 
tobacco mosaic virus (TMV). Accumulation levels doubled when this optimized cassette was used to 
drive expression of the same murine scFv and it even established an all-time record yield for a 
seed-produced PMP by reaching an accumulation level of no less than 36.5% of TSP in the seeds of 
homozygous transformants (De Jaeger et al., 2002).  
The importance of the regulatory elements that make up the expression cassette in achieving the 
above mentioned yields can hardly be overestimated. Accumulation of scFv-Fcs in Arabidopsis seeds 
under control of the strong, constitutive 35S promoter derived from the cauliflower mosaic virus was 
considerably less than when the β-phaseolin promoter was used (De Jaeger et al., 2002; Loos et al., 
2011b). The scFv-Fcs under control of the latter were also structurally more integer, showing less 
degradation than their 35S driven counterparts and this has been attributed to the different 
spatiotemporal expression pattern of both promoters (Loos et al., 2011b). The 35S promoter is active 
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during the early stages of seed development only whereas the β-phaseolin promotor is expressed 
during the entire period of seed filling and this might expose accumulating recombinant proteins to 
different sets of proteases, with the expression pattern of the β-phaseolin promotor being more 
beneficial for protein storage and integrity (Chen et al., 1986; Petruccelli et al., 2006; Virdi & 
Depicker, 2013).  
Ever since its conception, the cassette has been used to drive the seed specific expression of a 
multitude of recombinant proteins in Arabidopsis such as scFvs (De Jaeger et al., 2002; Van 
Droogenbroeck et al., 2007), fusions of scFvs with the “Fragment crystallizable” (Fc domain) of 
immunoglobulins (IgGs) (Loos et al., 2011b), entire monoclonal antibodies (Loos et al., 2011a), 
enzymes and auto-antigens (Morandini et al., 2011) and lately also a whole range of nanobodies 
(VHHs), VHH-Fc fusions (De Buck et al., 2013) and even synthetic, dimeric secretory IgA (Virdi et al., 
2013). With some exceptions, the accumulation of the recombinant proteins produced in the seeds 
of Arabidopsis ranged from <0.1 to 15% of TSP. Antibodies and synthetic variants thereof represent 
the upper end of the range and the Arabidopsis seed platform seems to be exceptionally suited for 
their production, as is exemplified by the record yield achieved by De Jaeger et al. (2002). The lower 
end of the range is mainly occupied by enzymes and auto-antigens although also VHHs as such do not 
accumulate very well and this has been attributed some instability at the protein level and/or 
transcriptional inefficiency (De Buck et al., 2013).   
Quite some exceptional yields have been achieved during the years using the seed-specific 
expression cassette and although it was shown that the accumulation of recombinant antibodies to 
as little as 1% of TSP is sufficient to induce an unfolded protein response, Arabidopsis seems rather 
tolerant to the high accumulation of heterologous proteins in its seed, showing no dramatic impact 
on seed germination and seedling growth (De Jaeger et al., 2002; De Wilde et al., 2013). This 
excellent capacity for the production of recombinant proteins combined with its small statue, short 
life cycle and its ease of transformation make the Arabidopsis seed-platform detailed here our 
system of choice. Additionally, the seed-platform offers possibilities for the production of 
recombinant proteins at a commercial scale. Automated sowing and harvesting of seeds is under 
investigation and it has been estimated that Arabidopsis grown in a greenhouse facility would yield 
between 180 and 240 grams of seeds per square meter on a yearly basis (He et al., 2013; Loos et al., 
2011a). Taking 10% of TSP as a realistic value for a product to be commercialized, these yield would 
translate to (approximately one fifth of the dry seed weight consists of extractable protein) between 
3.6 and 4.8 grams of recombinant protein per square meter.  
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With the excellent track record of the seed-platform as motivation, we wanted to extend the range 
of recombinant proteins produced towards antigens and evaluate the possibilities the platform offers 
for the production of subunit vaccines. More specifically, viral subunit vaccines were envisaged 
because viral proteins are complex and hence, to truthfully reproduce these, an eukaryotic system is 
needed. Plants could occupy a niche among the current available platforms by producing these 
exigent proteins. To deliver proof-of-principle of the suitability of the seed-platform for the 
production of antigenic proteins, the porcine reproductive and respiratory syndrome virus (PRRSV) 
was chosen as a model organism and a set of its glycoproteins was selected to be expressed in the 
seed-platform.  
 
The porcine reproductive and respiratory syndrome virus 
During the eighties a new disease emerged among swine typified by symptoms related to respiratory 
distress and reproductive failure. Initially a multitude of names was used to describe the disease such 
as the ‘swine infertility and respiratory syndrome’, ‘the mystery swine disease’ and the Dutch name, 
‘abortus blauw’, based on the observation that infected sows would occasionally present a blue 
discoloration of the ears (Collins et al., 1992; Wensvoort et al., 1991). Eventually porcine 
reproductive and respiratory syndrome (PRRS) was adopted as a common name to describe the 
disease and the causative organism, the porcine reproductive and respiratory syndrome virus 
(PRRSV) was almost simultaneously isolated by researchers in North America and The Netherlands 
(Collins et al., 1992; Terpstra et al., 1991; Wensvoort et al., 1991). The virus is classified among the 
order of the Nidovirales in the family of the Arteriviridae, together with the simian haemorrhagic 
fever virus, the lactate hydrogenase elevating virus and the equine arteritis virus, all of which are 
positive stranded RNA viruses (Meulenberg et al., 1993b; Snijder & Meulenberg, 1998). These viruses 
share many characteristics such as their genome organization, gene expression strategy, and the 
tendency to induce persistent infections (Meulenberg et al., 1997b). They also primarily infect cells of 
the monocyte/macrophage lineage and/or endothelial cells. Since its emergence, the PRRSV has 
spread around the globe and is now endemic in most pig-rearing countries of the world. It is 
considered to be one of the most important pig pathogens worldwide and it is estimated that in the 
US alone economic losses inflicted by the PRRSV amount to over 500 million dollars yearly (Neumann 
et al., 2005). Two genotypes exist, an American and North European, which in their turn can be 
divided into several subtypes (An et al., 2010; Karniychuk et al., 2010).  
The genome of the PRRSV is about 15 kilobases (kb) long and contains multiple open reading frames 
(ORFs) that are transcribed as a nested set of subgenomic mRNAs, a typical feature among the 
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Nidovirales (Figure 1B). The PRRSV mRNAs are coterminal, sharing their 3’-end and also have a 
common 5’-leader sequence that is derived from the genome 5’ end and is fused to the subgenomic 
mRNAs by a discontinuous transcription mechanism (Meulenberg et al., 1993a).  The first two ORFs 
that comprise about three quarters of the entire genome, ORF 1a and 1ab, encode two polyproteins 
that undergo auto-proteolytic processing to generate up to fourteen nonstructural proteins and 
these are involved in genome replication and immunomodulation of the host organism (Fang & 
Snijder, 2010; Kimman et al., 2009; Sun et al., 2010). The remaining ORFs code for the structural 
proteins of the virion and several of these are embedded in the lipid envelope surrounding the 
nucleocapsid (Figure 1A).  
The glycoproteins 2, 3 and 4 (GP2, 3 and 4) that result from translation of the ORFs 2a, 3 and 4, are 
the minor envelope proteins and are present in the lipid membrane as a non-covalently associated 
heterotrimer (Meulenberg et al., 1995; Meulenberg & PetersendenBesten, 1996). The major 
envelope proteins GP5 and the M proteins, encoded by ORF5 and 6 respectively, occur as disulfide 
bridge-linked dimers (Mardassi et al., 1996). Translation of ORF7 generates the N protein that makes 
up the nucleocapsid. The three main structural proteins, GP5, M and N are indispensable for viral 
particle formation whereas GP2, GP3 and GP4 are essential only for virus infectivity (Wissink et al., 
2005). Two additional genes are present in the PRRSV genome and these are entirely embedded 
within the existing ORF2 and 5. Translation of the former yields the small, non-glycosylated E protein, 
postulated to function as an ion channel during release of the genome in the cytosol, whereas the 
latter generates the ORF5a protein whose function is unknown (Johnson et al., 2011; Lee & Yoo, 
2006; Snijder et al., 1999; Wu et al., 2001).  
In nature, the PRRSV is primarily transmitted via the respiratory route but virions are also found in 
the semen of infected boars which makes sexual transmission another important route of infection 
(Snijder & Meulenberg, 1998). Additionally, the virus can cross the placenta during late gestation and 
infect unborn piglets thereby inducing reproductive failure (Rowland, 2010). PRRSV has a tropism for 
specific subsets of macrophages which it infects in the lungs, lymphoid tissue and placenta (Van 
Breedam et al., 2010a). Attachment to macrophages is initiated by loose binding of the GP5-M dimer 
to heparan sulfate moieties that are part of the O-linked glycans carried by glycoproteins anchored in 
the cell membrane (Delputte et al., 2002). The dimer then stably engages the sialoadhesin receptor 
via sialic acids present on the GP5 glycans and this triggers the clathrin mediated endocytosis of the 
virion (Delputte & Nauwynck, 2004; Nauwynck et al., 1999; Van Breedam et al., 2010b). Once 
internalized, a drop in pH is needed to uncoat the virion and deliver the genome to the cytosol so 
productive infection can occur. This process is crucially mediated by the interaction of the GP2, 3  
and 4 heterotrimer with the scavenger receptor CD163 and depends on the activity of the aspartic 
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protease cathepsin E, and an unidentified trypsin-like serine protease (Das et al., 2010; Misinzo et al., 
2008; Van Gorp et al., 2008).  
 
 
 
Figure 1. Overview of the PRRSV virion, genome organization and expression. (A) The PRRSV virion3. The 
singe-stranded RNA genome is enclosed in the nucleocapsid consisting of the N protein. The envelope 
glycoproteins are depicted embedded in the lipid membrane surrounding the nucleocapsid. (B) PRRSV 
genome organization and expression. The different ORFs and subgenomic mRNAs are depicted together 
with the polyproteins that give rise to the nonstructural proteins. Genome expression starts with the 
translation of the 1a and 1ab polyprotein (through a ribosomal frame shift), which are subsequently 
proteolytically processed into the nonstructural proteins that modulate the host’s immunity and are 
responsible for further viral replication. The different subgenomic mRNA’s that generate the structural 
proteins (the corresponding ORF is given as a white, numbered box) are depicted on the right showing 
their common 5’-leader sequence (black box). Once all the structural proteins are translated, they 
associate with the genome into infectious virus particles that are subsequently released from the host 
cell. Figure adapted from Snijder and Meulenberg (1998).  
                                                             
3
 http://education.expasy.org/images/Arteriviridae_virion.jpg 
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PRRSV causes respiratory distress among pigs of all ages but is especially problematic when infecting 
pregnant sows leading to abortion, early farrowing and birth of death or weakened piglets (Collins et 
al., 1992; Terpstra et al., 1991). The situation is further aggravated by the fact that during recent 
years also more virulent strains have been emerging with a high incidence of morbidity and mortality 
among pigs of all ages, as is exemplified by the 2006 outbreak in China infecting two million pigs of 
which 400.000 succumbed (An et al., 2010; Karniychuk et al., 2010; Tian et al., 2007; Zhou & Yang, 
2010). When not lethal, infection is very persistent and can take several months before it is 
completely resolved by the immune system that is apparently not able to cope efficiently with the 
virus (Figure 2). The initial immune response is crippled and typified by the late appearance of 
neutralizing antibodies and cell mediated immunity. Several mechanisms have been proposed to 
explain the delayed immune response mounted against the PRRSV. The virus has immune 
modulatory properties and interferes with the host’s interferon alpha production (Albina et al., 1998; 
Kimman et al., 2009). Sensitive epitopes on the envelope proteins are protected by glycan shielding 
(Ansari et al., 2006; Vu et al., 2011). The envelope proteins carry non-neutralizing, immunodominant 
decoy B-cell epitopes that are targeted by the initial non-effective antibody response and the 
neutralizing epitopes are often highly variable (Ostrowski et al., 2002; Vanhee et al., 2010).  
 
Figure 2. The course of a PRRSV infection. Taken from Lopez and Osorio (2004). PRRSV induces a 
defective immune response that is initially not able to cope with the virus and is characterized by the 
delayed onset of an efficient adaptive immune response; it is only after several weaks that neutralizing 
antibodies are generated and IFN-γ secreting cells arise. The latter two eventually reduce viremia, but the 
virus nevertheless persists in peripheral lymphoid tissues and it takes months before it is completely 
cleared from the host. Abbreviations used: mo(s), months; yr, year; IFN-γ, interferon gamma. 
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To combat PRRSV, prophylactic vaccines are administered that alleviate the clinical symptoms of a 
subsequent infection. However, their production is hampered by the genetic drift of the virus and it 
is generally accepted that no single vaccine will ever be capable of entirely controlling the PRRSV 
(Nauwynck et al., 2012). Strategies are thus being devised that incorporate the use of different types 
of vaccines to maximally profit from the specific benefit offered by each type. Naïve animals should, 
for example, be vaccinated with attenuated vaccines that have been shown to provide good 
protection, whereas inactivated or subunit vaccines should be used to boost the preexisting 
immunity of sows. The latter are safer and would result in increased levels of neutralizing antibodies 
in the blood and colostrum that protect sows against the transplacental spread of the PRRSV and the 
birth of viremic piglets (Nauwynck et al., 2012). With the intention of producing such a subunit 
vaccine, we selected the GP3, GP4 and GP5 as candidate antigens to be expressed in our 
seed-platform. Neutralizing antibodies play an important role in clearance of cell-free virus whereas 
cell-mediated immunity is needed to cope with PRRSV infected cells. The ideal vaccine should thus 
contain important B and T-cell epitopes. Pepscan analysis of antibodies in the sera of pigs after 
PRRSV infection revealed that both GP3 and GP4, but not GP5, carry neutralizing B-cell epitopes that 
were recognized by the sera of multiple pigs and these thus constitute antigens with vaccine 
potential (Vanhee et al., 2011). Although the GP5 selected in this study does not contain such 
epitopes, it was shown that it carries multiple important T-cell epitopes and hence, was also retained 
to be included in the experimental vaccine (Diaz et al., 2009; Vashisht et al., 2008). 
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Abstract 
Porcine reproductive and respiratory syndrome (PRRS) is a disease of swine, caused by an arterivirus, 
the PRRS virus (PRRSV). This virus infects pigs worldwide and causes huge economic losses. Due to 
genetic drift, current vaccines are losing their power. Adaptable vaccines could provide a solution to 
this problem. This study aims at producing in planta a set of antigens derived from the PRRSV 
glycoproteins (GPs) to be included in a subunit vaccine. We selected the GP3, GP4 and GP5 and 
optimized these for production in an Arabidopsis seed platform by removing transmembrane 
domains (Tm) and/or adding stabilizing protein domains, such as the green fluorescent protein (GFP) 
and immunoglobulin ‘Fragment crystallizable’ (Fc) chains. Accumulation of the GPs with and without 
Tm was low, reaching no more than 0.10% of total soluble protein (TSP) in homozygous seed. 
However, addition of stabilizing domains boosted accumulation up to a maximum of 2.74% of TSP 
when GFP was used, and albeit less effectively, also the Fc chains of the porcine IgG3 and murine 
IgG2a increased antigen accumulation, to 0.96% and 1.81% of TSP respectively, while the murine 
IgG3 Fc chain did not. Antigens with Tm were less susceptible to these manipulations to increase 
yield. All the antigens were produced in the endoplasmic reticulum and accordingly, they carried 
high-mannose N-glycans. The immunogenicity of several of those antigens was assessed and we 
show that vaccination with purified antigen elicited antibodies with virus neutralizing activity in mice 
but not in pigs. 
 
Introduction 
PRRSV is a pig pathogen that emerged in the late eighties in North America and North Europe (Collins 
et al., 1992; Wensvoort et al., 1991). Since its emergence, PRRSV has spread across the globe. It is 
considered one of the major pathogens affecting pig industries and causes severe economic losses 
worldwide (Neumann et al., 2005; Zhou & Yang, 2010). It provokes respiratory distress in pigs of all 
ages, but is especially problematic when infecting pregnant sows, leading to late abortion, early 
farrowing and birth of dead or weakened piglets (Terpstra et al., 1991). Lately, more virulent strains 
with a high incidence of pig mortality have been circulating (Karniychuk et al., 2010; Zhou & Yang, 
2010). 
PRRSV is an enveloped RNA virus belonging to the family of the Arteriviridae.  Two genotypes, a 
North American (NA-type) and a European (EU-type) have been identified, which again can be 
divided in several subtypes (Meulenberg et al., 1993b; Stadejek et al., 2008). It has multiple open 
reading frames embedded in its 15 kb long genome (Meulenberg et al., 1997b). Open reading frames 
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2 to 7 code for the glycoprotein (GP) 2, the E protein, GP3, GP4, GP5, the M protein and the 
nucleocapsid protein N, respectively (Meulenberg et al., 1995; Meulenberg et al., 1997b; Wu et al., 
2001; Wu et al., 2005). Of these structural proteins, the GP5 and the M protein are the major 
proteins found in the lipid envelope and occur as a disulfide-linked heterodimer (Mardassi et al., 
1996). The minor envelope proteins, i.e. GP2, GP3, GP4 and the E protein, are present as non-
covalently associated heteromultimers. 
PRRSV infection induces a defective immune response with late appearance of neutralizing 
antibodies and delayed cell mediated immunity (Kimman et al., 2009; Lopez & Osorio, 2004). This 
allows the infection to be persistent and makes it difficult to eliminate PRRSV from an infected herd. 
Control of PRRSV is focused on the administration of prophylactic vaccines to minimize the clinical 
impact of an infection. The vaccines currently used in the field consist of killed and live, attenuated 
vaccines. Commercial killed vaccines are safe and can provide some protection against homologous 
viruses, but are totally ineffective against heterologous strains (Geldhof et al., 2012; Zuckermann et 
al., 2007). The available attenuated vaccines, however, are very effective against homologous 
challenges and can, to a certain degree, even cross protect against heterologous strains, but they 
raise safety concerns because of their live viral content (Díaz et al., 2006; Geldhof et al., 2012; Key et 
al., 2003; Nielsen et al., 2001; Zuckermann et al., 2007). The attenuated vaccine can revert to 
virulence and cause infection in the vaccinated herd instead of preventing it. This has been 
documented for PRRSV on several occasions (Key et al., 2003; Nielsen et al., 2001; Opriessnig et al., 
2002). There is thus an urgent need for an adaptable, safe and effective PRRSV vaccine, such as a 
rationally engineered subunit vaccine. The latter is inherently safe because no virus is present and by 
incorporating elements known to be important in immunity against PRRSV, could be very effective. 
To this goal, we selected GP3, GP4 and GP5 of the European prototype PRRSV, the ‘Lelystad Virus’ 
(LV), to be included in a subunit vaccine. Since viral glycoproteins are complex proteins that cannot 
be correctly produced in bacteria, we opted to express them in the seed of Arabidopsis thaliana, a 
production platform that has previously been used to generate several heterologous proteins to 
levels as high as 15% of total soluble protein (TSP) (De Jaeger et al., 2002; Goossens et al., 1999; Loos 
et al., 2011a; Loos et al., 2011b; Van Droogenbroeck et al., 2007). Production of high-value 
pharmaceuticals in plants has gained popularity during the last decades, due to intrinsic advantages 
offered by this production platform, such as flexible scale up, the absence of human or animal 
pathogens, and the potential for the cheap production and storage of complex proteins (Nagels et 
al., 2012b; Paul & Ma, 2010; Rybicki, 2010). The technology has reached maturity and several plant 
made pharmaceuticals are in clinical trials, on the road to the market (Yusibov et al., 2011). Different 
plant species and tissues have been employed for the production of PRRSV vaccines. Banana leaves 
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(Chan et al., 2013), potato tubers (Chen & Liu, 2011) and tobacco leaves (Chia et al., 2011; Chia et al., 
2010) were used to express the GP5 and recombinant variants thereof. The M protein was produced 
in corn calli (Hu et al., 2012) and the N protein in soybean seed (Vimolmangkang et al., 2012). 
Antigen accumulation was relatively low, ranging from 0.011% of TSP for GP5 expressed in tobacco to 
0.65% of TSP for N protein expressed in soybean seed and none of the antigens were purified. 
However, to overcome economic hurdles during vaccine production, it is essential that the antigens 
accumulate to high levels and that an efficient purification protocol is in place. With this in mind, we 
manipulated the GP3, GP4 and GP5 coding sequence to augment their production and to facilitate 
purification by removing transmembrane domains (Tm), adding affinity tags and/or fusing them to 
stabilizing protein domains, such as the ‘Fragment crystallizable’ (Fc) of immunoglobulins (IgGs) or 
the green fluorescent protein (GFP), hence giving rise to an entire set of antigen formats derived 
from the EU-prototype LV. All these different constructs were cloned in a seed-specific expression 
cassette (Morandini et al., 2011), transformed into Arabidopsis thaliana and the resulting 
transformants screened for antigen content. The antigens were characterized and evaluated for their 
ease of production and purification. Further, the immunogenicity of the antigens and their potential 
to raise neutralizing antibodies were investigated by vaccinating mice, and subsequently piglets, with 
purified antigens.  
This paper details the in planta production of a set of antigenic proteins derived from the 
glycoproteins of the EU-prototype LV. We show that the antigens are correctly produced in the seed, 
accumulate to levels that are economically feasible (1% of TSP or more; (Rybicki, 2009)) and can be 
purified by single-step affinity chromatography. Additionally, we assayed the immunogenicity of 
several antigens in both a murine and porcine model. 
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Results 
Antigen expression in A. thaliana seed 
The PRRSV envelope proteins GP3, GP4 and GP5 (Figure 1B) were selected and expressed as different 
formats in A. thaliana seed (Figure 1C). Both full-length GP4 and GP5, as well as their truncated 
formats without Tm (hereafter referred to as GP4-Tm and GP5-Tm) were cloned into an expression 
cassette with regulatory sequences of Phaseolus vulgaris designed for high seed-specific expression 
(De Jaeger et al., 2002; Goossens et al., 1999; Morandini et al., 2011) (Figure 1A). All antigens were 
targeted to the endoplasmatic reticulum (ER) by N-terminal fusion to the signal peptide of a 2S2 seed 
storage protein, and retained there via a C-terminal KDEL-tag. Little is known about the 
transmembrane topology of the full-length GP4 and GP5. The C-terminal hydrophobic domain of GP4 
is predicted to span the membrane once, whereas the central hydrophobic domain of GP5 is 
predicted to span the membrane anywhere from one to three times (Meulenberg et al., 1995; 
Wissink et al., 2005). In vivo, transit through the secretory pathway decorates the GPs with complex 
mammalian N-glycans (Mardassi et al., 1996; Meulenberg et al., 1997a; Meulenberg et al., 1995). 
However, retaining the GPs in the ER will cause their N-glycans to be of the high-mannose type 
(Wissink et al., 2005). To evaluate the influence of these ER-associated high-mannose glycans on 
antigen immunogenicity, a deglycosylated format of the GP4-Tm (named sGP4-Tm) was designed. 
This was done by mutating the asparagine in the consensus sequence N-x-S/T (with x being any 
amino acid except proline) into a glutamine for each of the four N-glycan attachment sites that was 
present. For GP3, only a truncated format without Tm (named GP3-Tm) was cloned. Fusions were 
also made between these proteins and stable protein domains, such as the GFP and the Fc chains of 
the porcine IgG3 (pFc), the murine IgG3 (mFc3), and the murine IgG2a (mFc2a), generating a whole 
set of antigenic PRRSV proteins (Figure 1C). All constructs except the murine Fc fusions, contain the 
His6-tag. For every antigen construct, twenty transformants were generated, and the line with the 
highest antigen content and in which the T-DNA was integrated at a single locus, as determined by 
segregation analysis (see Material & methods and Supplemental Figures 1 to 3), was retained, selfed 
and propagated to homozygosity.  
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Figure 1. Schematic representation of the T-DNA bearing the seed-specific expression cassette (A), the 
PRRSV glycoproteins selected to be included in a vaccine (B) and the antigen formats derived thereof 
(C). (A) The T-DNA carrying the neomycin phosphotransferase II gene which confers resistance to the 
antibiotic kanamycin and the cassette for high seed-specific expression driven by the β-phaseolin 
promoter, the leader sequence of the tobacco mosaic virus and the arcelin5-I terminator. The cassette is 
further supplemented with sequences encoding an ER-targeting and retention signal. (B) The full-length 
PRRSV glycoproteins used in the current study and supplemented with a His6-tag (purple rod). The jagged 
line depicts the Tm. The full-length GP3 is placed between brackets as it was never produced as such. Only 
the GP3 without Tm was expressed, depicted as GP3-Tm in (C). (C) Overview of the manipulations 
performed on the GPs and the resulting set of antigenic proteins whose coding sequences were cloned 
into the seed-specific expression cassette. Abbreviations and symbols used: LB and RB, T-DNA left and 
right border, respectively; 3’ocs, 3’end of the octopine synthase gene; nptII, the neomycin 
phosphotransferase II gene; Pnos, promoter of the nopaline synthase gene; Pphas, promoter of the β-
phaseolin gene; Ω, leader sequence of the ‘tobacco mosaic virus’; SS, sequence coding for the signal 
peptide of the 2S2 Arabidopsis seed storage protein; GOI, gene of interest; KDEL, coding sequence of the 
ER-retention signal; 3’Arc, terminator of the arceline5-I gene; Tm, transmembrane domain, jagged line; 
His6-tag, immobilized metal affinity chromatography tag, purple rod; pFc, porcine IgG3 Fc, chain of blue 
ovals; mFc2a, murine IgG2a Fc, chain of orange ovals; mFc3, murine IgG3 Fc, chain of yellow ovals; GFP, 
green fluorescent protein, bright green oval.  
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For all the GP3 derived constructs, except the GP3-Tm, transformants could be obtained. Extracts 
from homozygous GP3-Tm:pFc, GP3-Tm:mFc2a and GFP:GP3-Tm seed stocks were analyzed by 
western blotting with the anti- (α-) GP3 monoclonal antibody (mAb) VII2D that recognizes the linear 
epitope MWCKIGHDRCEE (Van Breedam et al., 2011). This revealed several glycoforms migrating at 
their expected theoretical molecular weight (Mw) ranging from 46.3 kDa (one of the six or seven N-
glycan attachment sites occupied) to 60.3 kDa (fully glycosylated) (Figure 2A; Table 1). Mainly for the 
GFP:GP3-Tm also some non-reduced multimeric structures could be seen between 100 and 150 kDa, 
together with some degradation products around 37 kDa. 
The GP4 seed stocks were analyzed with the α-GP4 mAb XVI11C that recognizes the linear epitope 
GVSAAQEKISFG (Costers et al., 2010) (Figure 2B). Since GP4 and GP4-Tm carry four N-glycan 
attachment sites, four different glycoforms could be detected for both, with those of GP4 migrating 
slower than those of GP4-Tm, due to the presence of the Tm (Figure 2B). However, a differential 
glycosylation preference was observed, since GP4 showed a higher intensity of its upper band and a 
very weak signal of the second lowest band, whereas GP4-Tm showed higher intensity for the second 
band and equal intensities for the other three glycoforms. The signal of sGP4-Tm corresponded with 
the lower band of GP4-Tm (Figure 2B), confirming that this represents the unglycosylated GP4-Tm. 
Mutating the N-glycan sites seemed to have a deleterious effect on the accumulation of sGP4-Tm, as 
shown by the low intensity of its corresponding band. All fusions of GP4, GP4-Tm and sGP4-Tm with 
pFc, mFc3, mFc2a and GFP migrated at their expected theoretical Mw (Table 1), but with different 
signal intensities (Figure 2B), pointing toward differences in antigen accumulation in the seed. For 
GP4-Tm:mFc2a some non-reduced homodimers were visible around 100 kDa together with degraded 
fragments at 25 kDa (Figure 2B). To a lesser extent, non-reduced multimers and degradation 
products could also be observed for some of the other antigens (Figure 2B). 
Western blot analysis of seed extracts containing the different GP5 antigens and detected with the α-
GP5 mAb II5D (which recognizes the linear epitope DSSTYQYIYNLT (Van Breedam et al., 2011)), 
showed only for GP5-Tm:pFc a weak signal at 50 kDa (Figure 2C, left panel). In all samples however, 
even in the wild-type extract, a strong background band appeared around 20-25 kDa, possibly 
covering other signals. A similar pattern was observed when the α-GP5 mAbs II5A and VII2H were 
used to detect the antigens (data not shown, it should however be noted that the mAbs II5D, II5A 
and VII2H recognize the same linear epitope (Van Breedam et al., 2011)). Western blot analysis was 
further performed with an antibody against the His6-tag, which was also present in the constructs 
(Figure 1C) and enabled detection of all GP5 antigens (Figure 2C, right panel). As expected, GP5 
migrates slower than GP5-Tm. The smaller, faint bands were hypothesized to represent partially or 
unglycosylated proteins, since both GP5 and GP5-Tm carry two N-glycosylation sites, and this  was 
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confirmed by deglycosylation analyses (see next section). GP5:pFc migrates slower than GP5-Tm:pFc, 
but is only very faintly detected, indicating low expression. GP5-Tm:pFc on the other hand 
accumulates notably higher than the other GP5 antigens, but also shows a second band migrating at 
a size smaller than the theoretical Mw of 49 kDa, which does not correspond with the  partially or 
unglycosylated proteins, but represents a cleavage product (see next section). 
 
Figure 2. Characterization of the GP3, GP4 and GP5 antigens. Seed extracts of homozygous lines (unless 
stated differently) producing the different antigen formats were analyzed by western blotting under 
reducing conditions. Sixty µg of TSP was loaded. (A) The GP3 antigens detected with the α-GP3 mAb VII2D 
(Van Breedam et al., 2011). (B) The GP4 antigens detected with the α-GP4 mAb XVI 11C (Costers et al., 
2010). For the sGP4-Tm, sGP4-Tm:pFc and the GFP:GP4, segregating T2 stocks were analyzed and for the 
GFP:GP4-Tm and GP4-Tm:mFc2a, only 15 µg of TSP was loaded. (C) The GP5 antigens detected with the α-
GP5 mAb II5A (Van Breedam et al., 2011) (left panel) or an antibody against the His6-tag (right panel). For 
the GP5-Tm:pFc, a T2 segregating stock was analyzed. Abbreviations used: WT, wild-type seed extract; 
kDa, kilodalton. 
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In conclusion, all antigens, except the GP3-Tm for which no transformants could be obtained, are 
present in the seed of the transgenic A. thaliana and accumulate to different levels. Also, aside from 
the GP5-Tm:pFc that is partially cleaved, all antigens appear structurally integer and migrate 
according to their expected size.  
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Table 1. Physical parameters of the antigens  
Antigen Amino acids N-glycosylation sites Predicted molecular weight (kDa) 
   
Unglycosylated Fully glycosylated 
GP3-Tm 166 6 19.2 31.2 
GP3-Tm:pFc 407 7 46.3 60.3 
GP3-Tm:mFc2a 392 7 44.6 58.6 
GFP:GP3-Tm 410 6 46.6 58.6 
GP4 176 4 19.5 27.5 
GP4:pFc 417 5 46.7 56.7 
GFP:GP4 420 4 46.9 54.9 
GP4-Tm 158 4 17.6 25.6 
GP4-Tm:pFc 399 5 44.7 54.7 
GP4-Tm:mFc3 384 6 42.8 54.8 
GP4-Tm:mFc2a 384 5 43.0 53.0 
GFP:GP4-Tm 402 4 45.0 53.0 
sGP4-Tm 158 0 17.6 17.6 
sGP4-Tm:pFc 399 1 44.8 46.8 
sGP4-Tm:mFc2a 384 1 43.0 45.0 
GP5 179 2 19.9 23.9 
GP5:pFc 420 3 47.1 53.1 
GP5-Tm 119 2 13.6 17.6 
GP5-Tm:pFc 381 3 43.1 49.1 
 
 
 
Table 1. The molecular weight of the fully glycosylated antigens was obtained by taking the weight of the 
unglycosylated antigens and adding to that the number of potential N-glycosylation sites multiplied by 2 
kDa. Abbreviations used: kDa, kilodalton. 
 
Glycosylation of antigens produced in A. thaliana seed 
All antigens were translocated to the ER by an ER-targeting signal derived from the 2S2 albumin seed 
storage protein of A. thaliana (Krebbers et al., 1988) and retained there via a C-terminal KDEL 
sequence (Gomord et al., 1997a). If the antigens are indeed retained in the ER, they should carry N-
glycans of the high-mannose type (Pearse & Hebert, 2010). To verify their glycosylation status, all 
antigens (18 in total) were deglycosylated by treatment with either endoglycosidase H (endoH) or 
peptide-N-glycosidase F (PNGaseF), which differ in their substrate specificity. EndoH acts on 
high-mannose N-glycans only (Maley et al., 1989), whereas PNGaseF processes all N-glycans except 
core α1,3-fucosylated structures. In plants, this modification occurs in the late Golgi apparatus and 
can be found on hybrid and complex N-glycans (Gomord et al., 2010). When the antigen carries 
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ER-typical high-mannose N-glycans, it will be deglycosylated by both enzymes. However, if the 
antigen is present in other compartments of the secretory pathway and its glycans undergo 
maturation into hybrid or complex type glycans, then treatment with endoH and PNGaseF will yield 
differential deglycosylation, except for α1,3-fucosylated glycans that will not be processed by either 
of both glycosidases. However, glycoproteins carrying these structures will be resilient to digestion 
and hence, can be monitored as well. 
All antigens are susceptible to deglycosylation by endoH and PNGaseF and no differences can be 
discerned between treatment with either glycosidase, indicating that the proteins carry 
high-mannose N-glycans (Figure 3A, B and C). As hybrid and/or complex glycans have been reported 
on KDEL-tagged recombinant proteins before (He et al., 2012b; Loos et al., 2011a), it is possible that 
minute quantities of these are present on the antigens as well and that the mobility shift assay did 
not reveal these. However, the obtained results clearly identify high-mannose N-glycans as the 
predominant glycoforms. For GFP:GP3-Tm some degradation was observed (Figure 3A). Figure 3B 
shows that the banded pattern of both GP4 and GP4-Tm was reduced to a single band corresponding 
to the fully deglycosylated antigen, confirming that it indeed represents different glycoforms. Figure 
3B also shows some non-reduced multimers and degradation for GFP:GP4-Tm and GP4-Tm:mFc2a. 
Similarly, for the GP5 antigens no differential behavior could be observed when treated with endoH 
or PNGaseF (Figure 3C). Deglycosylation of GP5 and GP5-Tm showed that the faint bands present 
before treatment correspond to partially and unglycosylated antigens, since both deglycosylation 
treatments resulted in the reduction of this pattern to one single band (Figure 3C). Given that the 
pattern of GP5-Tm:pFc (right panel, Figure 2C and 3C) was not reduced to one single band after 
endoH or PNGaseF treatment, the lower band does not correspond to the unglycosylated protein, 
but to a cleavage product (Figure 3C right panel). 
To conclude, the antigens were post-translationally modified by N-glycosylation and glycosidase 
treatment showed that all antigens are decorated with ER-typical high-mannose N-glycans, indicating 
their correct production in the ER.  
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Figure 3. Glycan analysis of the GP3, GP4 and GP5 antigens. Seed extracts from homozygous lines (unless 
stated differently) producing the different antigen formats were treated with endoH or PNGaseF and 
analyzed by western blotting under reducing conditions. Thirty µg of TSP was loaded. (A) Glycan analysis 
of the GP3 antigens detected with the α-GP3 mAb VII2D (Van Breedam et al., 2011). (B) Glycan analysis of 
the GP4 antigens detected with the α-GP4 mAb XVI 11c (Costers et al., 2010). For the sGP4-Tm, sGP4-
Tm:pFc and GFP:GP4, a segregating T2 stock was used. (C) Glycan analysis of the GP5 antigens detected 
with an antibody against the His6-tag. For the GP5-Tm:pFc, a segregating T2 stock was analyzed. 
Abbreviations used: -, no treatment; E, endoH treatment; P, PNGaseF treatment: WT, non-treated wild-
type seed extract; kDa, kilodalton. 
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Accumulation levels of antigens produced in A. thaliana seed 
ELISAs were performed to determine the accumulation level of the antigens in the transgenic seed 
and to assess the effect of fusing them to stabilizing protein domains (Table S1). The antigen content 
was expressed as antigen mass per gram of dry seed and, after measuring the protein concentration 
of the seed extracts, as percentage of TSP. For most antigens, T3 homozygous (Ho) lines were 
analyzed. When not available, the T2 segregating (Se) seed stock was used (Table S1). Therefore, it 
should be taken into account that, due to a gene dosage effect (De Jaeger et al., 2002), it is possible 
that the accumulation of the antigens, for which a segregating seed stock was analyzed, could 
increase when these lines are propagated to homozygosity. During the ELISA experiments, no signal 
could be obtained for GP5 and GP5:pFc. However, western blotting clearly showed that they were 
present in seed extracts (Figure 2C, right panel), and thus GP5 and GP5:pFc antigen accumulation was 
determined by signal quantification after western blot analysis via the His6-tag (data not shown). 
A graphical representation of the accumulation of the antigens (given as percentage of TSP, Figure 4) 
shows that there was a large variation in accumulation between antigens, ranging from 0.005% of 
TSP for sGP4-Tm to 2.74% of TSP for GFP:GP3-Tm. Some trends could however be observed. The full-
length antigens GP4 and GP5 did not accumulate well (0.08% and 0.10% of TSP, respectively) and 
removing their Tm to generate GP4-Tm and GP5-Tm did not alter this considerably, but fusion to 
stabilizing protein domains increased accumulation by several factors, up to 2.36% of TSP for 
GFP:GP4-Tm. Fusions between GP3-Tm and the same stabilizing domains showed a similar increase, 
resulting in percentages as those measured for the corresponding GP4-Tm fusions. It is noteworthy 
that addition of an IgG Fc to the antigens without Tm can have a beneficial effect on their 
accumulation, as described by De Buck et al. (2013), but that this is highly dependent of the Fc 
added. Whereas the mFc3 did not enhance GP4-Tm accumulation, the pFc, and the mFc2a even more 
so, notably did so, boosting accumulation from 0.05% to 0.67% and 1.59% of TSP, respectively. The 
full-length antigens appeared to be less prone to manipulation by addition of stabilizing domains. In 
contrast to GP4, where addition of the pFc and GFP had little impact on accumulation (from 0.08% to 
0.14% and 0.15% of TSP, respectively), coupling of the pFc to GP5 actually reduced accumulation of 
the resulting GP5:pFc (from 0.10% to 0.01% of TSP). Removing the four N-glycan attachment sites of 
GP4-Tm in sGP4-Tm was also deleterious, since accumulation was diminished from 0.05% to 0.005% 
of TSP. Again, addition of the pFc and mFc2a to sGP4-Tm slightly increased accumulation. Far 
outperforming any other format, the N-terminal GFP fusions, i.e. GFP:GP3-Tm and GFP:GP4-Tm, 
accumulated to 2.74% and 2.36% of TSP, respectively. 
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Figure 4. Antigen accumulation in transgenic seeds as determined by ELISA and given as percentage of 
TSP. Values are the mean of three biochemical repeats, error bars represent the standard deviation. 
Accumulation of the GP3, GP4 and GP5 antigens is depicted as white, grey and black bars, respectively. 
Abbreviation used: TSP, total soluble protein.  
 
Purification of antigens produced in A. thaliana seed 
Several techniques can be used for purification. Antigens fused to an IgG Fc are suitable for protein-A 
affinity chromatography, whereas the formats carrying a His6-tag can be purified by immobilized 
metal affinity chromatography (IMAC).  
A high and low accumulating antigen, respectively GFP:GP4-Tm and GP4-Tm, were selected to be 
purified by IMAC. The IMAC purification of GP4-Tm resulted in fractions enriched with GP4-Tm as 
observed by western blot analysis (the banded pattern corresponds to the different glycoforms of 
GP4-Tm, Figure 5B), but GP4-Tm co-eluted with contaminating proteins as shown on the 
Coomassie-stained gel (Figure 5A). IMAC was thus efficient in capturing GP4-Tm, however, since the 
eluted fractions were only semi-pure, additional steps are necessary to obtain pure GP4-Tm. No 
degradation of the GP4-Tm was visible (data not shown). In contrast to GP4-Tm, the eluted 
GFP:GP4-Tm was of high purity (80 – 82%, Figure 5C). Western blot analysis (Figure 5D) showed that 
some GFP:GP4-Tm was still present in the flow through and after washing to remove imidazole, the 
final yield was only 40%. Nonetheless, successive rounds of loading the flow through onto the 
column and subsequent elution could increase the recovery up to 75% (data not shown). Also, small 
quantities of degraded GFP:GP4-Tm were visible both in the crude extract as in the purified samples 
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(Figure 5D). These experiments suggest that when IMAC is used to purify proteins from crude A. 
thaliana seed extracts, some endogenous proteins co-purify and that the level of contaminating 
protein depends on the amount of target protein present in the extract. When the target protein is 
abundant, then it is preferentially retained by the column. Low abundant proteins on the other hand 
are co-purified with higher levels of endogenous proteins. In summary, IMAC is suitable to capture 
GP4-Tm, but additional steps are necessary to obtain pure protein. Considering GFP:GP4-Tm and 
taking a yield penalty into account, IMAC can be used to directly purify the antigen.   
 
 
Figure 5. IMAC purification of selected antigens. One gram of homozygous seed stocks containing 
0.14 mg GP4-Tm or 7.37 mg of GFP:GP4-Tm was extracted and subjected to IMAC. Purification of the GP4-
Tm was analyzed by 12% SDS-PAGE and Coomassie Blue staining (A) or western blotting (B). Purification of 
the GFP:GP4-Tm was analyzed by SDS-PAGE (15%) and Coomassie Blue staining (C) or western blotting 
(D). All gels were run under reducing conditions and an antibody against the His6-tag was used to detect 
the antigens during western blot analysis. Abbreviations used: S, sample; F, flow through; W, wash; E, 
elution; kDa, kilodalton. 
 
The GP4-Tm antigens fused to pFc, mFc3 and mFc2a were selected to be purified by protein-A affinity 
chromatography (Figure 6). The strong and specific interaction between protein-A derived from 
Staphylococcus aureus and the Fc part of the antigens should allow for efficient purification (Goding, 
1978). Coomassie and western blot analysis showed that all three Fcs used had affinity for the 
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protein-A resin and that both low (GP4-Tm:mFc3  in Figure 6C) and high accumulating antigens 
(GP4-Tm:pFc and GP4-Tm:mFc2a, Figure 6A and B, respectively) could be captured and purified by 
single-step protein-A chromatography. The recovery and purity for GP4-Tm:pFc were 55 and 85%, 
respectively, and for GP4-Tm:mFc2a 60 and 88%, respectively (they were not determined for 
GP4-Tm:mFc3). 
 
 
Figure 6. Protein-A affinity chromatography of selected antigens. For each antigen, one gram of 
homozygous seeds (equivalent to 0.15 mg GP4-Tm:mFc3, 2.06 mg GP4-Tm:pFc and 5.15 mg 
GP4-Tm:mFc2a) was extracted and subjected to protein-A chromatography. Purification of GP4-Tm:pFc 
(A), GP4-Tm:mFc2a (B) and GP4-Tm:mFc3 (C) was analyzed by 12% SDS-PAGE and Coomassie Blue staining 
(upper panels) or western blotting (lower panels). All gels were run under reducing conditions and the α-
GP4 mAb XVI 11C was used to detect the antigens during western blotting. Abbreviations used: S, sample; 
F, flow through; W, wash; E, elution; kDa, kilodalton.  
 
Immunogenicity of antigens produced in A. thaliana seeds 
To study the immunogenicity of the plant-produced antigens, the GFP:GP4-Tm, GP4-Tm:mFc2a and 
sGP4-Tm:mFc2a, all carrying the GP4-Tm, were selected to vaccinate mice. The GP4-Tm was chosen 
as a model antigen as it contains a B-cell epitope that consistently induces neutralizing antibodies 
upon infection and neutralizing antibodies are considered a good correlate for protection against 
PRRSV (Lopez & Osorio, 2004; Meulenberg et al., 1997a). Mice were injected with 5 µg of purified 
antigen mixed with an oil-in-water adjuvant following a prime-boost protocol with three weeks 
between both vaccinations. Figure 7A shows that after six weeks high titers of GP4-Tm-specific 
antibodies were induced by all three antigens as measured by ELISA. The sera collected at week six 
were then subjected to an immuno peroxidase cell monolayer assay (IPMA) to check for viral antigen 
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recognition (Figure 7B). Despite the high antibody titers induced by all antigens, only GP4-Tm:mFc2a 
generated antibodies capable of PRRSV recognition in IPMA. Subsequently these sera were shown to 
have virus neutralizing capacity in a seroneutralization test (Figure 7C). All three antigens thus raised 
high levels of antigen-specific antibodies in a mouse model, and those of the GP4-Tm:mFc2a 
vaccinated group were also able to neutralize the PRRSV.  
 
 
Figure 7. Characterization of the immunogenicity of selected GP4 antigens in a mouse model. Per 
antigen, eight mice were vaccinated twice with 5 µg antigen mixed with an oil-in-water adjuvant. The 
booster vaccination was administered at week three (both vaccinations are depicted as black arrows). (A) 
Antigen-specific IgG titers induced by the GFP:GP4-Tm, GP4-Tm:mFc2a and sGP4-Tm:mFc2a  at weeks 
two, four, and six after vaccination as measured by ELISA. Per vaccinated group, the individual values for 
each mouse and the mean (horizontal line) are given.  (B) The titers of the sera collected at week six when 
tested via IPMA. Per vaccinated group the number of mice with a given titer is indicated. (C) The sera at 
week six of the GP4-Tm:mFc2a vaccinated mice were subjected to a seroneutralization assay to determine 
their virus neutralizing activity. The mean percentage of virus reduction (n= eight mice) in function of the 
dilution is given, error bars represent the standard deviation. 
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Upon completion of the murine vaccination trial, a second study was initiated to assess the 
immunogenicity of antigens carrying the pFc in pigs, the in vivo host of the PRRSV. During this 
preliminary trial three piglets were vaccinated with an antigen cocktail consisting of 100 µg purified 
GP3-Tm:pFc, 100 µg purified GP4-Tm:pFc and 100 µg purified GP5-Tm:pFc mixed with an oil-in-water 
adjuvant following a prime-boost protocol with a four-week interval between both vaccinations. High 
GP3-Tm, GP4-Tm and GP5-Tm-specific antibody titers were obtained after the booster vaccination 
from week four onward (measured by ELISA; Figure 8A, B and C). When sera were tested via IPMA, 
high titers were found for one piglet from week five onward, however, no response could be 
detected for the other two piglets (Figure 8D). Sera from all three piglets collected at week five and 
six were subjected to a seroneutralization test, but no response above the threshold could be 
detected (data not shown).  
 
 
 
Figure 8. Characterization of the immunogenicity of selected antigens carrying the pFc in a porcine 
model. Three piglets were vaccinated twice with an antigen cocktail consisting of purified GP3-Tm:pFc, 
GP4-Tm:pFc and GP5-Tm:pFc mixed with an oil-in-water adjuvant. The booster vaccination was 
administered at week four (both vaccinations are depicted as black arrows). At different time points, the 
titers of IgG antibodies specific for GP3-Tm (A), GP4-Tm (B) and GP5-Tm (C) was determined. The 
collected sera were also tested via IPMA and titers of sera collected from week zero to six given (D). 
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In summary, all antigens vaccinated in mice and piglets generated high titers of antigen-specific 
antibodies after the booster vaccination and the sera of mice vaccinated with GP4-Tm:mFc2a also 
had virus neutralizing capacity. In contrast to this, no such activity could be detected in any of the 
sera of the vaccinated piglets.  
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Discussion 
We designed, cloned and successfully expressed a set of antigenic proteins derived from the 
glycoproteins of the PRRSV EU-prototype LV in the seed of A. thaliana. Analysis of antigen 
glycosylation status showed that the antigens were post-translationally modified by N-glycosylation, 
and that they carried high-mannose N-glycans, corresponding to their production in the ER and 
possibly, also indicating their retention there. For GP4 this scenario would mean that its single-span 
transmembrane domain (Meulenberg et al., 1995), predicted to leave the KDEL-tag in the cytosol out 
of reach of the KDEL receptor, is not correctly inserted into the ER membrane or, that GP4 is retained 
in the ER in a KDEL-independent manner. In animal cells, GP4 is withheld in the ER until it associates 
with GP2 and GP3 to form a heterotrimer after which the complex is released (Wissink et al., 2005) 
and a similar mechanism might function in the seed. For GP5, the exact topology of the Tm, which is 
predicted to span the ER membrane anywhere from one to three times (Meulenberg et al., 1995), is 
not known, but the presence of high-mannose glycans would strengthen the hypothesis that the 
KDEL-tag is functional.  
On the other hand, we cannot exclude that the antigens have migrated to other subcellular 
compartments, since recombinant proteins with ER-typical glycosylation have been found in non-ER 
compartments before in the seed of Arabidopsis. Using the same expression vector, the anti-HIV 
monoclonal antibody 2G12 was found almost exclusively in protein storage vacuoles (Loos et al., 
2011a), whereas a synthetic antibody based on the 2G12 was deposited in newly formed ER-derived 
vesicles (Loos et al., 2011b) and another synthetic antibody even in the periplasmic space (Van 
Droogenbroeck et al., 2007). All these recombinant proteins carried the KDEL sequence and were 
decorated to some extent with high-mannose glycans, showing that the mere presence of these 
glycans is not sufficient to allocate a protein to the ER. Further localization studies are thus needed to 
pinpoint the exact subcellular compartment in which the antigens reside.  
Despite the advantages offered by the production of recombinant proteins in plants, such as safety, 
flexible scalability and complex protein synthesis, low protein yields have been a major problem 
during previous studies concerning PRRSV antigens (Chan et al., 2013; Chen & Liu, 2011; Chia et al., 
2011; Chia et al., 2010; Hu et al., 2012; Vimolmangkang et al., 2012). Antigen accumulation ranged 
from 0.011% of TSP for recombinant GP5 expressed transiently in tobacco leaves (Chia et al., 2010) 
to 0.65% of TSP for the N protein produced in soybean seed (Vimolmangkang et al., 2012). To 
overcome this hurdle, we included in our set of antigenic proteins a number of antigen formats 
carrying stable protein domains, such as GFP or an immunoglobulin Fc fragment, which are expected 
to increase antigen accumulation. Indeed, a 6-fold increase (taking into account the similar molecular 
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weight of GP4-Tm and the pFc domain) in accumulation of the GP4-Tm component was observed 
when comparing the GP4-Tm antigen (0.05% of TSP) to the GP4-Tm:pFc (0.67% of TSP), rising to over 
15-fold for the GP4-Tm:mFc2a (1.59% of TSP) and even more than 20-fold when comparing to the 
GFP:GP4-Tm (2.36% of TSP). Considering the GP5 antigens, both GP5 and GP5-Tm accumulated to 
about 0.09% of TSP and this rose to 0.83% of TSP for GP5-Tm:pFc, corresponding to 2.3 mg/g of seed 
weight. These numbers are considerably higher than those obtained for recombinant GP5 produced 
in banana (0.037% of leaf TSP (Chan et al., 2013)), potato (4.7µg/g of leaf fresh weight (Chen & Liu, 
2011)), tobacco (0.011% of TSP (Chia et al., 2010)) or for a fusion between GP5 and the B subunit of 
Escherichia coli heat-labile enterotoxin produced in tobacco (0.015% of TSP (Chia et al., 2011)).  
Further, our results are in line with those obtained by Obregon et al. (2006) who fused the HIV-1 p24 
antigenic protein to the Fc of human IgA, resulting in a 13-fold increase in antigen accumulation and 
those of De Buck et al. (2013) who could boost the accumulation of Nanobodies® (antigen-binding 
domains of camelid heavy-chain only antibodies) in the seed of Arabidopsis by 10- to 100-fold up to 
16% of TSP after fusion with Fcs of different origin. As a general tendency we observed that adding 
stabilizing domains to the truncated antigens GP3-Tm, GP4-Tm and GP5-Tm had a positive influence 
on antigen accumulation and that the extent of this influence depended on the domain added, with 
GFP giving the highest accumulation followed by, in decreasing order, the mFc2a, pFc and mFc3.  
GFP has a long history in the field of cell biology and GFP-fusion proteins have been made for 
decades (Cubitt et al., 1995). The main goal of these fusions has always been to create reporter 
proteins that could be followed at the cellular level. However, our data indicate that GFP can also 
effectively be used to augment target protein accumulation and, taken into account its stability and 
the fact that several GFP-based purification methods have been published (Peckham et al., 2006; 
Rothbauer et al., 2008), fusion to GFP could represent an alternative strategy to boost target protein 
production. However, caution should be taken in the context of vaccination where GFP might 
interfere with the immune response raised against the GFP-tagged antigen.  
Manipulation of the full-length antigens GP4 and GP5 by addition of stable protein domains was 
much less effective, indicating that the Tm somehow compromises antigen accumulation. Mutating 
the N-glycan attachment sites of the GP4-Tm profoundly disturbed accumulation of the resulting 
deglycosylated sGP4-Tm. Both sGP4-Tm, as well all fusions herewith, underperformed when 
compared to the corresponding glycosylated formats. It will be interesting to determine whether this 
is due to the change in primary structure after amino acid substitution or because of the absence of 
N-glycans, possibly resulting in a perturbation of interaction with chaperones and the quality control 
mechanism in the ER. In summary, we observed that stable protein domains can be added to the 
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antigens as a strategy to increase antigen accumulation with GFP being most beneficial, that the 
effect of such fusions depends on both the antigen and the stable domain, and that for each antigen 
the optimal manipulation should therefore be identified on a case by case basis.  
In addition to boosting accumulation, the Fc domains also allow for protein-A affinity 
chromatography. We showed that antigens carrying the pFc, mFc3 and mFc2a and varying in 
accumulation between 0.15 and 5.15 mg per gram dry seed could all be purified by single-step 
protein-A affinity chromatography with a recovery of about 60%. On the other hand, single-step 
IMAC purification of antigen formats with a His6-tag was restricted to high abundant antigens such as 
GFP:GP4-Tm. It seems that some seed proteins also show affinity for the resin and compete for 
binding sites on the IMAC column. If the antigen is low abundant, then more endogenous proteins 
will bind and co-elute, lowering the final antigen purity and increasing the need for an additional 
purification step. 
The platform to be chosen for subunit vaccine production should allow for high production and 
correct folding and assembly of the antigens. Regarding the latter, it is doubtful that complex PRRSV 
antigens can be produced correctly in bacteria. Indeed, disease enhancement was observed when 
recombinant GP5 from E. coli was vaccinated (Prieto et al., 2011). PRRSV antigens were also 
produced in baculovirus infected insect cells, but only low yields were achieved (Duran et al., 1997). 
Virus-like particles containing GP5 or GP5 and M could be isolated from the insect cell culture 
medium, but no yield parameter was reported (Nam et al., 2013; Wang et al., 2012). Also when 
PRRSV antigens were produced in planta, accumulation was rather low, with a maximum of 0.65% of 
TSP when the N protein was produced in soybean seeds (Vimolmangkang et al., 2012). In contrast to 
previous studies, we managed to produce several PRRSV-derived antigens to levels of 1% of TSP and 
higher, a level considered to be economically relevant (Rybicki, 2009), and extracted these to high 
purity.  Subsequently, the immunogenicity of the plant-produced antigens was assessed in a murine 
model. The GFP:GP4-Tm, GP4-Tm:mFc2a and sGP4-Tm:mFc2a were vaccinated in mice and although 
all antigens generated high titers of antigen-specific antibodies, only those induced by 
GP4-Tm:mFc2a were virus neutralizing. Whereas both GFP and mFc2a served to increase antigen 
accumulation in the seed, the latter also seemed to function as an immune enhancing tag, possibly 
by targeting the antigen to antigen-presenting cells via interaction with Fc receptors (Czajkowsky et 
al., 2012; Ye et al., 2011). Deletion of the N-glycans by amino acid substitution was detrimental for 
antigen immunogenicity, as the sGP4-Tm:mFc2a did not induce virus neutralizing antibodies. The 
ER-associated high-mannose glycans thus seem beneficial for antigen immunogenicity. Indeed, 
mannosylation of antigens has been shown to selectively target antigen presenting cells thereby 
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enhancing antigen immunogenicity (Engering et al., 1997; Tan et al., 1997). In short, GP4-derived 
antigen is capable of eliciting virus neutralizing antibodies in a murine model, confirming the 
immunogenicity of the plant-produced antigens. Upon completion of the murine trial, antigen 
immunogenicity was also preliminary assessed in a porcine model. Three piglets receiving an antigen 
cocktail consisting of purified GP3-Tm:pFc, GP4-Tm:pFc and GP5-Tm:pFc developed high titers of 
antigen-specific antibodies, but only the sera of one piglet recognized the PRRSV in the IPMA and no 
virus neutralizing activity could be detected. In this respect it is interesting to mention the findings of 
Plana-Durán et al. (1997) who observed that pigs having received an inactivated PRRSV vaccine were 
partially protected against reproductive failure even though their sera were unresponsive in IPMA 
before challenge. It has also been shown that some experimental, inactivated PRRSV vaccines confer 
partial protection even without the presence of virus neutralizing antibodies prior to challenge 
(Vanhee et al., 2009). Due to a priming effect these vaccinated piglets generate a faster and stronger 
neutralizing antibody response after challenge. Taken these considerations into account, it becomes 
clear that the antigens need to be further examined via a challenge experiment to study their 
capacity to prime the antibody response, stimulate a cellular response and reduce viremia. This will 
allow a final assessment of the protective capacity of a plant-produced PRRSV vaccine.  
In conclusion, we generated a set of antigenic proteins derived from the PRRSV, incorporating 
elements known to be important in immunity against PRRSV, in A. thaliana seed. The antigens were 
correctly produced in the ER, accumulated to levels that are economically relevant and could be 
purified by single-step affinity chromatography. The immunogenicity of the plant-produced antigens 
was confirmed in a murine model and preliminary tested in a porcine model. It is now time to 
perform a challenge experiment to assess the protective capacity of the plant-produced antigens and 
continue on the road towards a safe and effective PRRSV vaccine.  
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Material and methods 
Ethics Statement 
All animal experiments were approved by the Local Ethical Committee of the Faculty of Veterinary 
Medicine, Ghent University. 
Cloning and generation of transgenic lines 
The original sequences of the GP3, GP4 and GP5 genes were derived from the complete LV-genome 
(GenBank accession number M96262.2) and all the cloned genes described in the following 
paragraphs were deposited at GenBank (accession numbers KF983786 to KF983804). 
All the sequences coding for the antigens containing GP4, GP5 and their truncated counterparts GP4-
Tm, sGP4-Tm, and GP5-Tm were cloned in the seed-specific expression cassette of the gateway 
compatible pPphasGW destination vector (Morandini et al., 2011) containing the β-phaesolin 
promoter, the arcelin-5I terminator and the nptII gene for kanamycin resistance (De Jaeger et al., 
2002). The sequences of the antigens were further complemented at their 5’ end with the Kozak 
motif (CCACC) plus the coding sequence of the ER-targeting signal peptide from the Arabidopsis 2S2 
seed storage protein and at their 3’ end with the coding sequence of the KDEL ER-retention signal. 
The genes of the GP4, GP5 and truncated formats GP3-Tm, GP4-Tm, sGP4-Tm and GP5-Tm were 
chemically synthesized flanked by the gateway recombination sites attB1-B2. Additionally, a 
sequence coding for six histidines (His6-tag) was inserted upstream of the KDEL coding sequence. A 
BP recombination reaction with the pDON221 and LR reaction with the pPhasGW allowed transfer of 
all genes to the destination vector, except those coding for the GP3-Tm and fusions thereof. The 
latter were cloned into a multisite gateway destination vector using the aforementioned regulatory 
elements and complemented with the same sequences encoding the ER-targeting and retention 
signal, resulting in an expression vector bearing the bar gene as resistance marker (all Gateway 
reactions were performed according to the Gateway manual protocol). The codon use of all cloned 
sequences was optimized to resemble that displayed by Arabidopsis seed storage proteins and all 
genes were sequence verified before transfer to the destination vectors. 
Coupling of stabilizing domains to the GP4, GP5 and truncated formats GP3-Tm, GP4-Tm, sGP4-Tm 
and GP5-Tm was done via classical cloning of the corresponding coding sequences. The sequence of 
the porcine IgG3 Fc (accession no: EU372658; pFc) was added to that of the antigens using a Gateway 
compatible pDON221 vector that contained the gene of a camel-like antibody (a fusion between the 
antigen-binding domain of a heavy-chain camel antibody with an Fc fragment of choice) carrying the 
porcine IgG3 Fc (Virdi et al., 2013). The sequence of the antigen binding domain was swapped by 
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restriction digest with the enzymes EcoRI and AvrII and replaced by that of the desired antigen. To 
this goal the sequences of the GP4, GP5, and truncated counterparts, were amplified by polymerase 
chain reaction (PCR) to include the EcoRI and AvrII restriction sites (Table S2 and S3). An LR reaction 
transferred the resulting genes to the pPhasGW.  
A similar strategy was followed to incorporate the sequences of the murine IgG3 Fc (NCBI accession 
no X00915; UniProt accession no P03987; mFc3) and IgG2a Fc (derived from the full-length murine 
IgG2a heavy chain; NCBI accession no AAB59660.1). The sequences of the antigen binding domains of 
camel-like antibodies with murine IgG3 Fc and IgG2a Fc were swapped by restriction digest with 
EcoRI and SacII and substituted by those of selected antigens that had been amplified by PCR (Table 
S2 and S3). In contrast however to the cloning of the porcine IgG3 Fc, the sequence coding for the 
His6-tag was no longer included in the final product. Subsequently, genes were transferred to the 
destination vectors by LR reaction.  
Concerning the GFP fusions, the sequence of the enhanced green fluorescent protein (derived from 
the pFS7(GW)(Karimi et al., 2002)) was extended in silico at its 5’ end with the Kozak and 2S2 
sequence. At its 3’ end the coding sequences of the his6-tag, the GP4-Tm plus KDEL and a BamHI 
restriction site were added. The resulting GFP:GP4-Tm gene was embedded between the attL1-2 
sites and chemically synthesized. By PCR it was extended to form the GFP:GP4 gene (Table S2 and 
S3). The GP4-Tm sequence in the GFP:GP4-Tm gene was swapped by restriction digest with SacII and 
BamHI for an amplicon of the GP3-Tm generating the GFP:GP3-Tm gene (Tabel S1 and S2). LR 
reaction transferred all genes to the destination vectors. 
Heat shock delivered all expression vectors to Agrobacterium strain C58C1RifR containing the pMP90 
virulence plasmid (Koncz & Schell, 1986) and the resulting strains were used to transform Arabidopsis 
thaliana (L.) Heyhn, ecotype Columbia 0, by floral dip (De Buck et al., 2012). Transformed seeds 
containing the T-DNA were identified and lines propagated to homozygosity as detailed in (De Buck 
et al., 2012). In short, T1 seeds obtained after floral dip were grown on selective Murashige and 
Skoog medium for three to four weeks at 21 C° on a 16-h light / 8-h dark cycle. Twenty transformants 
were then transferred to soil and grown under the same conditions. These were selfed and when 
seed setting was complete, transferred to a room at 25 °C and low humidity until completely dry. The 
dry seeds of each transformant were harvested to obtain twenty T2 seed stocks. These stocks were 
screened for the presence of antigen by western blot analysis as detailed below and seven stocks 
with high antigen accumulation were analyzed for the number of integrated T-DNA loci. As the T1 
transformants are per definition hemizygous, the T-DNA locus number can be determined by the 
segregation ratio in the T2 generation. To identify the single locus T-DNA integration lines, seeds of 
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segregating T2 stocks were sown on selective medium and the observed ratio of germinated over 
sensitive seeds was compared to the expected 3:1 segregation ratio for single locus lines using a 
χ2-statistical test (De Buck et al., 2012). For each antigen the T2 stock with the highest antigen 
content and the T-DNA integrated at a single locus in the genome was retained and propagated to 
homozygosity. 
 
Protein extraction, protein concentration determination, SDS-PAGE, Coomassie staining and 
western blot analysis 
To characterize the antigen production in transgenic seed, TSP was extracted as described elsewhere 
(De Buck et al., 2012) with minor modifications: 1 ml of cold extraction buffer (50 mM Phosphate 
buffer, pH 7.8, 0.3 M NaCl, 0.1% (w/v) 3-[(3-Cholamidopropyl)dimethylammonio]-1-
propanesulfonate hydrate (CHAPS) supplemented with an ethylenediaminetetraacetic acid (EDTA) 
free, proteinase inhibitor cocktail (1 tablet per 50 ml; Roche)) was added to 10 mg of liquid nitrogen 
(N2) frozen, crushed seeds. Samples were vortexed for 1 minute and centrifuged at approximately 
20,000 g and 4°C for 30 minutes. 700 µl supernatant was removed, snap-frozen in liquid N2 and 
stored at -20°C. Total protein concentration was determined by the Lowry method as described in 
(De Buck et al., 2012).  
Seed extracts containing TSP were separated by reducing sodium dodecyl sulfate–polyacrylamide gel 
electrophoresis (SDS-PAGE). To visualize proteins by Coomassie staining, the gels were submerged in 
InstantBlueTM (Expedeon) solution for an hour and then washed three times for 20 minutes with 
double distilled water (ddH2O). Stained gels were photographed with the Molecular Imager® 
ChemiDocTM XRS+ Imaging System (Biorad). For western blot analysis the proteins were transferred 
electrophoretically from a polyacrylamide gel onto Immobilon-P polyvinylidene fluoride membrane 
(Millipore, Billerica, MA). Blots were blocked in 4% (w/v) skimmed milk and 0.1% (v/v) Tween 20 in 
phosphate-buffered saline (PBS). Several commercial secondary antibodies coupled to horse radish 
peroxidase (HRP) were used to develop the western blots. Anti-mouse IgG HRP-linked whole 
antibody (from sheep, GE healthcare) was used in combination with the α-GP4 mAb XVI11C and α-
GP5 mAbs II5D, II5A and VII2H at a dilution of 1:5000 in blocking buffer. The α-GP4 mAb XVIII5G and 
α-GP3 mAb VII2D were detected with α-mouse IgG1 (gamma-chain)-HRP (from rabbit, Sigma Aldrich) 
diluted 1:5000 in blocking buffer. As an antibody against the His6-tag, a penta-His HRP conjugate 
(Qiagen) was used diluted 1:2000 in blocking buffer. Western blotting was further performed as 
described in (De Buck et al., 2012) and the released chemiluminescent signal measured with the 
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abovementioned imaging system. Quantification of signal intensities was performed with the Image 
Lab 3.0 software (Biorad). 
 
Glycan analysis 
Seed extracts containing TSP were treated with peptide N-glycosidase F (PNGaseF, New England 
Biolabs) and recombinant endoglycosidase H (endoH, New England Biolabs) to analyze antigen 
glycosylation status. Glycosidase reactions were performed according to the manufacturer’s 
protocol. In short, to 9 µl of extract, 1 µl of 10x denaturing buffer was added and the sample was 
incubated at 100°C for 10 minutes. Then, for the PNGaseF digest, 2 µl G7-buffer, 2 µl 10% NP-40 and 
2 µl PNGaseF was added to the sample whereas for the endoH digest, 2 µl reaction buffer and 1 µl 
endoH was added. Sample volume was adjusted to 20 µl with ddH2O, after which the sample was 
incubated at 37°C for one hour and analyzed by western blotting.  
 
Antigen purification by IMAC 
The GP4-Tm and GFP:GP4-Tm antigens were purified by IMAC on an Äkta Explorer® purification 
system fitted with a His Trap® Fast Flow column (1ml, GE healthcare). Seed extracts were prepared in 
binding buffer (50 mM phosphate buffer pH 7.4, 0.3 M NaCl, 20 mM imidazole, 0.1% CHAPS 
supplemented with an EDTA-free proteinase inhibitor cocktail (1 tablet per 50 ml; Roche)) by adding 
frozen and pulverized seeds to cold buffer at a fixed w/v of 1 g seeds per 70 ml buffer. The extract 
was vortexed and centrifuged for 30 minutes at 4°C and 40,000 g to remove cell debris. The 
supernatant was removed, passed through a GF-prefilter (Sartorius) and a Millex®-HP filter unit 
(Millipore) and then flowed over the IMAC column. After washing the column with binding buffer, 
antigens were eluted with 0.5 M imidazole (in binding buffer). To remove the imidazole, the antigens 
were washed with PBS on Amicon® Ultra centrifugal filters (Millipore, 3kDa molecular weight cutoff). 
Antigen purity was determined by densitometric analysis of Coomassie-stained polyacrylamide gels 
using the aforementioned imaging system and the Image Lab 3.0 software (Biorad). Antigen 
concentration was derived from the sample optical density at 280 nm measured by a NanoDrop® 
ND-1000 spectrophotometer.  
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Antigen purification by protein-A affinity chromatography  
To purify antigens carrying an Fc chain (mFc3, mFc2a or pFc) protein-A affinity chromatography was 
performed as described in (De Buck et al., 2013) with minor modifications. Seed extracts were 
prepared in binding buffer (50 mM phosphate buffer pH 7.4, 0.3 M NaCl, 0.1% CHAPS supplemented 
with an EDTA-free proteinase inhibitor cocktail (1 tablet per 50 ml; Roche)) by adding frozen and 
pulverized seeds to cold buffer at a fixed w/v of 1 g seeds per 70 ml buffer. The extract was vortexed 
and centrifuged for 30 minutes at 4°C and 40,000 g to remove cell debris. The supernatant was 
removed, passed through a GF-prefilter (Sartorius) and a Millex®-HP filter unit (Millipore) and then 
flowed over the protein-A column (MabSelect SuRe 1ml; GE Healthcare) fitted onto Äkta Explorer® 
purification system. After washing the column with binding buffer, antibodies were eluted with 1 M 
arginine buffer (pH 2.7) and immediately neutralized with 1 M TrisHCl (pH 9.0). To remove the 
arginine, the antigens were washed with PBS on Amicon® Ultra centrifugal filters (Millipore, 3kDa 
molecular weight cutoff). Antibody concentration was derived from the sample optical density at 
280 nm measured by a NanoDrop® ND-1000 spectrophotometer. 
 
Antigen purification by gel filtration 
After an initial chromatography step, antigens to be used in ELISA and in the vaccination trials were 
further subjected to gel filtration to remove remaining impurities. To this goal, IMAC or protein-A 
elution fractions were passed over a Superdex-200 column (GE Healthcare) fitted onto an Äkta 
Explorer® purification system with lipopolysaccharide-free PBS as the mobile phase. Removal of 
impurities and/or degradation products was assayed by Coomassie staining of polyacrylamide gels 
and whenever necessary, pure, gel-filtrated antigen was concentrated using Amicon® Ultra 
centrifugal filters (Millipore, 3kDa molecular weight cutoff). The antigen concentration was derived 
from the sample optical density at 280 nm measured by a NanoDrop® ND-1000 spectrophotometer. 
 
ELISA to determine antigen accumulation in the seed 
The antigen content of the seed of high accumulating lines was analyzed by ELISA. Seed extracts 
were prepared as detailed above, dilution series were made in duplicate with PBS as coating buffer, 
loaded onto Maxisorp 96-well plates (Nunc, Sigma Aldrich) and coated overnight at 4°C. Wells were 
washed three times with 270 µl washing buffer (PBS, 0.1% (v/v) Tween-20) and this was repeated 
between all subsequent steps. Remaining protein-free binding sites were blocked with 270 µl 
blocking buffer (PBS, 1% (w/v) bovine serum albumin (BSA, Sigma Aldrich), 0.1% (v/v) Tween-20) for 
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60 minutes at room temperature. 100 µl primary antibody solution was added and plates incubated 
for 60 minutes at room temperature. Secondary antibody solution was added (100 µl) and plates 
again incubated for 60 minutes at room temperature. Plates were then washed five times with 
washing buffer and 100 µl 3, 3’, 5, 5’-Tetramethylbenzidine Liquid Substrate (TMB, Sigma Aldrich) 
was added. After 10 minutes, color development was terminated by addition of 100 µl 1 M HCl and 
plates were read at 450 nm in a VERSAmax tunable microplate reader. Standard curves were derived 
from duplicate two-fold serial dilutions of purified antigen, measured values were plotted against 
standard curves and antigen content of the seed calculated after correcting for antigen molecular 
weight. For analysis of the GP3-Tm fusion antigens, the mAb α-GP3 VII2D was used (diluted 25:1000 
in blocking buffer) as primary antibody together with α-mouse IgG1 (gamma-chain)-HRP (from rabbit, 
Sigma Aldrich), diluted 1:5000 in blocking buffer, as the secondary antibody and protein-A purified 
GP3-Tm:pFc as standard. The GP4, GP4-Tm and sGP4-Tm containing antigens were analyzed with the 
α-GP4 mAb XVIII5G (diluted 25:1000 in blocking buffer) as primary antibody, the α-mouse IgG1 
(gamma-chain)-HRP (from rabbit, Sigma Aldrich), diluted 1:5000 in blocking buffer, as the secondary 
antibody and protein-A purified GP4-Tm:pFc as standard. For all antigens carrying GP5 or GP5-Tm, a 
murine anti His6-tag (Serotec) primary antibody was used (diluted 1:1000 in blocking buffer), 
together with an α-mouse IgG HRP-linked whole antibody (from sheep, GE healthcare) as secondary 
antibody (diluted 1:5000) and protein-A purified GP5-Tm:pFc as standard. 
 
Immunization of mice 
Six- to eight-week-old female C57BL/6 mice were obtained from Janvier (Belgium). Mice were 
housed under specific pathogen-free conditions. All animal experiments were approved by the Local 
Ethical Committee of Ghent University. Mice were vaccinated twice with a 3-week interval by 
subcutaneous injection with either 5 µg purified GFP:GP4-Tm, GP4-Tm:mFc2a or sGP4-Tm:mFc2a 
mixed in a 1:1 ratio with the squalene-based oil-in-water adjuvant AddaVax (Invivogen). The antigens 
were isolated and purified from crude seed extracts by IMAC (GFP:GP4-Tm) or protein-A affinity 
chromatography (sGP4-Tm:mFc2a and GP4-Tm:mFc2a), followed by a gel filtration step as described 
before. During the trial, blood samples were collected at week zero (preimmune), two, four and six 
post immunization. Serum samples for IPMA and detection of virus neutralizing antibodies were 
incubated 30 minutes at 56 °C prior to freezing. Mice were euthanized after the final bleeding at 
week six.  
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Characterization of the antibody response in mice 
For detection of the α-GP4 antibodies, ELISA was performed on serum samples with purified GP4-
Tm:pFc as antigen. Maxisorp 96-well plates (Nunc, Sigma Aldrich) were coated overnight at 4°C with 
1 µg antigen per well (in 100 µl PBS). Wells were washed three times with 270 µl washing buffer 
(PBS, 0.1% v/v Tween-20) and this step was repeated between all following steps unless stated 
differently. Wells were blocked with 270 µl blocking buffer (PBS, 0.1% Tween-20, 1% BSA) for two 
hours at room temperature. 100 µl of four-fold serial dilutions (diluted in blocking buffer with an 
initial dilution of 1:50) of sera were added and plates incubated for 90 minutes at room temperature. 
Subsequently 100 µl of goat anti-mouse IgG-HRP (Southern Biotech) diluted 1:10.000 in blocking 
buffer was added and plates incubated 90 minutes at room temperature. Wells were washed five 
times with 270 µl blocking buffer and 100 µl TMB (Sigma Aldrich) was added. After 10 minutes color 
development was terminated by addition of 100 µl 1M HCl and plates were read at 450 nm in a 
VERSAmax tunable microplate reader.  
To determine if the antibodies elicited by vaccination were able to recognize the PRRSV, the 
collected sera were tested via an IPMA as described elsewhere (Labarque et al., 2000). Virus 
neutralizing antibody titers were detected by a single-replication virus-neutralization test as 
described in (Vanhee et al., 2009) with minor modifications. Two-fold serial dilutions of sera (starting 
from a 1:10 dilution) were mixed with equal volumes of porcine alveolar macrophage-grown LV 
resulting in a final titer of 105 TCID50/ml. Virus-sera mixtures were incubated for one hour at 37°C and 
transferred to a 96-well plate (50 µl/well) with Marc-145 cells that were cultivated 48 hours prior to 
use. The inoculum was removed after one hour and replaced by medium, after which the cells were 
incubated for another 11 hours, fixed by drying and stored at -20°C. The cells were stained for PRRSV 
infection with mAb 13E2 (Van Breedam et al., 2011) against the nucleocapsid protein of PRRSV and 
peroxidase conjugated goat α-mouse polyclonal antibodies (Dako), followed by development with 3-
amino-9-ethylcarbazole. The number of infected cells in each well was counted in three fields at 200× 
magnification, and expressed relative (%) to the mean number of infected cells for all mock 
conditions within the same experiment. 
 
Immunization of piglets 
Three piglets four weeks of age were purchased from a PRRSV-negative farm, their 
PRRSV-seronegative status was confirmed by IPMA (Labarque et al., 2000) upon arrival and animals 
were housed in isolation units with HEPA-filtered air. Heat lamps were provided during the first few 
weeks and piglets were fed grains sprinkled with milk powder and had access to water ad libitum. 
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The animal experiment was approved by the local ethical committee of the Faculty of Veterinary 
Medicine, Ghent University. The three piglets were injected twice in the neck muscles behind the ear 
(intramuscular) with an experimental vaccine following a prime – boost protocol. The vaccine 
consisted of an antigen cocktail containing 100 µg purified GP3-Tm:pFc, 100 µg purified GP4-Tm:pFc 
and 100 µg purified GP5-Tm:pFc (300 µg antigen in total) mixed with an oil-in-water adjuvant in a 1:1 
ratio (Suvaxyn, Fort Dodge Animal Health). The antigens were isolated and purified from crude seed 
extracts by protein-A affinity chromatography followed by a gel filtration step as described before. 
The booster vaccination was administered at week four and blood samples (5 ml taken from the 
jugular vein with disposable syringes) were collected at a weekly basis from week zero (preimmune) 
onward. Serum samples for IPMA and detection of virus neutralizing antibodies were incubated 30 
minutes at 56 °C prior to freezing. Piglets were euthanized at the end of the experiment by slow 
injection of an overdose (15 ml) of a central nervous system depressant (Natrium Pentobarbital 20%) 
in the jugular vein. 
 
Characterization of the antibody response in piglets 
Different ELISA protocols were used to measure the α-GP3, α-GP4 and α-GP5 antibodies in the piglet 
sera. To detect the α-GP3 and α-GP4 antibodies, purified GP3-Tm:mFc2a or GP4-Tm:mFc2a was used 
as antigen respectively. ELISA was further performed as described above except that 100 µl of 
polyclonal α-porcine IgG-HRP diluted 1:40.000 in blocking buffer was added to the wells to detect the 
α-GP3 or α-GP4 antibodies. To measure α-GP5 antibodies, the wells were coated with a seed extract 
containing the GP5-Tm. To this goal one gram of homozygous GP5-Tm seed stock was extracted with 
10 ml of PBS, the extract diluted 1:100 in PBS and 100 µl containing 0.3 µg GP5-Tm added to the 
wells. Plates were incubated overnight at 4°C and protocol was followed as described for the α-GP3 
and α-GP4 antibodies. To determine if the antibodies elicited by vaccination were able to recognize 
the PRRSV, the collected sera were tested via an IPMA as described elsewhere (Labarque et al., 
2000). Virus neutralizing antibody titers were detected by a single-replication virus-neutralization 
test as described above. 
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Supplemental information 
 
Supplemental figure S1. T2-analysis and inter-transformant variation in accumulation level of the GP3 
derived antigens. For each antigen, 20 transformed T2 seed stocks were analyzed by western blot to 
determine their antigen content, except for the GP3(-Tm):mFc2a, for which only 17 T2 seed stocks were 
screened. After visual inspection of the western blots, seven stocks were selected, analyzed for single 
locus T-DNA integration and the stock with the highest antigen content and the T-DNA integrated at a 
single locus was retained, selfed and further propagated. A hollow arrow (and their corresponding 
number) marks the propagated stocks. Seed extracts were prepared at a fixed w/v ratio, subjected to 
western blotting and analyzed with (A) α-pig IgG-HRP to detect the GP3(-Tm):pFc, (B) an α-mouse IgG-HRP 
conjugate to visualize the GP3(-Tm):mFc2a and (C) an antibody against the His-tag to probe for the 
GFP:GP3(-Tm). 10 µl was loaded and gels were run under reducing conditions. The postion of the antigens 
on the blots is indicated with a black arrow. Abbreviations used: kDa, kilodalton; wt, wild-type seed 
extract. 
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Supplemental figure S2. T2-analysis 
and inter-transformant variation in 
accumulation level of the GP4 
derived antigens. The GP4(-Tm) and 
GP4 transgenic lines were 
propagated to homozygousity by Dr. 
A. De Paepe and provided as such. 
Information on inter-transformant 
variation was not at hand for these 
lines. For each of the other antigens, 
20 transformed T2 seed stocks were 
analyzed by western blot to 
determine their antigen content, 
except for the sGP4(-Tm):pFc, for 
which only 17 T2 seed stocks were 
screened and the GFP:GP4 that was 
screened by ELISA (data not shown). 
After visual inspection of the 
western blots, seven stocks were 
selected, analyzed for single locus 
T-DNA integration and the stock 
with the highest antigen content 
and the T-DNA integrated at a single 
locus was retained, selfed and 
further propagated. A hollow arrow 
(and their corresponding number) 
marks the propagated stocks. Seed 
extracts were prepared at a fixed 
w/v ratio, 10 µl was loaded onto the 
gels that were run under reducing 
conditions. The seven GP4(-Tm):pFc 
(A) and GP4:pFc stocks (B) selected 
for single locus determination and 
detected with the α-GP4 mAb XVI 
11C (Costers et al., 2010). (C) The 
twenty screened GP4(-Tm):mFc2a 
stocks visualized with α-mouse 
IgG-HRP. (D) The twenty screened 
GP4(-Tm):mFc3 stocks assayed with 
goat α-mouse IgG3-HRP. (E) Twenty 
screened GFP:GP4(-Tm) stocks 
probed with an antibody against the 
His6-tag. (F) The seven sGP4(-Tm) 
stocks selected for single locus determination and detected with the α-GP4 mAb XVI 11C (Costers et al., 
2010). (G) Twenty screened sGP4(-Tm):pFc stocks probed with an antibody against the His6-tag. (H) 
Twenty screened sGP4(-Tm):mFc2a stocks visualized with goat α-mouse IgG-HRP. Abbreviations used; 
kDa, kilodaltion; wt, wild-type seed extract. 
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Supplemental figure S3. T2-analysis and inter-transformant variation in accumulation level of the GP5 
derived antigens. The GP5(-Tm) and GP5 transgenic lines were propagated to homozygousity by Dr. A. De 
Paepe and provided as such. Information on inter-transformant variation was not at hand for these lines. 
For the GP5:pFc and GP5(-Tm):pFc twenty transformed T2 seed stocks were analyzed by western blot to 
determine their antigen content. After visual inspection of the western blots, seven stocks were selected, 
analyzed for single locus T-DNA integration and the stock with the highest antigen content and the T-DNA 
integrated at a single locus was retained, selfed and further propagated. A hollow arrow (and their 
corresponding number) marks the propagated stocks. Seed extracts were prepared at a fixed w/v ratio, 10 
µl was loaded onto the gels that were run under reducing conditions and detected with an antibody 
against the His6-tag. (A) The twenty screened GP5(-Tm):pFc stocks. (B) The seven GP5:pFc stocks selected 
for single locus determination.  
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Supplemental table 1. Antigen accumulation level 
Antigen Line mg/g DS( +/- SD) % of TSP 
GP3-Tm:pFc  Ho 5-1-9 2.905  +/- 0.289 0.96  +/- 0.09 
GP3-Tm:mFc2a  Ho 1-1-8 6.185  +/- 2.235 1.81  +/- 0.36 
GFP:GP3-Tm  Ho 5-3-2 7.858  +/- 0.404 2.74  +/- 0.16 
GP4  Ho 5/1-5 0.245  +/- 0.033 0.08  +/- 0.01 
GP4:pFc  Ho 1-5-3 0.485  +/- 0.048 0.14  +/- 0.01 
GFP:GP4 Se 1-2 0.467  +/- 0.038 0.15  +/- 0.02 
GP4-Tm Ho 5/3-4-1 0.170  +/- 0.015 0.05  +/- 0.01 
GP4-Tm:mFc3  Ho 3-5-13 0.151  +/- 0.019 0.05  +/- 0.01 
GP4-Tm:pFc  Ho 3-1-4 2.064  +/- 0.086 0.67  +/- 0.04 
GP4-Tm:mFc2a  Ho 3-1-4 5.153  +/- 0.276 1.59  +/- 0.11 
GFP:GP4-Tm  Ho 5-4-5 7.377  +/- 0.334 2.36  +/- 0.30  
sGP4-Tm Se 3-6 0.019  +/- 0.003 0.005  +/- 0.001 
sGP4-Tm:pFc  Se 4-15 0.183  +/- 0.014 0.06  +/- 0.002 
sGP4-Tm:mFc2a Ho 2-3-1-1 0.133  +/- 0.011 0.04  +/- 0.01 
GP5  Ho 3/2-5-1 0.273  +/- -   0.10  +/- - 
GP5:pFc  Ho 5-1-3-2 0.015  +/- - 0.01  +/- - 
GP5-Tm Ho 4/9-E-7 0.258  +/- 0.059 0.09  +/- 0.005 
GP5-Tm:pFc  Se 1-15 2.333  +/- 0.077 0.83  +/- 0.022 
 
    
Table S1. For each antigen given values are the mean of three biochemical repeats. Abbreviations used: 
Ho, homozygous seed stock; Se, segregating seed stock; DS, dry seed; SD, standard deviation; TSP, total 
soluble protein. Numbers in italic are derived from signal quantification after western blotting via the 
His6-tag, since the GP5 and GP5:pFc antigen could not be detected by ELISA. 
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Supplemental table 2. Extension PCR data 
Primer T ann 
Project Target of amplification PCR reaction Forward Reverse 5x 20x 
Cloning GP3(-Tm):pFc GP3(-Tm) 1 ropir1 ropir12 65 72 
2 ropir1 ropir4 64 69 
3 ropir1 ropir5 61 72 
Cloning GP4(-Tm):pFc GP4(-Tm) 1 ropir9 ropir10 58 62 
2 ropir1 ropir4 62 69 
3 ropir1 ropir5 60 69 
Cloning sGP4(-Tm):pFc sGP4(-Tm) 1 ropir1 ropir2 54 71 
2 ropir1 ropir5 60 69 
Cloning GP4:pFc GP4 1 ropir9 ropir10 58 62 
2 ropir1 ropir4 62 69 
3 ropir1 ropir5 60 69 
Cloning GP5(-Tm):pFc GP5(-Tm) 1 ropir9 ropir10 58 62 
2 ropir1 ropir4 62 69 
3 ropir1 ropir5 60 69 
Cloning GP5:pFc GP5 1 ropir9 ropir10 58 62 
2 ropir1 ropir4 62 69 
3 ropir1 ropir5 60 69 
Cloning GP4(-Tm):mFc3 GP4(-Tm) 1 ropir1 mFc3R3 52 70 
Cloning  GP3(-Tm):mFc2a GP3(-Tm) 1 ropir9 mFc2aR2 54 63 
Cloning GP4(-Tm):mFc2a GP4(-Tm) 1 ropir1 mFc3R3 52 70 
Cloning sGP4(-Tm):mFc2a sGP4(-Tm) 1 ropir9 mFc3R3 52 63 
Cloning GFP:GP4(-Tm) GFP:GP4(-Tm) 1 ropir1 JaR5 53 69 
2 ropir1 JaR6 65 69 
Cloning GFP:GP3(-Tm) GP3(-Tm) 1 JaF7 JaR8 58 71 
 
Table S2. (Multistep) extension PCR data. Are given, the cloning project involved, the target of amplification, the forward and reverse primer used in each reaction, the number of 
consecutive extension PCRs performed for each project and the annealing temperature of the first five and last twenty cycles. The Phusion® High-Fidelity DNA Polymerase (Finnzymes) 
was used for all reactions according to the manufacturer’s guidelines. Abbreviations used; T ann, annealing temperature. 
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Supplemental table 3. Primer sequences 
 
Primer name 
 
Sequence (5' to 3') 
 
ropir1 CCGGAATTCCGGCCACCATGGCAAACAAGCTTTTCCT 
ropir2 AGATGGGTGTGGGGGGTTCGATGTCGCTTCCTCTTGGAACGAGGTGATGGTGATGGTGGTG 
ropir4 AGCAAATTTCGGGACAGATGGGTGTGGGGGGTTCGATGTCGCTTCCTCTTGGAACGAGGTGATGG 
ropir5 TACGCCTAGGACCTCTGCAGCTGGGCATGAGCAAATTTCGGGACAGATGGGTGT 
ropir9 TGAATTCCCACCATGGCAAACAAGCTTTTCCT 
ropir10 GCTTCCTCTTGGAACGAGGTGATGGTGATGGTGGTGGCTTGGTGTAAGGA 
ropir12 GCTTCCTCTTGGAACGAGGTGATGGTGATGGTGGTGTTCCAAGTGGAACC 
mFc2aR2 TGGACCCCGCGGTTCCAAGTGGAACCAGTTGCC 
mFc3R3 GTATCCGCGGGCTTGGTGTAAGGAAGTGGA 
JaF7 ATCACTCCGCGGACGAAGTTGATTCAAACTCCAGCTCTACGCTATGCTTT 
JaR5 TGGCGAACAAGCAAGCAATGGTTGTAGCCCACCTCATTGCGCTTGGTGTAAGGAAGTGGA 
JaR6 GGTGGATCCTTAAAGCTCGTCTTTGATTGCCAAGAGAATGGCGAACAAGCAAGCAATG 
JaR8 GGGTGGATCCTCAAAGCTCGTCTTTTTCCAAGTGGAACCAGTTGCCACCG 
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Glycosylation 
Protein glycosylation, or the covalent linkage of an oligosaccharide side chain to the amino acid 
backbone of a protein, represents the most widespread PTM.  One third of all therapeutic proteins 
approved for human use are glycosylated and it is estimated that this also holds true for 50 % of all 
human proteins (Campbell & Yarema, 2005; Saint-Jore-Dupas et al., 2007; Walsh & Jefferis, 2006). 
Glycosylation profoundly influences several critical characteristics of a protein such as solubility, 
stability, susceptibility to proteases, serum half-life, function and activity (Jacobs & Callewaert, 2009; 
Nagels et al., 2012b). Glycosylation is of such importance that the platform used for therapeutic 
protein production is often chosen based on its capacity to decorate the therapeutic with those 
glycans that are required for its optimal performance (Saint-Jore-Dupas et al., 2007). This is the main 
reason why mammalian cells are preferred over organisms such as yeasts for the production of 
therapeutic proteins. Indeed, the glycosylation performed by mammalian cells is very similar (but not 
identical) to that of humans (Jacobs & Callewaert, 2009). 
There are, however, several drawbacks associated with protein production in mammalian cells. A 
glycoprotein that enters the ER will be decorated with a defined glycan structure at specific sites. 
Once folded, the glycoprotein will pass through the secretory pathway were the attached glycan 
structures will be modified by the sequential action of an array of glycosidases and 
glycosyltransferases. Differences in accessibility of the glycans on the protein combined with the 
non-template driven nature of the glycosylation machinery introduce a large heterogeneity in the 
final glycan structures. One glycoprotein will thus exists as several ‘glycoforms’, sharing the same 
protein backbone but decorated with different glycans (Jacobs & Callewaert, 2009). This 
heterogeneity is highly undesirable from both a practical as a regulatory point of view. Different 
glycoforms will show differential behavior during downstream processing and in vivo. This requires 
that each glycoform is extensively characterized, which complicates therapeutic protein production.  
Cultivation of mammalian cells is a costly process, expensive high-tech equipment is needed and the 
cultivation process needs to be closely monitored to guarantee batch-to-batch reproducibility (Saint-
Jore-Dupas et al., 2007). Moreover, mammalian cells are prone to contamination with pathogens 
such as viruses and prions and glycan heterogeneity is rather high (Bosch et al., 2013; Bosch & 
Schots, 2010). To avoid these drawbacks, alternative production platforms are being investigated 
such as, for example, plants. An advantage about plants in the context of therapeutic glycoprotein 
production is that they are not susceptible to mammalian pathogens, production is scalable and 
possibly cheap and last but not least, plant glycans are more homogeneous than mammalian glycans, 
with all the associated benefits (Faye et al., 2005; Gomord & Faye, 2004). Also, plants seem to be 
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quite tolerant to alterations of their N-glycosylation machinery (Bosch et al., 2013). This sparked the 
production of therapeutic proteins in several plant species and tissues, ranging from plant cell 
cultures to entire plants and this via stable and/or transient expression, which has been covered in 
more detail in the section ‘Transgenic plants as biofactories’. 
 
Plant N-glycosylation 
Proteins can be glycosylated by attachment of a glycan structure to an asparagine residue in the 
consensus sequence Asn-X-Ser/Thr, with “X” being any amino acid except for proline, and this is 
referred to as N-glycosylation. Additionally, glycans can be transferred to the hydroxyl groups of 
serine, threonine and for plants, also hydroxyproline. This type of glycosylation, termed 
O-glycosylation, will not be detailed here but is extensively reviewed by Gomord et al. (2010). In 
many aspects, plant O- and N-glycosylation are alike; both have a profound influence on the 
biochemical characteristics and biological function of proteins, they are considered to be different 
between humans and plants and they can be immunogenic. As O-glycosylation is not within the 
scope of the later presented work, we will here focus on N-glycosylation in plants and contrast this 
with the N-glycans found on human proteins.  
The entire N-glycosylation machinery is located in the secretory pathway (Figure 1) and starts with 
the co-translational addition of the oligosaccharide precursor Glc3Man9GlcNAc2 onto the nascent 
protein at N-x-S/T attachment sites. Once transferred to the glycoprotein, the precursor recruits 
chaperones and oxidoreductases that aid the glycoprotein to reach its correct fold (Pearse & Hebert, 
2010). During this process, the quality control mechanism in the ER trims the precursor down to 
Man8GlcNAc2 (Figure 1, glycan 1) on correctly folded glycoproteins and these are subsequently 
released to continue towards the Golgi apparatus (Pearse & Hebert, 2010).  These initial steps are 
shared between all higher eukaryots; it is only after transit through the Golgi that species-specific 
N-glycans arise and these are known as ‘complex N-glycans’. When a glycoprotein reaches the 
cis-Golgi the mannose residues on its glycans are further trimmed and an N-acetylglucosamine 
residue (GlcNAc) is added to each branch. The resulting GlcNAc2Man3GlcNAc2 (Figure 1, glycan 5) is 
basically the branching point from where plant and human N-glycosylation differ (Bosch et al., 2013).  
In plants, further passage through the medial and trans-Golgi adds a bisecting β1,2-xylose to the core 
mannose and an α1,3-fucose to the innermost GlcNAc, respectively (Figure 1). These modifications 
(one or both) are omnipresent on complex plant N-glycans, but are absent in humans and are 
potentially problematic (see later). Most recombinant glycoproteins that are produced in plants will 
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thus predominantly carry GnGnXF N-glycans4 (Figure 1, glycan 7; (Bosch et al., 2013)). Nonetheless, 
two additional modifications can be found on secretory glycoproteins. Proteins that are targeted to 
the vacuole tend to carry MMXF glycans (Figure 1, glycan 10) and it is believed that they are the 
product of vacuolar hexosaminidases that trim off terminal GlcNAc residues (Liebminger et al., 2011). 
The resulting glycan structures are known as ‘paucimannosidic N-glycans’ and are considered to be a 
hallmark of proteins with a vacuolar localization. These paucimannosidic N-glycans are also present 
on some secreted glycoproteins and recently, a hexosaminidase associated with the plasma 
membrane was discovered (Liebminger et al., 2011). Alternatively, although this generally occurs at 
very low level on recombinant glycoproteins, the terminal GlcNAc residues of some secretory 
proteins are further extended with both an α1,4-fucose and a β1,3-galactose (Fitchette-Laine et al., 
1997). This structure, known as the ‘Lewis A epitope’ (Figure 1, glycan 9) can also be found on some 
human glycans (Sourrouille et al., 2008). 
In humans, integration of additional GlcNAc residues in the Golgi can lead to further branching such 
that the final complex N-glycan can be anywhere from bi- to tetra-antennary (Figure 2B). Another 
major difference is that terminal GlcNAc residues can be further extended with galactose moieties 
which are then capped with a sialic acid. Besides sialic acid, also a terminal ‘Lewis X epitope’ is 
sometimes present. Substituting the plant β1,2-xylose, a bisecting β1,4-GlcNAc can be found 
attached to the core mannose instead, and the innermost GlcNAc often carries a fucose in an α1,6 
linkage as opposed to the α1,3-fucose encountered in plants. 
To summarize, plants are capable of producing glycoproteins decorated with complex, bi-antennary 
N-glycans that are mainly GlcNAc-terminated and rather homogeneous when compared to their 
mammalian counterparts (compare Figure 2A and 2B). However, these glycans carry plant specific 
fucose and xylose residues and lack some typical mammalian residues. Furthermore, these 
characteristics seem to be conserved across the plant-kingdom (Bosch & Schots, 2010; Nagels et al., 
2011a).  
 
 
                                                            
4
 Bi-antennary plant N-glycans are abbreviated in the tekst using the nomenclature proposed on 
www.proglycan.org  
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Figure 1. The plant N-glycosylation pathway. Figure taken from Bosch et al. (2013). A correctly folded 
glycoprotein will exit the ER carrying Man8GlcNAc2 glycans (1) and these are subsequently modified by the 
sequential action of glycosidases and glycosyltransferases located in the different compartments of the 
secretory pathway. Paucimannosidic glycans are a hallmark of vacuolar proteins but can also be found in 
minor quantities on secreted proteins. Hexosaminidase processing is a likely mechanism for their 
formation. Abbreviations used: ER, endoplasmic reticulum; ERV, ER-derived vesicle; PSV, protein storage 
vacuole; Apo, apoplast; GMI, Golgi-α-mannosidase I; GntI and II, N-acetylglucosaminyltransferase I and II 
respectively; GMII, Golgi-α-mannosidase II; XylT; β1,2-xylosyltransferase; α1,3-FucT, core 
α1,3-fucosyltransferase; β1,3-GalT, β1,3-galactosyltransferase; α1,4-FucT, α1,4-fucosyltransferase; HEXO1 
and HEXO3, β-N-acetylhexosaminidase 1 and 3 respectively.  All glycan structures are depicted according 
to the recommendations of the international consortium of functional glycomics5. 
                                                             
5
 www.functionalglycomics.org 
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Figure 2. Overview of the difference between plant and human complex N-glycans. (A) Typical glycan 
structures found on therapeutic proteins produced in plants. Fucose and/or xylose bearing complex 
glycans with one or two terminal GlcNAcs (1) are the predominant structures present on secretory 
recombinant proteins expressed in planta. Paucimannosidic structures with fucose and/or xylose but 
lacking terminal GlcNAcs (2) are sometimes also found, together with small quantities of high-mannose 
glycans that can have from five to eight mannoses but never carry fucose and xylose (3). (B) Typical glycan 
structures found on human secretory proteins. Anywhere from two (5) to four antennae (4) can be 
present on a human glycans and these tend to carry terminal sialic acids. An exception are the glycans of 
human IgG Fc domains that are predominantly biantennary with terminal galactoses (6) and only a minor 
fraction of these glycans is further extended with sialic acid (5). Fucose is always attached through an 
α1,6-linkage to the proximal GlcNAc and instead of β1,2-xylose, a bisecting GlcNAc can be present on 
bi-antennary, but not tri- or tretra-antennary structures. All glycan structures are depicted according to 
the recommendations of the international consortium of functional glycomics.  
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Immunogenicity of plant N-glycans 
Plant N-glycosylation in the context of therapeutic protein production is a controversial topic, mainly 
because of the two sugar residues, β1,2-xylose and α1,3-fucose, that are ubiquitously present on 
complex plant N-glycans, but are absent in human glycans and thus can be immunogenic (Figure 2). 
There are several observations to support their immunogenicity, namely that vaccination of lab 
animals with plant glycoproteins raises antibodies specific for these glycans and that a whole range 
of plant-glycan specific antibodies, covering almost all immunoglobulin isotypes, can be found in the 
blood of humans. These observations are further detailed in the following paragraphs.  
Firstly, immunization with proteins decorated with complex plant N-glycans consistently generates 
antibodies specific for both β1,2-xylose and α1,3-fucose in goats, rabbits and rats, but not mice who, 
depending on their genetic background (e.g. BALBc mice), do not seem to respond against these 
residues (Bardor et al., 2003; Chargelegue et al., 2000; Jin et al., 2008a; Kurosaka et al., 1991). 
Secondly, anti α1,3-fucose and β1,2-xylose IgG and IgM antibodies are present in the blood of 25 and 
50% of non-allergic human blood donors respectively (Bardor et al., 2003). Thirdly, β1,2-xylose and 
α1,3-fucose constitute carbohydrate epitopes that can be recognized by IgE antibodies and both are 
present on a wide range of allergens, hence they are termed ‘cross-reactive carbohydrate 
determinants’ (CCDs; (Aalberse & van Ree, 1996)) .  
Apparently, IgE antibodies specific for plant N-glycans are quite widespread with a high prevalence 
among the pollen-allergic and it is believed that they arise in response to insect stings and/or 
exposure to pollen (van Ree, 2002). More than 20% of persons with an allergic respiratory disease 
were shown to carry plant-specific CCD-IgE antibodies and this number rose to about 70% for 
persons with multiple pollen allergies (Mari, 2002). Strikingly, plant-specific CCD-IgE could also be 
found in 5% of the non-allergic persons. CCD-IgE could potentially be very dangerous as cross-linking 
of receptors by IgE molecules on effector cells such as mast cells causes mediator release that can 
result in an allergic reaction. It should be noted however that presence of an IgE showing biological 
activity (mediator release) does not necessarily translate into a severe allergic reaction and this 
apparent contradiction is reflected in the ongoing debate about the clinical relevance (role in causing 
allergic symptoms) of these plant-specific CCD-IgE antibodies (van Ree, 2002). 
Plant-specific CCD-IgE antibodies from the sera of allergic persons are capable of causing histamine 
release from basinophils in vitro and although this is only true for a subset of the tested sera, this has 
been regarded as evidence of their biological activity in vivo (Bublin et al., 2003; Foetisch et al., 
2003).  However, an argument against the clinical relevance of CCD-specific IgE is that topical 
application of plant glycoproteins carrying complex N-glycans is generally well tolerated, even in the 
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allergic (Ma et al., 1998; Mari et al., 2008; Zeitlin et al., 1998). For example, when allergic patients 
were screened for reactivity against a rice-produced human lactoferrin carrying complex plant 
N-glycans, poor or no biological activity of the lactoferrin-binding IgE antibodies was found. Although 
almost all the sera with plant-specific CCD-IgE antibodies could bind to the recombinant lactoferrin, 
only half of the sera tested in vitro were found to be biologically active releasing histamine and when 
compared to a major grass pollen allergen, the concentrations required for biological activity were 5 
to 6 orders of magnitude higher. Eventually patients that tested positive for biological activity in vitro 
were also submitted to a skin prick test and an oral challenge with the lactoferrin, but without any 
adverse reactions. This led the authors to conclude that the plant-specific CCD-IgE antibodies had 
poor or no biological activity and lacked any clinical relevance whatsoever (Mari et al., 2008).  
Several explanations can be given for this apparent lack of clinical relevance. A prerequisite for 
biological activity of the IgE is that it binds with sufficient affinity to its target and that this is at least 
bivalent so that crosslinking occurs on the surface of the effector cell and mediator is released 
(Altmann, 2007; Foetisch et al., 2003). However, it was recently reported that human IgE and IgG 
specific for plant-CCDs have high affinities for their carbohydrate epitopes, debasing this affinity 
argument (Jin et al., 2008b). This led Altmann (2007) to doubt the CCD-valency of the recombinant 
lactoferrin used during the study performed by Mari et al. (2008). Nevertheless detailed glycan 
analysis showed that two out of three N-glycan sites were occupied with MMXF and MUXF, 
representing 83 % of the total glycan pool of which no less than 93 % carried xylose or fucose 
(Fujiyama et al., 2004). Also, only about 21 % of patients carrying plant-specific CCD-IgE tested 
positive in a skin-prick test when horse radish peroxidase was applied and these generally presented 
very mild symptoms (Mari, 2002). Horse radish peroxidase carries six identical MMXF N-glycans 
(Kurosaka et al., 1991). Given these results it seems reasonable to discard valency as an explanation 
for low plant-glycan CCD-IgE activity. What is more probable is that an initial insect sting and/or 
pollen exposure generates CCD-IgE, but humans are desensitized by the continuous contact with and 
ingestion of plant proteins decorated with CCDs. In this respect, the high prevalence of plant-glycan 
specific IgG and IgM in the blood of humans (Bardor et al., 2003) offers a plausible explanation for 
this desensitization. The low titers of plant-glycan specific IgG and IgM, present in the blood because 
of continuous exposure to plant glycoproteins, could compete for binding to complex plant glycans. 
This would block interaction of CCD-IgE with its target thus reducing its biological activity and 
concomitantly, its clinical relevance (Altmann, 2007). 
To summarize, plant-specific CCD-IgE is quite widespread in the human population but seems of little 
clinical relevance for the topical or oral application of a PMP carrying complex N-glycans. 
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Nonetheless, this picture changes when parenteral delivery of a PMP is envisaged, especially when 
considering a therapeutic protein that needs to be administered repeatedly. One could argue that 
many if not all persons with plant-specific CCD-IgE also have plant-specific CCD-IgG in their blood 
stream that block the biological activity of the CCD-IgE and that plant-CCDs are thus rather 
innocuous. However a recent incident serves to remind us that one should not thread lightly with 
respect to CCDs. Severe hypersensitivity reactions were reported for cetuximab, a recombinant 
monoclonal antibody approved for cancer therapy and delivered via the parenteral route. Most 
subjects who had a hypersensitivity reaction were shown to have CCD-IgE antibodies capable of 
binding to cetuximab in their serum before therapy. These antibodies were specific for 
galactose-α1,3-galactose, a CCD that is present on glycoproteins from most non-primate mammals 
and was introduced on cetuximab as an artefact of its production in the mouse myeloma cell line 
SP2/0 (Chung et al., 2008). 
The previous discussion clarifies that, in the context of therapeutic protein production for parenteral 
delivery, plant-specific sugar residues should be avoided whenever possible. The widespread 
presence of antibodies specific for plant glycans in the serum of patients might result in an 
accelerated clearance of the therapeutic and, in a worst-case scenario, might provoke a severe 
hypersensitivity reaction.  
 
‘Humanizing’ the plant N-glycosylation pathway 
Major efforts have been done to ‘humanize’ plant N-glycans, more specifically by avoiding the 
addition of immunogenic glycans and/or introducing human glycan residues into the plant 
N-glycosylation pathway. Several strategies have been pursued to obtain these goals. The 
N-glycosylation pathway only differs from the Golgi apparatus onward, so the most straightforward 
manner to avoid immunogenic plant glycans is to retain the therapeutic in the ER. This is in theory 
easily achieved by adding the ER-retention sequence ‘H/KDEL’ to the C-terminus of the protein 
(Gomord et al., 1997b). One should be aware that the KDEL sequence is actually a retrieval sequence 
so the therapeutic can cycle between the ER and the cis-Golgi were it might come into contact with 
mannosidases and glycosyltransferases. Hence if it is correctly retrieved it will present glycoforms 
that can vary from Man9GlcNAc2 to Man5GlcNAc2 with only minor levels of Golgi typical 
modifications. These are collectively termed ‘high-mannose’ N-glycans 6  and are typical for 
ER-localized proteins. Overexpression and retention of a recombinant glycoprotein in the ER can give 
                                                            
6
 These will further be depicted in the text as ‘Manx’, with ‘x’ being the number of mannose residues 
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rise to ER-derived vesicles and glycoproteins present in these vesicles also carry typical high-mannose 
N-glycans (Loos et al., 2011b). However, the functionality of ER-retention tags is not absolute and 
some proteins can escape the retrieval mechanism, which results in increased glycan heterogeneity 
and, worse, glycoforms carrying immunogenic complex N-glycans (He et al., 2012b). Also, for some 
tagged proteins, complex N-glycans represent the majority of the glycoforms indicating that the 
retention tag is non-functional and this supports the consensus that retention in the ER by a retrieval 
sequence is protein specific (Gomord et al., 2010).  
Another strategy to avoid the incorporation of β1,2-xylose and α1,3-fucose is to inactivate the 
enzymes responsible for their transfer. This has been achieved by two methods. For Arabidopis 
thaliana and the moss Physcomitrella patens, mutants were obtained defective in the genes coding 
for xylosyl and fucosyltransferase, respectively by screening mutant libraries and by targeted 
knockout via homologous recombination (Huether et al., 2005; Koprivova et al., 2004; Strasser et al., 
2004). Homologous recombination is exceptionally straightforward in the moss Physcomitrella. 
However for other species these resources were not available and the fact that plant genes tend to 
be found in multigene families further complicated matters. Hence, gene silencing was employed to 
prevent the production of active enzymes and this method has proven more or less successful for a 
range of plant species including Nicotiana benthamiana, Medicago sativa and Lemna minor (Cox et 
al., 2006; Sourrouille et al., 2008; Strasser et al., 2008) and a number of the different lines lacking 
fucose and xylose obtained by these methods were used for further manipulations of the plant 
N-glycosylation pathway.  
For example, a silenced N. benthamiana line was combined with human β1,4-galactosyltransferase 
to produce the anti-HIV 2G12 monoclonal antibody devoid of xylose and fucose but with terminally 
galactosylated N-glycans, a prerequisite for the subsequent addition of terminal sialic acids (Strasser 
et al., 2009). The galactosyltransferase had been expressed in planta before, but only mixtures of 
galactosylated complex glycans still bearing some fucose and xylose were obtained, highlighting the 
importance of the fucosylation and xylosylation deficient lines (Bakker et al., 2001; Bakker et al., 
2006; Palacpac et al., 1999).  
By now, most of the structures typical for human N-glycans have been introduced in planta (Figure 
3). Often by tedious coordinated multigene expression as exemplified by the work of Castilho et al. 
(2010) who managed to produce a sialylated version of the 2G12 anti-HIV monoclonal antibody in 
silenced N. benthamiana plants. Genes coding for the biosynthesis, activation, transport and transfer 
of sialic acid onto the N-glycan were transiently expressed in a coordinated manner resulting in no 
less than six proteins that were targeted to different subcellular locations. Another major 
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achievement was the introduction of the transferases responsible for the addition of branching 
GlcNAcs in silenced N. benthamiana lines. Both stable transformation and transient expression of the 
two genes coding for the transferases resulted in the formation of bi-, tri- and tetra-antennary 
N-glycans on the reporter protein erythropoietin C-terminally fused to an IgG Fc domain (Castilho et 
al., 2011; Nagels et al., 2012a; Nagels et al., 2011b). However, it should be noted that in all cases the 
introduced conversions were far from completely efficient, and more complex glycan mixtures were 
formed than encountered in the wild type plants.  
Besides sialylation and multi-antennary structures, other human N-glycan structures have been 
introduced in planta, such as bisecting GlcNAc (Castilho et al., 2011; Rouwendal et al., 2007), core 
fucose in a α1,6-linkage (Forthal et al., 2010) and the Lewis X epitope, which differs from the Lewis A 
epitope by the linkages through which the galactose and fucose are attached to the terminal GlcNAc 
(Lewis A: Fuc-α1,4(Gal-β1,3)GlcNAc, Lewis X: Fuc-α1,3(Gal-β1,4)GlcNAc; (Rouwendal et al., 2009)). 
The only remaining feature of human N-glycans that has not been introduced in plants yet, are 
multi-antennary, terminally sialylated N-glycans (Nagels et al., 2011b). As both components that 
make up this structure (multiple antennae and sialylation) were individually successfully integrated in 
the plant N-glycosylation machinery, it is plausible to assume that this is only a matter of time until 
both elements are combined. Although theoretically feasible, this once more presents a practically 
daunting task requiring the balanced expression of many genes whose products will need to be in the 
correct subcellular compartment at the right moment and in the needed quantity. Moreover, the 
hexosaminidase problem has not been satisfactorily solved, and this would require several more 
gene knock-outs.  
The previous paragraphs reflect the research effort that has been done up to today to ‘humanize’ 
plant glycans and although major advances have been made during the years, some unresolved 
issues still remain. Firstly, most modification are not entirely effective and this can actually augment 
glycan heterogeneity when compared to the wild type plant, which is highly undesirable from both a 
regulatory as a commercial point of view. Secondly, some topics, e.g. the hexosaminidases have not 
been touched yet, and doing so will only further enhance the complexity of the final ‘humanized’ 
plants. Thirdly, although proof-of-concept has been delivered for most of these modifications by 
co-expression of reporterproteins, this has always been done on a lab scale and it will be extremely 
difficult to translate these results into industrial applications. Taken into account that not all 
commercially interesting crops are easily transformed, together with long regeneration times, 
polyploidy and the need for multiple crosses to integrate all favorable attributes into one elite 
cultivar, development times of ten years plus, are not exaggerated and actually, most efforts by 
industry to achieve this have been halted due to not economically feasible.  
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Figure 3. Engineering the plant N-glycosylation pathway. Overview of all the effort dedicated to 
humanize plant N-glycans by knockout of endogenous transferases (hollow arrows, the inactivated 
enzyme is preceded by the symbol ‘Δ’) and knock in of heterologous transferases (full arrows). A typical 
immunogenic plant complex N-glycan structure is highlighted in green on the left. Inactivation of the 
genes coding for β1,2-xylosyltransferase and core α1,3-fucosyltransferase yields a non-immunogenic 
structure with terminal GlcNAcs, indicated by a blue circle,  that forms the basic structure for almost all 
further manipulations. Although not depicted here, also the Lewis X epitope has been introduced in 
planta. The multiantennary, sialylated glycan structure is placed between brackets as it has not been 
produced as such yet. Abbreviations used:   XylT, β1,2-xylosyltransferase; FucT, core 
α1,3-fucosyltransferase; α1,6-FucT, α1,6-fucosyltransferase; β1,4-GalT, β1,4-galactosyltransferase; GnT I 
to V, N-acetylglucosaminyltransferase I to V; ST, set of enzymes responsible for the biosynthesis, 
activation, transport and transfer of sialic acid onto N-glycans. All glycan structures are depicted according 
to the recommendations of the international consortium of functional glycomics7. 
 
 
  
                                                             
7
 www.functionalglycomics.org 
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A key for each lock, towards the desired glycoform 
Ever since the conception of PMPs and the discovery of immunogenic plant N-glycans, major efforts 
have been dedicated towards ‘humanizing’ the plant N-glycosylation pathway. At the very least this 
meant silencing or knocking out the genes coding for fucosyl and xylosyltransferase combined with 
the introduction of somewhere from one up to no less than six recombinant enzymes to obtain more 
human-like N-glycans devoid of xylose and fucose (see previous section). All the work done to 
engineer the plant N-glycosylation pathway is justified by the fact that different glycans are required 
to bestow different characteristics onto a therapeutic protein. For example, glycoforms of 
recombinant erythropoietin for human use with sialylated, multi-antennary N-glycans would be 
highly desirable because these large structures would overall significantly increase the size of the 
otherwise small erythropoietin (Nagels et al., 2012a). This would decrease the clearance of 
erythropoietin by the kidneys and result in an increased circulation half-life and hence less frequent 
administration would be needed.  
Another good example are the immunoglobulins that carry two bi-antennary N-glycans on their Fc 
domain (Figure 2B, glycan 5 and 6). These N-glycans do not interfere with antigen recognition but 
determine the three-dimensional shape of the Fc domain and by doing so, modulate binding to 
activating and inhibitory Fc receptors, thus influencing the biological activity of the IgG (Buck et al., 
2013; Shields et al., 2001; Umana et al., 1999). Most glycoforms of human IgG carry N-glycans with 
terminal galactoses and it has been shown that removal of core fucose attached to the innermost 
GlcNAc enhances antibody dependent cellular cytotoxicity (ADCC), an important effector function of 
IgGs (Shields et al., 2002). Interestingly, this observation was made for both α1,3 as α1,6-fucose, 
respectively from plant and mammalian origin (Forthal et al., 2010). Moreover, sialylated IgGs, which 
represent less than 10 % of all glycoforms, were shown to have anti-inflammatory properties 
(Anthony et al., 2008; Kaneko et al., 2006; Nimmerjahn & Ravetch, 2007). The N-glycans on the 
Fc-domain are thus a crucial determinant of the biological activity of any given antibody. 
All the above mentioned examples concern cases where the presence of specific glycan groups is 
advantageous. The opposite also holds true and in some cases the absence of glycans, such as 
immunogenic plant glycans, is beneficial. This idea can be further expanded to situations where it 
would be interesting to avoid a glycan structure entirely. Exposed viral proteins can be heavily 
glycosylated and it is believed that this serves to shield sensitive epitopes from the immune system, a 
phenomenon known as ‘glycan shielding’ (Vu et al., 2011). Vaccines based on viral proteins lacking 
these glycans might be more efficacious (Wang et al., 2009). In another interesting line, for some 
monoclonal antibodies that bind and eliminate a factor circulating in the blood, effector functions are 
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undesirable and could provoke unwanted side effects, such as is the case for e.g. the therapeutic 
antibody infliximab that binds the potent proinflammatory cytokine tumor-necrosis-factor alpha 
(TNF-α). Removing the N-glycans on the Fc domain changes the 3D conformation impeding 
interaction with activating and inhibitory Fc receptors and hence abolishing effector functions (Buck 
et al., 2013; Shields et al., 2001).  
Taken together, there is a demand for deglycosylated variants of specific therapeutic glycoproteins. 
This could simply be achieved by amino acid substitution of the asparagines to which the N-glycans 
are attached. Nevertheless, this would change the primary structure of the recombinant protein, 
possibly negatively influencing its desired therapeutic characteristics. Moreover, N-glycans play a 
pivotal role in the correct folding of a glycoprotein in the ER by attracting chaperones and 
oxidoreductases and interacting with the quality control mechanism (Pearse & Hebert, 2010). This 
generates a paradox, where N-glycans on a therapeutic are both necessary and unwanted.  
A solution to this problem would be to produce a therapeutic glycoprotein and then treat it 
enzymatically with an endoglycosidase. However, this adds a number of steps to the entire 
production process, which would further increase its complexity. Recently this process was simplified 
by combining these steps in vivo via the transient co-expression of glycoproteins together with the 
bacterial endoglycosidase PNGaseF in Nicotiana benthamiana (Mamedov et al., 2012; Mamedov & 
Yusibov, 2013). The goal of these experiments was to produce a non-glycosylated version of a 
vaccine candidate from the malaria parasite Plasmodium falciparum. The antigen carries several 
putative N-glycosylation sites to which glycans are attached upon its recombinant expression in 
plants. However, the native protein is not glycosylated and the presence of the N-glycans interferes 
with its correct folding. Co-expression together with the PNGaseF effectively deglycosylated the 
antigen that was significantly better detected by monoclonal antibodies raised against the native 
antigen than its glycosylated counterpart (Mamedov et al., 2012). 
 Although this system is undoubtedly useful on specific occasions, for most proteins (those that are 
glycosylated in their native form) the innermost GlcNAc, which is cleaved of by PNGaseF, is an 
integral structural element, because of its direct contact with the peptide backbone, and is required 
to maintain the protein’s native fold. Release of this GlcNAc by PNGaseF will alter the conformation 
of the protein and this can result in loss of stability and degradation of the protein. For example, full 
truncation of the glycans present on the Fc-domain of IgGs has been shown to increase susceptibility 
to the protease papain, drastically lower the thermal stability and increase the propensity to 
aggregate (Buck et al., 2013; Latypov et al., 2012; Mimura et al., 2000).  
Chapter III 
80 
 
Engineering the Arabidopsis seed platform, Glycodelete TechnologyTM 
Rationale 
Up to date, no production platform exists that can efficiently cope with the removal of the glycans on 
a native glycoprotein without affecting its overall fold. Therefore, we set out to glycoengineer the 
Arabidopsis seed-platform to expand its capacities towards the production of glycoproteins with a 
homogeneous glycoprofile that could show reduced immunogenicity and possibly enhanced 
therapeutic efficacy when minimally glycosylated.  
In an interesting line of work, mammalian cells were engineered to produce glycoproteins with short, 
truncated glycans only. This ingenious strategy referred to as ‘GlycoDelete Technology’ was 
conceived with the intention of reducing the heterogeneity that is associated with complex N-glycans 
and that is detrimental for the downstream processing of a therapeutic protein, but without 
interfering with the folding-catalyzing function of N-glycans in the ER (Meuris et al., manuscript in 
press by Nature Biotechnology). The authors hypothesized that a single endoglycosidase delivered to 
the Golgi would be able to hydrolyse the glycans present on therapeutic proteins between the two 
GlcNAc residues of the chitobiose core. The single GlcNAc residue still attached to the protein 
backbone would then serve as substrate for the endogenous galactosyltransferase and 
sialyltransferase thus generating short trisaccharides with terminal sialic acids as is encountered on 
the larger complex glycans. The trisaccharides mimic the the latter, but without the associated 
heterogeneity and this is a desireable feature for most therapeutic proteins. Indeed, when a fungal 
endoglycosidase was targeted to the trans-Golgi of a cell line producing high-mannose N-glycans, it 
completely trimmed the glycans present on a set of therapeutic reporterproteins that were 
coexpressed. These truncated glycans were then effectively further elongated with galactose and 
sialic acid, albeit to various degrees. Despite the fact that some heterogeneity remained due to the 
concurrent presence of mono-, di- and trisaccharides, the overall glycan heterogeneity had been 
considerably reduced. Moreover, a neutralizing monoclonal antibody (anti-CD20) produced in the 
‘GlycoDelete’ cells showed enhanced serum half-life and better safety profile because the truncated 
glycans on its Fc-domain interfered with binding to activating an inhibitory Fc-receptors, hence 
abolishing unwanted effector functions.  
Based on these previous results validated in mammalian cells we implemented the GlycoDelete 
concept in A. thaliana to tackle the issue of complex N-glycan heterogeneity and immunogenicity. To 
achieve this goal, an Arabidopsis line has to be created that allows the addition of N-glycans to a 
glycoprotein in the ER, so that it can reach its correct fold, and delivers the protein in a minimally 
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glycosylated state after passage through the secretory pathway. In accordance with the mammalian 
GlycoDelete technology, a recombinant endoglycosidase present in the Golgi apparatus should be 
able to digest a glycoprotein passing through the secretory pathway (Figure 4). The glycoprotein 
would only be released from the ER upon reaching its correct fold and hence this system would 
deliver a correctly folded, minimally glycosylated protein. The different components of this system 
are discussed in the following paragraphs. 
 
 
Figure 4. The GlycoDelete concept implemented 
in planta. An endoglycosidase, more specifically 
the endoT from Trichoderma reesei (Stals et al., 
2010), is expressed in a background lacking GnTI 
activity (i.e. the Arabidopsis thaliana 
complex-glycan-deficient mutants that are GnTI 
knockout lines (von Schaewen et al., 2008; von 
Schaewen et al., 1993)), such that proteins 
passing through the secretory pathway will be 
decorated with high-mannose glycans only, 
which are the substrate of the endoT. This results 
in the trimming of these glycans to completely 
homogenous, minimal structures, consisting of a 
single GlcNAc that lack possibly immunogenic 
plant glycans while maintaining the native 
protein fold. Abbreviations used: ER, endoplasmic 
reticulum; GMI, Golgi-mannosidase-I; GnTI, 
N-acetylglucosaminyltransferase-I; E, endoT. 
 
 
 
The Trichoderma reesei Endo-N-acetyl-β-D-glucosaminidase 
The Trichoderma reesei endo-N-acetyl-β-D-glucosaminidase (endoT, Figure 5) was selected as tool to 
glycoengineer the Arabidopsis seeds. It was discovered as an extracellular component in the growth 
medium of the fungus Trichoderma reesei, also known as Hypocrea jecorina (Stals et al., 2010); the 
different names refer to the asexual and sexual phase of the fungus respectively. It is an important 
industrial microorganism renowned for its extraordinary capacity of secreting large quantities of 
biomass-degrading enzymes, which can amount up to 100 grams per liter for some industrial strains 
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(Druzhinina et al., 2011; Martinez et al., 2008).  Enzymes excreted by Trichoderma carry truncated 
N-glycans consisting of a single GlcNAc attached to the amino acid backbone and it was discovered 
that the endoT is responsible for this activity (Stals et al., 2010).  
Purification of the enzyme from the growth medium and subsequent characterization revealed 
several interesting features; the active form is both N and C-terminally processed releasing peptides 
of respectively 9 and 46 amino acids long, endoT has a substrate specificity for high-mannose, but 
not complex N-glycans and cleaves the bond between the innermost and second GlcNAc moieties of 
the glycan leaving one GlcNAc residue attached to the protein backbone. Three N-glycan attachment 
sites are present of which two are occupied with a single GlcNAc suggesting auto-cleavage. The 
enzyme is both structurally and functionally related to other endoglycosidases (Stals et al., 2012; 
Stals et al., 2010).  
 
 
 
Figure 5. Structure of the Trichoderma reesei endoT. Figure taken from Stals et al. (2012). Crystallized 
endoT was shown to have a complete (β/α)8-TIM barrel fold. The structure is rainbow colored according 
to the residue number, starting with blue at the N-terminus and ending with red at the C-terminus. The 
single GlcNAc residues at position N70 and N240 resulting from auto-deglycosylation are represented as 
orange-colored stick models. (A) Upper view of the endoT with indication of the α-helices and β-sheets 
that make up the barrel fold. (B) Side view of the endoT with an octasaccharide modeled into the active 
site to indicate its position. 
 
An advantage of endoT in the glycoengineering context is that, in contrast to other endoglycosidases 
that completely remove the N-glycan, endoT releases the N-glycan while leaving the proximal GlcNAc 
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residue attached to the protein. This is of considerable significance since this residue is in direct 
contact with the protein backbone and forms an integral part of the overall structure of the protein. 
EndoT activity thus eliminates the glycan structure while leaving the structurally important proximal 
GlcNAc in its place, hence conserving the native protein fold.  
 
The Arabidopsis thaliana complex-glycan-deficient mutant  
To ensure optimal deglycosylation, the Arabidopsis thaliana complex-glycan-deficient (cgl) mutant 
was selected as host for the glycoengineering. The cgl mutant was discovered during a chemical 
mutagenesis screen and solely carries N-glycans of the high-mannose type, with a predominance of 
Man5, which are an excellent substrate for the endoT (Stals et al., 2010; von Schaewen et al., 1993). A 
deficiency in the N-acetylglucosaminyltransferase I (GnTI) that initiates the conversion of 
high-mannose to complex N-glycans, lies at the base of this observed glycan profile (Gomez & 
Chrispeels, 1994; von Schaewen et al., 1993). GnTI catalyzes the transfer of a terminal GlcNAc to the 
α1,3 branch of Man5 in the cis-Golgi and its product is a prerequisite for all further maturation steps 
(Wenderoth & von Schaewen, 2000).  
Analysis showed that point mutations are responsible for the lack of GnTI function in both allelic cgl 
variants (Frank et al., 2008). In the cgl1-1 mutant (Nottingham Arabidopsis stock centre number 
N6192) this point mutation leads to the introduction of an additional N-glycan in the active site of the 
enzyme, impeding it of reaching its correct fold (Strasser et al., 2005). The resulting enzyme is 
inactive and retained in the ER, however, conditions that stimulate underglycosylation can partially 
lift the block in conversion of high-mannose to complex N-glycans because in absence of the N-glycan 
attached to it, the asparagine introduced by point mutation in the enzyme’s active site still allows for 
residual GnTI activity (Frank et al., 2008; Strasser et al., 2005). The cgl1-1 mutant thus represents a 
conditional mutant and it has recently been reported that recombinant glycoproteins expressed in its 
seed carried predominantly high-mannose N-glycans, but with a significant fraction of complex 
N-glycans, arguing for some GnTI activity during seed development (He et al., 2012a; He et al., 
2012b; He et al., 2013).  
In contrast to the cgl1-1 mutant, the cgl1-2 is a true null mutant (Nottingham Arabidopsis stock 
centre number N16366). Here, a point mutation at the end of an intron splice site creates a frame 
shift that introduces a premature stop codon and no residual enzymatic activity can be found (Frank 
et al., 2008). Both cgl mutants perform similar to wild type Arabidopsis (Col-0) under normal 
conditions and specific heat, cold and light stress although they are possibly more susceptible to 
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stray pathogen infection and, except for longer root hairs, they display no obvious phenotype (Frank 
et al., 2008; von Schaewen et al., 1993). 
Although the glycans present on proteins produced in the cgl mutants are of the high-mannose type 
and are non-immunogenic by nature, they are still considerably heterogeneous, ranging from Man5 
to Man8, and give rise to different glycoforms, which is an undesireable feature for any therapeutic 
protein. Additionally, high-mannose glycans can target a therapeutic protein to a specific subset of 
cells that carry the mannose receptor, which results in the rapid clearance of the therapeutic from 
the blood stream. All in all, the presence of these high-mannose glycans on a therapeutic protein 
should, except for specific applications, be avoided.  
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A reporter protein for the GlycoDelete technology, the activation-associated 
secretory protein 1 
The activation-associated secretory protein 1 (ASP1, Figure 1) from the helminth Ostertagia ostertagi 
was selected to serve as reporter glycoprotein to probe the functionality of the GlycoDelete 
technology implemented in planta. The organism is the major parasitic nematode of cattle in the 
temperate regions of the world and poses a serious problem (Geldhof et al., 2002). Treatment is 
based on anti-helmintic drugs but because of concerns about resistance to these drugs and their 
residual presence in consumer goods, e. g. milk and meat, alternative measures for control, such as 
vaccination, are being investigated. So far, excretory/secretory proteins from adult larvae that were 
purified by thiol-sepharose chromatography were shown to provide the strongest protective 
immunity (Geldhof et al., 2002; Geldhof et al., 2000; Geldhof et al., 2004). Further analysis revealed 
that ASP1 and ASP2 are the predominant components of this ES-thiol fraction and purified ASPs 
elicited the same response as the crude fraction, identifying them as the main immunogens (Geldhof 
et al., 2003; Meyvis et al., 2007).  
However, isolation of large quantities for vaccination is difficult and there is great interest to produce 
recombinant versions of these antigens. ASPs have been produced in the yeast Pichia pastoris and in 
baculovirus-infected insect cells, but while very high antibody titers were elicited, neither 
recombinant version was able to provide any protection whatsoever in vivo and the antibodies raised 
in calves against these ASPs  were not able to recognize the native ASP, pointing towards structural 
differences between the recombinant and native ASPs (Geldhof et al., 2008; Van Coppernolle et al., 
2012). The crystal structure of Pichia-produced ASP1 has recently been elucidated and reveals that 
the antigen consists of an N-terminal domain with an α-β-α fold, a typical feature for ASPs, and a 
C-terminal hinge region that allows for dimerization, as occurs in vivo (Borloo et al., 2013; Meyvis et 
al., 2007). Six internal disulfide bridges are present that stabilize the monomer and a peculiar feature 
is that one of these links the C to the N-terminus, thus generating a cyclic structure. The seventh 
bridge connects both monomers and it is postulated that its location in the less rigid hinge region 
allows the dimer to be quite flexible. This is probably related to the in vivo function of the ASPs in the 
host-parasite interaction although their exact role still awaits elucidation (Borloo et al., 2013). 
The two N-glycan attachment sites of both ASPs are occupied in vivo with predominantly (90 %) 
paucimannosidic and hybrid glycans that are core α1,6-fucosylated, but their function is still unclear 
(Meyvis et al., 2008). Antibodies raised against the native ASP recognize the ASP in a 
glycan-independent manner. However, reduction and denaturation of the ASP drastically reduced 
antibody binding, revealing the importance of conformational epitopes of the protein backbone 
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(Meyvis et al., 2008). As native ASP is purified through a thiol-sepharose chromatography step, the 
purified product is a disulfide-scrambled mixture, in contrast to the recombinant proteins produced 
in P. pastoris and insect cells. It is possible that this disulfide scrambling exposes epitopes to which 
antibodies are raised that are important in the vaccine-induced protection.  Anyhow, the 
recombinant ASP1 from Pichia and baculovirus-infected insect cells apparently lack some structural 
element, rendering them unprotective, and this spurred the production of recombinant ASP1 in the 
seeds of Arabidopsis thaliana (unpublished results, Dr. A. De Paepe). It was hypothesized that the 
seed platform might just be capable of correctly incorporating this enigmatic structural element into 
the seed-produced ASP1 and bestow it with protective properties. The ASP1 could indeed be 
produced in the seeds of Arabidopsis, however, competitive ELISA showed that the seed-produced 
ASP1 is not recognized by neutralizing ASP1 antibodies, what seems to indicate that the 
seed-produced ASP1 also lacks the structural element that is absent in the other recombinant ASP1s.   
 
 
 Figure 1. Structure of the 
Osteragia ostertagi ASP1. 
Figure adapted from Borloo 
et al. (2013). Recombinant 
ASP1 was produced in P. 
pastoris, crystallized and its 
structure elucidated. (A) 
Cyclic ASP1 monomer with its 
secondary structure 
highlighted and six internal 
cysteine bridges indicated. 
Cys 195 is involved in 
dimerization of the ASP1 
monomers. Αlpha-helices and 
β-sheets are depicted in red 
and yellow respectively. (B) 
ASP1 dimer connected by the 
disulfide bridge formed by 
both Cys 195 residues. 
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Results 
EndoT expression in Arabidopsis thaliana complex-glycan-deficient seeds 
A first step towards the generation of an Arabidopsis-seed platform capable of producing correctly 
folded therapeutic proteins with truncated N-glycans is the coordinated integration of the endoT into 
the secretory pathway of the seeds of the Arabidopsis cgl mutant. To avoid interference with the 
folding of nascent proteins in the ER, the endoT needs to be targeted to the Golgi apparatus and this 
in a seed-specific way. To this goal, the signal sequence of the endoT was swapped for that of the 
Arabidopsis β1,2-xylosyltransferase which resides in the stacks of the medial-Golgi. The 
xylosyltransferase is a type-II integral membrane protein, i.e. with an N-terminal cytoplasmic tail that 
is 10 amino acids long, a single-span transmembrane domain and C-terminal catalytic domain facing 
the lumen of the ER (Strasser et al., 2000). The first 32 amino acids that make up the cytoplasmic tail 
and transmembrane domain were shown to be sufficient for correct localization in the medial-Golgi 
(Pagny et al., 2003) and these were used to substitute the endoT signal sequence (Figure 2B). The 
construct was cloned into a seed-specific expression cassette under control of the β-phaseolin 
promoter the arcelin5-I terminator and used to transform the Arabidopsis cgl1-1 and 1-2 mutants 
(Figure 2A). T1 transformants were selfed to obtain T2 segregating seed stocks which were analyzed 
by western blot for the presence of endoT (Figure 3).  
A similar pattern of endoT expression can be observed in both allelic mutant backgrounds (Figure 3A 
and 3B), typified by a doublet band around 40 kDa and another major band around 30-33 kDa that is 
surrounded by three additional bands of lower intensity of which one is situated higher at about 37 
kDa and the remaining two lower in the 15 – 25 kDa range. The highest band of the doublet 
corresponds to a glycoform of the lower band as it disappears after digestion with PNGaseF (see 
later) and the latter probably represents the unprocessed endoT, as its observed size corresponds 
with that of the full length, unglycosylated endoT (41.3 kDa, lsx:endoT; Table 1). The other major 
band around 30 – 33 kDa seems to coincide with the size of the endoT catalytic domain (31.7 kDa) as 
it is encountered in the extracellular medium of its host, the fungus Trichoderma reesei. In vivo, the 
active extracellular endoT is the product of proteolytic processing at its N and C-terminus, releasing 
peptides of 1.1 and 4.7 kDa respectively. These propeptides are present in the construct that was 
used to transform the Arabidopsis cgl mutants and it is thus possible that the endoT is processed in a 
similar way in Arabidopsis cgl seeds as occurs in vivo. In accordance with this hypothesis, the lower 
doublet band could represent non glycosylated and unprocessed endoT (lsx:endoT, 41.3 kDa), the 
highest low intensity band around 37 kDa may represent the C-terminally processed endoT (36.6 
kDa) and the major band 30 – 33 kDa would then be the fully processed endoT catalytic domain (31.7 
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kDa). The two remaining low intensity bands could be the result of degradation. An important remark 
to be made is that if full processing indeed occurs in the seed, then the lsx will be released from the 
endoT catalytic domain as an integral part of the N-terminal propeptide and this would convert the 
endoT into a secretory protein instead of retaining it in the medial-Golgi.  
 
 
 
Figure 2. T-DNA bearing the lsx:endoT gene and translation thereof. (A) The T-DNA from the binary 
vector used to transform Arabidopsis, carrying the seed-specific expression cassette in which the endoT 
construct was cloned and the bar gene to convey phosphinothricin (ppt) resistance to transformed 
seedlings. The lsx:endoT gene is placed under control of the β-phaseolin promoter and the arcelin5-I 
terminator, both derived from seed storage proteins of Phaseolus vulgaris (common bean), to promote 
high, seed-specific expression. (B) The lsx:endoT fusion protein, consisting of the unprocessed endoT 
without ER signal sequence coupled at its N-terminus to the medial-Golgi targeting signal of the 
Arabidopsis β1,2-xylosyltransferase (lsx). Given are the fully processed endoT catalytic domain, both N 
and C-terminal propeptides, the medial-Golgi targeting signal, the two sites that carry single GlcNAc 
residues in vivo (red triangle) and the two remaining potential N-glycan attachment sites (pink triangles). 
Abbreviations used: aa, amino acids; Pnos, nopaline synthase gene promoter; 3’ocs, octopine synthase 
gene terminator; bar, bar gene conveying phosphinothricin resistance; Pphas, β-phaseoline gene 
promoter; Ω, leader sequence of the ‘tobacco mosaic virus’; 3’Arc, 600 basepairs arceline5-I gene 
terminator; lsx:endoT, gene construct coding for the lsx:endoT fusion protein; lsx:endoT, translational 
fusion between the β1,2-xylosyltransferase medial-Golgi targeting signal and the N-terminus of the endoT 
without signal sequence.  
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Figure 3. Expression analysis of endoT in the Arabidopsis cgl 1-1 and 1-2 mutant. Extracts of T2 
segregating seed stocks of Arabidopsis cgl 1-1 (A) and cgl 1-2 (B) transformed with the endoT construct 
were analyzed by western blotting using a polyclonal rabbit α-endoT serum (1:5000). Gels were run under 
reducing conditions and 20 µg of protein was loaded. T-DNA single locus integration lines that were 
selected to be propagated to homozygosity are marked with an arrow. A diamond indicates the doublet 
band, whereas the major band around 30 kDa is represented by a star and the three additional bands of 
minor intensity by hollow arrowheads. Abbreviations used: kDa, kilodalton; cgl, Arabidopsis 
complex-glycan-deficient mutant; ColO, Arabidopsis thaliana ecotype Columbia. 
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Table 1. Physical parameters of the recombinant endoT  
 
Amino acids 
 
Glycosylation sites 
 
Predicted Mw (kDa) 
 
min max 
     Lsx:endoT 374 3 41,3 47,3 
EndoT propeptide 342 4 37,4 45,4 
EndoT catalytic domain 290 3 31,7 37,7 
lsx 32 0 3,9 3,9 
N-terminal fragment 9 0 1,1 1,1 
C-terminal fragment 43 1 4,7 6,7 
          
 
Table 1. Characteristics of the recombinant endoT. For any peptide, the number of amino acids, number 
of N-glycosylation sites and the minimum and maximum size are given (minimum size plus 2 kDa 
multiplied by the number of potential glycosylation sites). EndoT propeptide and catalytic domain 
correspond to the un- and fully processed endoT. Abbreviations used: Mw, molecular weight; kDa, 
kilodalton; pI, isoelectric point; Lsx, Arabidopis β1,2-xylosyltransferase medial-Golgi targeting signal; 
Lsx:endoT, endoT fused at its N-terminus to the lsx. 
 
After segregation analysis the cgl1-1 endoT 2-2 and cgl1-2 endoT 5-3 were identified as the single 
locus T-DNA integration lines with the highest endoT expression and these were subsequently 
propagated to homozygosity. To further elucidate the endoT expression pattern, seed extracts of 
both homozygous endoT lines were subjected to a PNGaseF treatment and analyzed via western 
blotting (Figure 4). This revealed that only the most upper band is susceptible to glycan digest and 
results in the collapse of the doublet band showing that it consists of two glycoforms of the same 
protein (black diamond, Figure 4). Again, no difference could be observed between both allelic 
mutant backgrounds. An interesting detail that is also revealed by this blot is that the intensity of the 
endoT pattern is different for the extracts with and without the detergent dodecylmaltoside. The 
latter is used to solubilize the endoT from the membrane in which it is anchored through its 
N-terminal Golgi localization signal. Hence, the doublet band and the low intensity band right below 
it that are only faintly stained in the extracts without detergent probably represent 
membrane-anchored variants of the endoT. In accordance with the hypothesis postulated in the 
previous section, the doublet band then represents two glycoforms of the unprocessed (lsx:endoT), 
membrane-anchored endoT. The fainter band right below the doublet then corresponds to partially 
processed endoT and its lower intensity in the detergent-free extract would suggest that it is 
membrane-anchored and thus C-terminally, but not N-terminally processed. Finally, the equal 
intensity of the band at around 33 kDa in both types of extract points towards loss of the membrane 
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anchor and hence, this represents the fully processed endoT catalytic domain only, which is 
confirmed by comparison to the catalytic domain of yeast-produced endoT (see later). 
 
  
Figure 4. Glycan analysis of the endoT produced in cgl seeds. Seed stocks of cgl lines T3 homozygous for 
endoT (cgl 1-1 endoT 2-2-7 and cgl 1-2 endoT 5-3-1) were extracted at a fixed w/v ratio, with or without 
the detergent dodecylmaltoside. The resulting extracts were digested with PNGaseF and analyzed via 
western blot using a polyclonal rabbit α-endoT serum (1:5000). 10 µl of seed extract was incubated with 
PNGaseF, loaded onto the gel and run under reducing conditions. The collapsed doublet band is indicated 
with a black diamond. Abbreviations used: kDa, kilodalton; cgl, Arabidopsis complex-glycan-deficient 
mutant. 
 
EndoT deglycosylates endogenous seed glycoproteins 
After transformation of the endoT in the cgl mutants and confirmation of its presence in the seeds, 
the next step towards a functional GlycoDelete platform is to show enzymatic activity. EndoT has a 
substrate specificity for high-mannose N-glycans, which are the predominant, if not only glycans 
present on proteins in both allelic cgl backgrounds. It was hypothesized that if the seed-produced 
endoT would show enzymatic activity, then it should also digest the endogenous seed glycoproteins. 
To study the glycans present on these proteins, crude seed extracts were prepared from Arabidopsis 
ecotype Columbia, both cgl mutants and low to high endoT expressing lines. These were separated 
by SDS-PAGE and visualized by western blotting using the lectin Concanavalin-A (ConA) coupled to 
horse radish peroxidase (HRP). ConA binds high-mannose N-glycans and together with the HRP 
enzymatic moiety, this allows for chemiluminescent detection of high-mannose bearing 
glycoproteins. A first western blot shows the endoT content of the selected lines ranging from 
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non-detectable over intermediate to high (from ‘-‘ over ‘+’ to ‘++’ respectively, Figure 5A). The 
second western blot reveals the high-mannose bearing proteins present in the extracts (Figure 5B). In 
the Columbia extract, where N-glycans can mature into hybrid and complex glycans, only a few bands 
are visible (Figure 5B). As expected, in the cgl mutants were high-mannose glycans are the sole 
glycoforms present, much more proteins are stained. However, when comparing the profile of both 
mutants to transformed lines expressing endoT, it immediately becomes clear that endoT expression 
reduces this pattern and that there is an inverse relation between the endoT content of the extracts 
and the number of bands detected with only two major bands remaining in the high and homozygous 
endoT lines (‘++’ and ‘H’ respectively, Figure 5A & 5B). To confirm that the patterns revealed by ConA 
detection (Figure 5B) truly represent high-mannose bearing glycoproteins, the western blot was 
performed in duplicate and an excess of soluble ConA ligand (methyl-α-D-mannopyranoside) was 
added during the incubation of the blot with ConA to specifically inhibit the glycan-binding site of 
ConA (Figure 5C) showing that binding of the lectin was indeed through its mannoside binding site,  
except for a remaining band around 20 kDa. 
  
Figure 5. EndoT deglycosylates endogenous 
seed proteins. Seed extracts from Arabidopsis 
ecotype Columbia, both cgl mutants and 
endoT expressing lines were prepared at a 
fixed w/v ratio and analyzed by western blot 
using (A) a polyclonal rabbit α-endoT serum to 
assay the endoT content of the different lines, 
(B) ConA to detect high-mannose bearing 
glycoproteins and (C) ConA in the presence of 
excess soluble ligand to reveal binding of 
ConA through other sites than its mannoside 
binding site. 10 µl of extract was loaded and 
the gels were run under reducing conditions. 
Abbreviations used: Col-0, Arabidopsis 
ecotype Columbia; cgl, Arabidopsis 
complex-glycan-deficient mutant; -/+/++, 
non-detectable, intermediate and high endoT 
content respectively; H, homozygous. 
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ASP1 expression in wild type, cgl and glycodeleteTM Arabidopsis seed 
The reduction in ConA-sensitive seed glycoproteins in cgl lines expressing endoT delivered the 
proof-of-concept of the activity of the recombinant endoT. This left one final question to be 
addressed to demonstrate the full utility of the GlycoDelete seed-platform, namely that a foreign 
glycoprotein would also be processed by the endoT upon coexpression in the seed. To tackle this 
issue, the ASP1 from the parasitic nematode Ostertagia ostertagi was selected to be introduced in 
the endoT expressing cgl lines. For both the cgl 1-1 as the cgl 1-2 mutant a line homozygous for 
endoT was available (EndoT 2-2-7 and 5-3-1 respectively, propagated from line 2-2 and 5-3, Figure 3) 
and although both mutants share the same phenotypical characteristics, they are genotypically 
different and represent a conditional and a true null mutant respectively. To ensure complete 
absence of GnTI functionality and complex plant N-glycans, we opted to continue only with the 
Arabidopsis cgl 1-2 mutant homozygous for endoT (EndoT 5-3-1, propagated from line 5-3, Figure 3) 
in further experiments. From here on we will refer to the latter as the GlycoDelete seed-platform.  
A secretory version of ASP1 was N-terminally fused to the ER signal sequence of the Arabidopsis 2S2 
seed storage protein and cloned into a seed-specific expression cassette under control of the same 
regulatory elements that were used to drive expression of the endoT, except that the short version of 
the arceline5-I 3’-UTR, 600 basepairs (bps), was substituted for the full length 3’-UTR (4000 bps; 
unpublished results, Dr. A. De Paepe). The resulting construct was transformed into Arabidopsis 
ecotype Columbia, the Arabidopsis cgl 1-2 mutant and the Arabidopsis cgl 1-2 line homozygous for 
endoT (generation T3, line 5-3-1). The resulting T1 transformants were selfed to obtain twenty T2 
segregating seed stocks per background. An acid buffer, that does not solubilizes the majority of the 
endogenous seed proteins, facilitates selective extraction of the ASP1 from ground seeds, yielding 
semi-pure extracts (see Material & methods). This allowed the T2 segregating seed stocks to be 
visually screened for ASP1 content by SDS-PAGE and Coomassie staining of the corresponding acid 
extracts (Supplemental Figure S1). Segregation analysis was subsequently performed to identify the 
single locus T-DNA integration lines and for each background, the line with the highest ASP1 
accumulation and the ASP1 T-DNA integrated at a single locus and was retained and propagated to 
homozygosity.  
Two patterns are observed when the recombinant ASP1 is produced in the different Arabidopsis 
backgrounds. In Columbia, two predominant, similarly stained bands are visible with a molecular 
weight just over 25 kDa and right below these, a third band of weak intensity (Figure 6). As ASP1 has 
two potential N-glycosylation sites, we hypothesize that the three bands represent different ASP1 
glycoforms and thus correspond to ASP1 carrying no, one and two N-glycans. Apparently, most ASP1 
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is glycosylated, with an even distribution of the glycoforms with one and two N-glycans, whereas 
only little ASP1 carries no N-glycans. The pattern of ASP1 from Columbia is identical to that of the 
ASP1 expressed in the cgl1-2 mutant and this seems to indicate that the presence or absence of 
complex plant glycosylation does not influence the production of ASP1 in Arabidopsis seed. When 
looking at the ASP1 derived from the GlycoDelete lines, a strikingly different pattern is visible (Figure 
6). Here, only one band is present around 25 kDa and it coincides with the lowest band of the ASP1 
from Columbia and the cgl1-2 background. This confirms that the three bands of the Columbia and 
cgl1-2 ASP1 indeed represent different glycoforms and that the lowest band corresponds to the 
unglycosylated ASP1. The more important conclusion to be drawn, however, is that the ASP1 seems 
fully susceptible to the endoT activity of the GlycoDelete line as no other glycoforms can be discerned 
on the gel 
.  
Figure 6. Analysis of recombinant ASP1 expression in different Arabidopsis backgrounds. Seed stocks of 
different lines producing recombinant ASP1 were extracted with an acid buffer at a fixed w/v ratio, 
separated by SDS-PAGE and Coomassie-stained. 10 µl of extract was loaded and the gels were run under 
reducing conditions. A BSA standard was included to allow densitometric quantitation of the ASP1 present 
in the different extracts. Abbreviations used: BSA, bovine serum albumin; T2, single locus ASP1 T2 seed 
stock; T3, single locus ASP1 T3 seed stock; T3 H, homozygous ASP1 T3 seed stock; Col-0, Arabidopis 
ecotype Columbia; cgl1-2, Arabidopsis complex-glycan-deficient 1-2 mutant. EndoT cgl1-2, Arabidopsis 
complex-glycan-deficient 1-2 mutant homozygous for endoT.  
 
As the seed extracts are sufficiently pure, the signal intensity of the ASP1 bands was measured and 
used to determine the ASP1 content of the different extracts via the reference BSA standards that 
were also run on the gels. Together with the known w/v ratio at which the extracts were prepared, 
this allowed to calculate the ASP1 accumulation for each line, which was expressed as milligram 
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extractable ASP1 per gram of dry seed weight (Table 2). The accumulation of ASP1 in the Columbia 
and cgl1-2 background, with an average of 27.8 and 27.2 mg per gram of dry seed weight 
respectively, is very similar for the three homozygous lines under study. This again supports the 
notion that the presence/absence of complex N-glycosylation does not alter the production of ASP1 
in Arabidopsis seed. However, this picture is quite different for the GlycoDelete lines, where the 
average ASP1 accumulation for the three studied homozygous lines is only 7.1 mg per gram of dry 
seed weight. When compared to the Columbia and cgl1-2 lines, this is approximately a four-fold 
reduction. Nevertheless, the ASP1 produced in the GlycoDelete background still reaches an 
accumulation of 3.5% of TSP, which is considerably higher than the 1% deemed the minimal treshold 
for economic viability of a PMP (Rybicki, 2009). It should be noted that for the cgl and the 
GlycoDelete ASP1 the three homozygous lines under study are derived from the same transformation 
event and hence, caution should be taken when interpreting the observed differences in ASP1 
accumulation. However, lower accumulation of the ASP1 in the GlycoDelete background when 
compared to the cgl (and wild type) background seems a general tendency (compare Figure S1A and 
B). An additional detail revealed by table 2 is that a clear dosage effect can be observed when the 
seed stocks are propagated from heterozygous to homozygous and this characteristic is shared by all 
backgrounds. 
 
Table 2. ASP1 content of different transformed lines. 
Line Background Generation mg/g seed % of TSP  
ASP1 1-4-26 Col-0 T3 He 20,4 10,2% 
ASP1 2-1-17 Col-0 T3 Ho 28,6 14,3% 
ASP1 2-1-25 Col-0 T3 Ho 24,8 12,4% 
ASP1 5-2-2 Col-0 T3 Ho 29,9 14,9% 
ASP1 1-4 cgl1-2 endoT T2 He 5,9 2,9% 
ASP1 1-4-5 cgl1-2 endoT T3 Ho 8,0 4,0% 
ASP1 1-4-6 cgl1-2 endoT T3 Ho 7,1 3,6% 
ASP1 1-4-8 cgl1-2 endoT T3 Ho 6,0 3,0% 
ASP1 2-2 cgl1-2 T2 He 19,8 9,9% 
ASP1 2-2-7 cgl1-2 T3 Ho 28,7 14,4% 
ASP1 2-2-8 cgl1-2 T3 Ho 23,5 11,8% 
ASP1 2-2-10 cgl1-2 T3 Ho 29,3 14,7% 
 
Table 2. Seed extracts were prepared from all the different recombinant ASP1 producing lines at a fixed 
w/v ratio and subjected to SDS-page. Densitometric analysis of Coomassie-stained gels, as shown in figure 
5, allowed to calculate the ASP1 content of the different lines which was expressed as milligram ASP1 per 
gram of dry seed weight and also as % of TSP (for 200 mg TSP per gram of dry seed). Abbreviations used: 
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Col-0, Arabidopsis thaliana ecotype Columbia; cgl1-2, Arabidopsis complex-glycan-deficient 1-2 mutant; 
cgl1-2 endoT, Arabidopsis cgl1-2 mutant homozygous for endoT; He, heterozygous; Ho, homozygous; TSP, 
total soluble protein. 
 
One possible explanation for the observed difference in accumulation of the ASP1 from the cgl 
background and the GlycoDelete line would be that deglycosylation of the ASP1 alters its solubility in 
the acid buffer used to extract the seeds. To check this the corresponding T3 seed stocks of both 
ASP1 variants were extracted three consecutive times with the acid buffer and a final fourth time 
with a buffer with a high concentration of detergent and reducing agent. The latter served to 
solubilize the pellet of seed debris and extract any remaining protein. All the collected extracts were 
analyzed by western blot to compare their ASP1 content and this shows that after three washing 
steps with the acid buffer a considerable fraction of both ASP1 variants remain in the pellet (Figure 
7). However visual inspection of the western blot reveals no major difference in extraction pattern 
for both ASP1 variants and thus a difference in solubility can be discarded as an explanation for the 
earlier observed four-fold difference in accumulation of both variants. An interesting observation is 
made when looking at the pellet extraction of the GlycoDelete ASP1. Here, some faint bands of 
slightly higher molecular mass appear that are not present in the preceding acid extracts. These 
might correspond to intermediates of the ASP1 whose glycans have not yet been trimmed by endoT. 
This might represent the nascent ASP1 population in the ER.   
 
 
 
Figure 7. Solubility assay of the ASP1 produced in the 
cgl1-2 and the GlycoDelete line.  T3 seed stocks were 
extracted three times with an acid buffer (numbers 1 to 
3) and a final fourth time with a buffer to solubilize the 
pellet (P). Extracts were prepared at a fixed w/v ratio and 
analyzed by western blot using a polyclonal rabbit α-ASP1 
serum (1:1000). 10 µl of extract was loaded and the gel 
was run under reducing conditions. Abbreviations used: 
cgl1-2, Arabidopsis complex-glycan-deficient 1-2 mutant; 
EndoT cgl1-2, Arabidopsis cgl1-2 line homozygous for 
endoT; P, pellet extraction; kDa, kilodalton. 
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EndoT accumulation level and stability over generations 
We wanted to further characterize the seed-produced endoT by determining its accumulation level 
in both homozygous cgl lines and assessing its stability over multiple generations. To this goal, seed 
extracts were prepared from T3 seed stocks of both cgl lines homozygous for endoT, the endoT T3 2-
2-7 cgl1-1 and endoT T3 5-3-1 cgl1-2 respectively, and from a T5 seed stock that is derived from the 
latter and co-expresses the ASP1 with the endoT. This line was created by supertransforming the 
parental T3 5-3-1 endoT cgl1-2 line with the ASP1 construct and subsequent propagation to obtain 
the T5 5-3-1/1-4 endoT cgl1-2 ASP1 seed stock that is homozygous for endoT and heterozygous for 
ASP1. The seed extracts were analyzed via ELISA and the obtained OD values plotted against a 
standard curve of purified fully processed endoT produced in the yeast Pichia pastoris to calculate 
the endoT content of the corresponding lines (Figure 8A). The seed and yeast-produced endoT were 
also subjected to western blot to assure recognition of both forms by the polyclonal α-endoT rabbit 
serum used in the ELISA and compare the patterns revealed for both enzymes (Figure 8C).  
 
 
 
Figure 8. Quantification of seed-produced endoT and comparison to yeast-produced endoT. For  each 
mutant background, cgl1-1 and cgl1-2, the T3 seed stock of the line homozygous for endoT was selected 
to be analyzed (endoT 2-2-7 and 5-3-1, respectively), together with a T5 seed stock of the GlycoDelete line 
(endoT cgl1-2) that co-expresses endoT and ASP1 and is heterozygous for the latter (ASP1 endoT 5-3-1/1-
4). Crude seed extracts were prepared and (A) subjected to ELISA using a polyclonal rabbit α-endoT 
serum. Are given, the dilution at which the extracts were coated and the obtained OD values. Numbers #1 
to #3 represent biochemical repeats from the same seed stock. (B) The measured values were plotted 
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against an endoT standard curve and used to calculate the endoT content of the three analyzed lines. (C) 
Western blot comparison of the yeast- and seed-produced endoT detected by a polyclonal rabbit α-endoT 
serum (1:5000). Seed extracts were prepared at a fixed w/v ratio and 20 µl was loaded, whereas for the 
purified Pichia-produced endoT 200 ng was loaded. The gel was run under reducing conditions and a black 
arrow indicates the endoT catalytic domain. 
 
The ELISA shows that the endoT content of the GlycoDelete line in generation T3 (Figure 8A, EndoT 
cgl1-2) and generation T5 co-expressing ASP1 (Figure 8A, ASP1 endoT cgl1-2) is similar and, without 
even reaching 0.5% of TSP, quite low (Figure 8B). Supertransformation of the GlycoDelete line with 
the ASP1 construct under control of the same regulatory elements does not alter the endoT 
accumulation in the offspring line, which in generation T5 is still identical to that of  the parental line 
(0.60 and 0.57mg, respectively) indicating stable inheritance of the endoT over several generations 
(T3 to T5). When the seed-produced endoT is compared to the yeast-produced endoT on western 
blot, the main signal of the catalytic domain of the endoT purified from yeast coincides with the 
major band around 33 kDa in the seed extracts, hereby supporting the earlier formulated hypothesis 
that this band indeed represents the fully processed endoT calatytic domain (Figure 8C).  
 
Purification of recombinant ASP1 
To obtain purified ASP1 for further in-depth analysis, the extraction of ASP1 by acid buffer from the 
seed was combined with a three-step purification protocol consisting of two consecutive 
ion-exchange chromatography steps followed by a final gel filtration step (Figure S2). When the 
protocol was applied to the wild type, cgl, and GlycoDelete ASP1, this yielded recombinant ASP1 of 
high purity (see Figure 9A and 9B). Under non-reducing conditions all the purified ASP1 variants are 
present as dimers that run at an apparent molecular weight of 37 to 50 kDa (Figure 9B). When the 
dimers are reduced the different ASP1 glycoforms can be discerned running at or right above 25 kDa 
(Figure 9A and 9B). It should be noted that prior to purification, the ASP1 proteins are predominantly 
present in the seed as dimers, but there is also a small fraction present as multimers and this is 
independent of the Arabidopsis background in which the ASP1 was produced (Figure S2). 
Nevertheless, as the ASP1 is encountered in vivo as a dimer of about 50 kDa (Meyvis et al., 2007), the 
ASP1 dimers were selectively separated from the ASP1 multimers during the final gel filtration step 
of the purification protocol and retained for further analysis. The presence of a fraction of the 
seed-produced ASP1s as multimers might point to a structural difference between the latter and the 
native ASP1 that occurs as dimers. 
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Figure 9. Characterization of purified recombinant ASP1. ASP1 produced in Col-0, cgl1-2 and GlycoDelete 
seeds was purified by three consecutive chromatography steps and subjected to SDS-PAGE. Gels were 
Coomassie-stained and run under reducing (A) and non-reducing conditions (B) or analyzed via western 
blot using a polyclonal rabbit α-ASP serum (1:1000) and run under reducing conditions (C). 4 µg of purified 
ASP1 was loaded onto the Coomassie-stained gels whereas 2 µg was loaded onto the gel analyzed by 
western blot. Abbreviations used: Col-0, Arabidopsis ecotype Columbia; cgl1-2, Arabidopsis 
complex-glycan-deficient 1-2 mutant; E cgl1-2, Arabidopsis cgl1-2 line homozygous for endoT.  
 
Glycan analysis of ASP1 produced in wild type, cgl and GlycoDelete Arabidopsis seeds 
ASP1 cgl1-2, but not ASP1 Col-0 is susceptible to in vitro endoT digestion 
The profiles that the wild type and cgl ASP1 display under reducing conditions correspond to their 
different glycoforms, i.e. carrying no, one or two N-glycans (Figure 9A), and are almost identical 
pointing towards a similar N-glycan site occupancy in wild type and cgl Arabidopsis.  
However, because of their production in the wild type and cgl Arabdidopsis, the ASP1 variants should 
be decorated with complex and high-mannose N-glycans respectively, which cannot be distinguished 
as such on the gel. Nevertheless, the presence of these glycans on the recombinant ASP1 variants 
can be assayed by in vitro digest of both ASP1s by endoT, since it has substrate specificity for 
high-mannose, but not complex glycans. To this goal, purified wild type and cgl ASP1 was incubated 
with a dilution series of yeast-produced endoT subjected to SDS-PAGE and visualized via Coomassie 
staining (Figure 10).  
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As expected, the cgl ASP1 is susceptible to endoT treatment in vitro and the complete disappearance 
overnight of the bands representing glycosylated cgl ASP1 shows that it solely carries high-mannose 
N-glycans (Figure 10). On the other hand, the ASP1 wt is predominantly resistant to endoT digestion 
although the slight increase in intensity of the lower band indicates that some endoT sensitive 
glycans are also present.  This points towards the acquisition of a majority of complex endoT 
resistant glycans together with some remaining high-mannose endoT sensitive glycans, which is in 
accordance with the glycan profile that is expected to be found on a secretory glycoprotein produced 
in wild type Arabidopsis. 
  
 
Figure 10. EndoT susceptibility of the ASP1 wt and cgl. Purified ASP1 wt and cgl was incubated overnight 
with a serial dilution of yeast-produced endoT (the ratio of endoT over target protein is indicated above 
the corresponding slots) and then subjected to SDS-PAGE and visualized by Coomassie staining. 5 µg of 
protein was loaded onto the gel that was run under reducing conditions. For each sample the ratio of 
endoT over the recombinant ASP1 is given. Abbreviations used: wt, Arabidopsis ecotype Columbia; cgl, 
Arabidopsis complex-glycan-deficient 1-2 mutant; E, endoT. 
 
DSA-FACE analysis of recombinant ASP1 and the plant glycan substrate specificity of 
endoT 
In concordance with the theoretically predicted profiles, the wt ASP1 carries endoT resistant complex 
glycans, the cgl ASP1 endoT sensitive high-mannose glycans and the GlycoDelete ASP1 glycans that 
are trimmed down to single GlcNAcs. To corroborate these findings and investigate the presence of 
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minor, previously undetected glycoforms, the ASP1s were further analyzed by DNA 
sequencer-assisted, fluorophore-assisted carbohydrate electrophoresis (DSA-FACE) and/or 
matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry.  
The precise glycan profiles of the wt and cgl ASP1, predicted to contain predominantly complex 
glycans and high-mannose glycans respectively, were elucidated by releasing their glycans by 
PNGaseA digestion and sequential treatment of the total glycan pools with different glycosidases. 
DSA-FACE analysis of the glycan profile before and after each treatment then allowed annotation of 
each of the glycans in the total glycan pool (Figure 11B and 12E). If a glycan is susceptible to 
treatment with a specific glycosidase, its corresponding peak in the DSA-FACE electropherograms will 
shift after the reaction to that of the smaller product and hence comparison of both 
electropherograms can identify these glycans. After sequential treatments, eventually the exact 
structure of the glycans present in the electropherograms can be deduced (Laroy et al., 2006). 
Digestion with broad-spectrum mannosidase reveals glycans with terminal mannoses, whereas 
α1,2-mannosidase identifies glycans with terminal α1,2 mannoses only (Man6 to Man9). Treatment 
with hexosaminidase shows glycans with one or two terminal GlcNAcs (both complex and hybrid 
glycans) and any of these enzymes can be combined to digest structures with both terminal GlcNAcs 
and mannoses. To identify the peaks that represent complex α1,3-fucosylated glycans the 
electropherogram of the total glycan pool released by PNGaseA can be compared to that of the 
glycans released by PNGaseF, which does not digest core α1,3-fucosylated structures (Figure 12B and 
12C).  
When these techniques were applied to the wt ASP1 and its exact glycan profile was elucidated 
(Figure 11B, 12B and S3), several interesting observations were made. All glycans, except the 
high-mannose glycans that represent a small fraction of the total glycan pool, are core 
α1,3-fucosylated and the majority of these also carry a bisecting β1,2-xylose. Among these 
immunogenic plant glycans some paucimannosidic (Figure 11B peak 1 and 2) and hybrid structures 
(peak 6 and 7) can be discerned, but the predominant glycoforms are complex glycans with one 
terminal GlcNAc (and a fully processed α1,3 arm, peak 2 and 3) or two terminal GlcNAcs (peak 4 and 
5).  This confirms the previous observation that wt ASP1 is mostly decorated with complex, endoT 
resistant, N-glycans. Indeed, all the glycans that are released by endoT treatment of wt ASP1 are 
exclusively of the high-mannose type (Figure 12D). Production of the ASP1 in the Arabidopsis cgl 
mutant drastically simplifies the glycan profile showing high-mannose glycans only with the structure 
Man5 as the main glycoform (Figure 12E) and this is consistent with the lack of GnTI activity in the cgl 
background that blocks conversion of high-mannose to complex glycans.  
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Figure 11. DSA-FACE analysis of the wt ASP1 glycan pool and glycosidase treatments thereof. The total 
glycan pool of wt ASP1 was released by PNGaseA digest, fluorescently labeled, treated with different 
glycosidases and subjected to DSA-FACE. (A) Oligomaltose standard (glucose polymer), the number of 
glucose units is indicated. (B) Total glycan pool released by PNGaseA and digested with (C) broad 
spectrum jack bean α1,2,3,6-mannosidase, (D) hexosaminidase or (E) hexosaminidase and jack bean 
mannosidase. (F) High-mannose glycan profile of RNAseB. Maltopentaose was added to all samples as an 
internal standard. Abbreviations used: M5 to M9, Man5 to Man9; JB Man, jack bean 
α1,2,3,6-mannosidase; Hex, jack bean β-N-acetylhexosaminidase.  
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Figure 12. DSA-FACE analysis of the wt and cgl ASP1 glycan pool and the substrate specificity of endoT 
towards plant glycans. (A) Oligomaltose standard. (B)  Glycans released from wt ASP1 by digestion with 
PNGaseA, (C) PNGaseF and (D) endoT. (E) Cgl ASP1 total glycan pool released by PNGaseA digest. (F) 
High-mannose glycan profile of RNAseB. Abbreviations used: M5 to M9, Man5 to Man9.   
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Mass spectrometry analysis of GlycoDelete ASP1 
The only remaining glycan profile to be characterized in detail was that of the GlycoDelete ASP1, which 
could not be analyzed by DSA-FACE because of the small size of its trimmed glycans, which are not 
susceptible to PNGaseA or PNGaseF release. Hence, the GlycoDelete ASP1 was treated with the 
protease trypsin and the resulting tryptic peptides were subjected to MALDI-TOF spectrometry, which 
should allow precise identification of the glycan structures still present on the GlycoDelete ASP1. 
Initially the purified GlycoDelete ASP1 was trypsinized in solution following a two-step protocol to 
ensure maximal proteolytic cleavage. The peptide mixture was then analyzed by MALDI-TOF 
spectrometry and the resulting spectrum screened for the two glycopeptides that were predicted to 
be released by tryptic digest of the GlycoDelete ASP1 (Figure 13A). All the peptides that could be 
identified in the spectrum are depicted with their corresponding apparent masses in Figure 13B and 
their peaks indicated on the spectrum (Figure 13C). Glycopeptide one and two are indeed present as 
glycoforms carrying a single GlcNAc and for both peptides tryptic variants can be found that are 
similarly decorated with a single GlcNAc.  For glycopeptide one and its tryptic variant also the 
unglycosylated amino acid backbones can be discerned. Interestingly, no other glycoforms were 
present in the spectrum, pointing to complete digestion of the ASP1 glycans by endoT in the 
Arabidopsis GlycoDelete background. In general, several tryptic variants are visible, both for the 
glycopeptides as among the other peptides identified in the spectrum and these are the result of 
incomplete proteolytic digestion. Trypsin cleaves after a lysine (K) or arginine (R), however, sequences 
consisting of any two of the latter tend to be incompletely digested and apparently even the two-step 
digestion protocol could not ensure complete cleavage. Also some minor, unidentified peaks remain in 
the spectrum. 
To further optimize the spectrum, the purified GlycoDelete ASP1 was run on a polyacrylamide gel prior 
to mass spectrometric analysis. The area corresponding to single GlcNAc and possible larger 
glycoforms was excised and the GlycoDelete ASP1 trypsinized in gel. The resulting peptides were then 
solubilized and subjected to MALDI-TOF mass spectrometry. When comparing the spectra obtained 
after both methods, an immediate and obvious difference is the reduction in number of tryptic 
variants and smaller peaks (Figure 13C and 14C). No tryptic variants of the glycopeptides are 
encountered and both glycopeptides are again present as glycoforms with single GlcNAcs although the 
peak corresponding to glycopeptide 1 is of low intensity (Figure 14C). No other glycoforms could be 
discerned confirming the previous observations that the ASP1 glycans are completely trimmed by the 
endoT in the GlycoDelete Arabidopsis background. By comparing the masses of the predicted tryptic 
peptides with those observed in the spectrum all major peaks could be annotated, except three peaks 
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at m/z 1975.02, 2185.15 and 2386.22. Nevertheless, aspecific cleavage of the GlycoDelete ASP1 in 
silico yields several peptides with m/z values that are nearly identical to those of the observed peak 
thus indicating that these probably also correspond to internal peptides of the GlycoDelete ASP1 (see 
Table S1).  
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Figure 13. MALDI-TOF analysis of in-solution trypsinized glycodelete ASP1. Purified GlycoDelete ASP1 was 
carboxymethylated, trypsinized in-solution and subjected to MALDI-TOF spectrometry in the positive ion 
mode [M+H]+. (A) The amino acid sequence of the GlycoDelete ASP1. Tryptic glycopeptide one and two are 
depicted in blue and orange, respectively, and the N-glycan attachment sites underlined. Other tryptic 
peptides found in the spectrum are indicated in green. (B) The different peptides identified in the spectrum 
and their masses (in kilodalton) given as the molecular weight plus one proton. (C) Mass spectrum of the 
trypsinized GlycoDelete ASP1. The peptide corresponding to a specific peak is indicated. A blue square 
represent a glycopeptide carrying a single GlcNAc. 
 
Glycoengineering in Arabidopsis seeds, results. 
109 
 
 
 
Figure 14. MALDI-TOF analysis of in-gel trypsinized glycodelete ASP1. Purified glycoDelete ASP1 was run 
on gel, carbamidomethylated and the corresponding band area excised and digested with trypsin. The 
resulting tryptic peptides were then solubilized and subjected to MALDI-TOF spectrometry in the positive 
ion mode [M+H]+. (A) The amino acid sequence of the GlycoDelete ASP1. Tryptic glycopeptide one and two 
are depicted in blue and orange, respectively, and the N-glycan attachment sites underlined. Other tryptic 
peptides found in the spectrum are indicated in green. (B) The different peptides identified in the spectrum 
and their mass (in kilodalton) given as their molecular weight plus one proton. (C) Mass spectrum of the 
trypsinized GlycoDelete ASP1. The peptide corresponding to a specific peak is indicated. A blue square 
represent a glycopeptide carrying a single GlcNAc.   
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ASP1 carrying complex plant N-glycans, but not GlycoDelete ASP1 induces an 
anti-carbohydrate response in rabbits 
Two groups of five rabbits were injected subcutaneously with GlycoDelete or wild type ASP1 following 
a prime-boost protocol. Rabbits received 35 µg of recombinant ASP1 mixed with complete freund’s 
adjuvant at day zero and 35 µg mixed with incomplete freund’s adjuvant at days 14, 28 and 56. Blood 
samples were taken on day zero prior to immunization (preimmune) and at days 28, 36 and 80 when 
the rabbits were euthanized. The goal of the experiment was to assess the immunogenicity of the wild 
type ASP1 with its fucose and xylose bearing complex plant glycans and compare this to the 
GlycoDelete ASP1 that carries truncated glycans.  
After the final vaccination, all rabbits had developed high titers of IgG antibodies specific for the 
peptide backbone of the recombinant ASP1 (Figure 15A). These were measured by an direct ELISA in 
which denatured, reduced and deglycosylated ASP1 was coated as the antigen (Figure S4). Variation in 
titer was higher among the GlycoDelete ASP1 vaccinated group, but the average titer was similar and 
high for both groups (Figure 15A). To evaluate the immunogenicity of the glycan structures of both 
ASP1s, it was decided to study the presence/absence of IgG antibodies specific for plant glycans in the 
sera of the vaccinated rabbits. To measure the latter, a recombinant glycoprotein not related to ASP1 
was used as a neutral carrier of glycan structures that served as antigens in ELISA to allow selective 
binding of glycan-specific IgGs. More specifically, a synthetic antibody was used that consisted of the 
antigen-binding domain of a camelid heavy chain only antibody (nanobody), i.e. the GFP-binding 
protein (GBP) coupled to the Fc domain of the murine IgG3 and this fusion protein is hereafter referred 
to as GBP-Fc. The recombinant GBP-Fc has two N-glycosylation sites located in its Fc-domain and had 
been expressed in different organisms, so different glycoforms were at hand. Production in Pichia 
pastoris yielded high-mannose glycoforms (Man5 to Man8) whereas the GBP-Fc produced in 
Arabidopsis seeds almost exclusively consisted of glycoforms with complex plant glycans bearing 
immunogenic fucose and xylose residues (PhD dissertation 2013, Dr. T. De Meyer; Figure 15C). It 
should be noted that approximately 30% of the Arabidopis-produced GBP-Fc is unglycosylated (Dr. T. 
De Meyer, personal communication). 
To probe the presence of plant-glycan specific IgGs, the sera of the vaccinated rabbits were subjected 
to ELISAs, using the high-mannose and immunogenic GBP-Fc glycoforms as coated antigens. Prior to 
the coating step, the purified glycoforms were reduced and denatured to expose their N-glycans that 
otherwise might have been shielded from the sera because of their inward orientation due to the fold 
of the Fc domain. The stripped GBP-Fc peptide backbone, obtained by reduction, denaturation and 
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digestion of the high-mannose glycoform with PNGaseF and monitored by mobility shift assay (Figure 
15B), was also coated to measure non-glycan specific detection (background).  
Three out of the five rabbits that had been injected with the recombinant ASP1 bearing complex plant 
N-glycans had generated IgGs specific for β1,2-xylose and core α1,3-fucose, confirming that these are 
indeed immunogenic (Figure 15A). Interestingly, the other two rabbits seemed unresponsive to the 
plant glycans despite having high titers of IgG specific for the ASP1 peptide backbone in their sera. No 
plant-glycan specific IgGs could be detected in the sera of the rabbits vaccinated with the GlycoDelete 
ASP1. For all ten rabbits, no signal could be measured when the high-mannose GBP-Fc was coated as 
antigen, pointing out that the detection of the fucose and/or xylose bearing GBP-Fc by three of the 
wild type ASP1 vaccinated rabbits was specific for the latter two residues.  
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Figure 15. Overview of the ASP1 and plant-glycan specific IgG titers after vaccination together with the 
structure of the glycoforms of the GBP-Fc used during ELISAs. (A) Overview of the IgG titers measured in 
the sera obtained after the final bleeding of the rabbits. Both vaccinated groups are indicated above the 
figure. Are given, the IgG titers specific for the ASP1 peptide backbone and for both glycoforms of the 
GBP-Fc decorated with high-mannose and plant glycans respectively. The mean titer is depicted by a 
horizontal line. (B) Mobility shift assay to corroborate the deglycosylation of the ASP1 and GBP-Fc 
high-mannose glycoforms by PNGaseF digestion. (C) DSA-FACE electropherogram of the glycans released by 
PNGaseA from the GBP-Fc produced in yeast and Arabidopsis seed respectively. Abbreviations used: ‘–‘, no 
PNGaseF; ‘+‘, active PNGaseF; ‘H’, heat-inactivated PNGaseF; Vacc, vaccinated; kDa, kilodalton; P.p., Pichia 
pastoris; A.t., Arabidopsis thaliana; HM, high-mannose glycoform; X/F, complex glycoform bearing 
immunogenic xylose and fucose residues.   
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Discussion 
The endoT was transformed into the seeds of the Arabidopsis cgl mutant and targeted to the 
medial-Golgi via the localization signal of the Arabidopsis β1,2-xylosyltransferase. Expression analysis 
revealed that that the majority of the endoT is both C and N-terminally processed, as occurs in vivo. 
Nonetheless, N-terminal processing would result in loss of the Golgi targeting signal as integral part of 
the cleaved propeptide and release the endoT from the medial-Golgi. It will be interesting to study the 
subcellular localization of the endoT in more detail to determine if the endoT, for example, 
accumulates in the apoplast, which would confirm its secretion and argue for loss of the medial-Golgi 
targeting signal. To characterize the engineered GlycoDelete platform, the endoT content of the 
GlycoDelete line was determined and shown to be stable over several generations and upon 
co-expression with a reporter glycoprotein. Despite the fact that the β-phaseolin promoter and 
arcelin5-I terminator, regulatory sequences derived from the common bean Phaseolus vulgaris and 
designed for high seed-specific expression of recombinant proteins, were used to drive endoT 
expression in the cgl seeds, endoT did not accumulate to more than 0.3% of TSP (or 60 milligram per 
gram of dry seed weight). A rather low number when compared to the levels, up to 15% and more of 
TSP, that have been achieved for synthetic antibodies produced in wild type Arabidopsis seeds using 
the same regulatory elements (De Buck et al., 2013; De Jaeger et al., 2002). Anyhow, massive endoT 
production during co-expression of a therapeutic protein is undesirable as it would deviate resources 
from the latter and might result being detrimental for its accumulation. Under the condition that 
sufficient endoT is present in the seed to completely process any therapeutic protein that is expressed 
in the GlycoDelete line, the low endoT content achieved actually represents an advantage rather than 
disadvantage and apparently, the low endoT content of the GlycoDelete line was perfectly capable of 
digesting a ten-fold excess of target protein (0.3 and 3.5% of TSP respectively), therefore 
demonstrating the functionality of the GlycoDelete platform.  
A peculiarity here were the accumulation levels observed for the different recombinant proteins 
expressed in Arabidopsis seeds, with endoT showing the lowest number (0.3% of TSP), followed by the 
GlycoDelete ASP1 (3.5% of TSP) and similar and high levels for both the cgl and wild type ASP1 (13.6% 
and 13.9% of TSP respectively), despite sharing the same regulatory elements to drive their expression. 
It must be noted that, for cloning purposes, a shorter version (600 basepairs (bp)) of the arcelin5-I 
terminator was used to control endoT expression, whereas for the recombinant ASP1s the original 
terminator was employed (4000 bp). Although according to Goossens et al. (1999) the first 600 bp of 
the arcelin5-I terminator contain nearly all the necessary information for high expression, it was later 
shown that a transgene under control of the β-phaseolin promoter and the 600 bp arcelin5-I 
terminator did not achieve the same expression level as when the 4000 bp full-length terminator was 
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used, indicating that the shortened terminator is less potent (Dr. K. De Wilde, PhD dissertation 2013). 
Additionally, the lower endoT accumulation could also be a reflection of some of its intrinsic 
characteristic, e.g. the fact that is a membrane-anchored protein which tend to more difficult to 
express and it is probably the combination of these two factors that is responsible for the low endoT 
accumulation observed, which is actually beneficial for the GlycoDelete platform. 
Another interesting feature was that the Arabidopsis line used for expression of the recombinant 
ASP1s seemed to influence the accumulation level with a four-fold reduction observed for the 
GlycoDelete ASP1 when compared to the cgl and wild type ASP1 (3.5% versus 13.6% and 13.9% of TSP 
respectively). The presence/absence of complex glycosylation did not seem to impact ASP1 expression 
as the cgl and wild type ASP1 accumulated to nearly identical levels, but co-expression with endoT 
apparently did, although it should be mentioned that the GlycoDelete ASP1 lines under study were 
offspring of the same transformation event and this should be kept in mind when extrapolating the 
observed differences between the GlycoDelete and the cgl and wild type ASP1. Nevertheless, 
comparison of supplemental figure S1A and S1B seems to indicate a general tendency of the 
recombinant ASP1 to accumulate less in the GlycoDelete background. As the only difference between 
the GlycoDelete and cgl ASP1 resides in the presence/absence of the endoT gene construct and the 
corresponding translated protein in its host, it is plausible to attribute the lower accumulation of the 
GlycoDelete ASP1 to one of the latter two and several explanations are possible. Firstly, despite leaving 
the proximal GlcNAc attached to the peptide backbone, the trimmed ASP1 might just be less stable 
and hence, not accumulate to the same levels as its cgl and wild type counterparts. Secondly, although 
the endoT is targeted to the medial-Golgi to avoid interference with protein folding in the ER, the 
GlycoDelete ASP1 and endoT are under control of the same promoter and thus have an identical 
temporal expression pattern what allows for contact between both proteins in the ER and this might 
interfere with the correct folding of a fraction of the ASP1 leading to its degradation by the 
ER-associated degradation pathway (ERAD). Thirdly, since both proteins share the same promoter they 
might compete for resources during production lowering final GlycoDelete ASP1 accumulation, 
although this seems little credible given that the endoT accumulation in the GlycoDelete line is low 
(0.3% of TSP) and was identical before and after co-expression of the ASP1.  
A final possibility that cannot be excluded, is that by mere chance only low GlycoDelete ASP1 
accumulators were found among the 20 transformants that were screened (supplemental Figure S1A) 
and that by amplifying the initial screen, transformants would have been picked up with accumulation 
levels similar to those observed for the cgl and wild type ASP1. To exclude this chance factor, a well 
characterized cgl ASP1 producing line should be supertransformed with the endoT construct, the 
opposite operation of how the GlycoDelete ASP1 was generated during this work, and the 
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accumulation of the GlycoDelete ASP1 in the offspring should be compared to the parental line 
without endoT. This will allow an exact determination of the influence of the endoT on the ASP1 
accumulation and unveil the mechanism for lowering GlycoDelete ASP1 accumulation.  
With 3.5, 13.6  and 13.9% of TSP the accumulation levels achieved for the GlycoDelete, cgl and wild 
type ASP1, respectively, compare favorably to those obtained for other recombinant proteins that 
were produced in Arabidopsis seeds using the same expression cassette and displayed accumulation 
levels generally ranging from  <0.1 up to 15% of TSP (Loos et al., 2011a; Loos et al., 2011b; Morandini 
et al., 2011; Van Droogenbroeck et al., 2007). Apparently, the Arabidopsis seed platform seems to be 
exceptionally suited for the production of antibodies and derivatives thereof, given that these make up 
the higher end of the accumulation range with even an all-time record yield of 36.5% of TSP for a 
murine single-chain variable fragment (De Buck et al., 2013; De Jaeger et al., 2002; Virdi et al., 2013). 
On the lower end of the range, enzymes and antigenic proteins are found and these often need 
extensive optimization to reach reasonable yields (Morandini et al., 2011; Piron et al., 2014). Despite 
the fact that the cgl and wild type ASP1 are not structurally related to antibodies, they also rank 
among the high accumulating recombinant proteins produced in Arabidopsis seeds. In fact, the 13.6% 
of TSP reached by the cgl ASP1 is to our best knowledge the highest yield ever reported for a 
recombinant protein expressed in this specific Arabidopsis background. The seeds of the cgl mutant 
have been regularly used as a platform for the production of enzymes destined for enzyme 
replacement therapy of lysosomal storage diseases because of the high-mannose glycans introduced 
on the enzymes in this background that allow them to be specifically targeted to macrophages 
(Downing et al., 2006; Downing et al., 2007; He et al., 2012a; He et al., 2012b). Several enzyme variants 
have been produced in the cgl seeds and despite extensive optimization and the use of similar 
regulatory elements to drive expression, i.e. the arcelin5-I promoter and terminator, the highest yield 
reported for a recombinant variant of human α-L-iduronidase was only 5.7% of TSP (He et al., 2013). In 
summary, recombinant ASP1 accumulated to high levels in both wild type and cgl Arabidopsis seeds 
and although the accumulation of the GlycoDelete ASP1 was fourfold less, it still by far exceeded 1% of 
TSP, a value that has been designated to be the minimum required for economic viability of a PMP 
(Rybicki, 2009).  
To study the immunogenic potential of the complex plant glycans present on the wild type ASP1 but 
absent on the GlycoDelete ASP1, rabbits were immunized with purified GlycoDelete and wild type 
ASP1. More specifically, this experiment was performed to determine if the plant specific β1,2-xylose 
and core α1,3-fucose that were almost ubiquitously present on the glycans of the wild type ASP1, had 
induced glycan-specific antibodies and in case this was true, to see if this response was lacking among 
the GlycoDelete ASP1 immunized rabbits. Administration of the GlycoDelete and wild type ASP1 
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resulted in high titers of IgG antibodies specific for the ASP1 peptide backbone in all immunized 
animals and indeed, also three out of five rabbits that had received the wild type ASP1 had generated 
IgG antibodies against the glycans carried by the wild type ASP1. The specificity of these antibodies for 
the plant specific β1,2-xylose and core α1,3-fucose was demonstrated by the fact that only complex 
plant glycans, but not high-mannose glycans were recognized by the sera with glycan specific IgGs. 
Curiously, the remaining two rabbits from the wild type ASP1 immunized group had not mounted a 
glycan specific antibody response and this probably reflects genetic differences in susceptibility to 
these potential immunogenic plant glycans. As was expected, no glycan specific IgG antibodies could 
be detected in the sera from the rabbits immunized with the GlycoDelete ASP1 confirming the lack of 
immunogenic glycans on the latter. To sum up, this trial once more validates the immunogenic nature 
of the structures β1,2-xylose and α1,3-fucose that are omnipresent on complex plant glycans but 
absent on mammalian glycans (reviewed by Altmann (2007)). However it also identifies genetic 
disposition as a key factor in determining the individual outcome of exposure to a potentially 
immunogenic structures, i.e. if it is tolerated or if an antibody response is mounted against it. Most 
importantly, It also demonstrates that the GlycoDelete platform can be effectively used for the 
production of therapeutic proteins decorated with minimal, homogeneous glycans that are devoid of 
β1,2-xylose and α1,3-fucose, structures whose presence could otherwise invoke an anti-carbohydrate 
response upon parenteral administration of the therapeutic and could be potentially dangerous. 
The GlycoDelete platform presented here is a very ingenious approach to tackle the problem that 
immunogenic plant glycans (and glycan heterogeneity) pose. It does not suffer from the drawbacks 
that other strategies aimed at ‘humanizing’ plant glycans display. It is based upon a single inactivated 
endogenous glycosyltransferase and one introduced glycosidase, whereas other methods require the 
knock-out and knock-in of multiple genes and these manipulations are in general not completely 
efficient, which can actually even result in increased glycan heterogeneity. This is in sharp contrast 
with the GlycoDelete seed platform that fully trimmed the glycans on a ten-fold excess of ASP1 to 
homogeneity. None of the strategies for which proof-of-concept was delivered on a lab scale has so far 
been introduced in a commercial crop and industrialized, because of the excessively large timescale it 
would take to introduce all these traits to homozygousity, and then into an elite cultivar. In soybean, 
for example, a year and half is needed between transformation and the generation of seeds 
homozygous for the introduced trait (Dr. V. Virdi, personal communication). Stable integration of the 
six genes needed for sialylation of plant glycans would then take about ten years, without even having 
dealt with the introduced glycan heterogeneity and the inactivation of the genes responsible for the 
immunogenic glycans, and this is were the GlycoDelete technology could mark a difference. Its 
two-component setup would greatly reduce development time and facilitate its transfer to any crop 
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for which a GnTI knock-out can be obtained. A task that is considerably less cumbersome now 
meganucleases and genome-editing technologies are making their entry into research and 
development. The GlycoDelete technology has great potential and could be put to use in a whole 
range of applications. Actually, any protein that is produced in plants, but should lack immunogenic 
plant glycans and show great homogeneity, would benefit from the latter. One could envisage the 
large scale production in soybean or pea, whose seeds have a remarkably high protein content, of 
monoclonal antibodies (or Fc-fusion proteins) for which effector functions are unwanted, or vaccines 
that show enhanced efficacy when minimally glycosylated. Needless to say, the options for the use of 
the GlycoDelete technology are ample and it will be interesting to see the future development of the 
technology in planta.  
Immunization of calves with native ASP1 provides sufficient protection to allow them to build up 
natural immunity against Ostertagia. However, because of difficulties to obtain large quantities of 
native ASP1, there is great interest to produce recombinant ASP1s and despite the setbacks 
experienced with the recombinant ASP1s from baculovirus-infected insect cells, Pichia and wild type 
Arabidopsis, i.e. their non-protective nature, hopes are still high that at some point recombinant ASP1 
can be produced for vaccine purposes. To achieve the latter, the structural element that embows the 
native ASP1, but not the recombinant versions, with protective capacities must be identified and 
analyses are ongoing to solve this issue. Although the glycans present on the native ASP1 did not 
influence the binding of neutralizing antibodies, it will be interesting to analyze the effect of the 
different glycans present on the wild type, cgl and GlycoDelete ASP1 upon immunization and this will 
contribute to a better understanding of the characteristics of the ASP1, which will eventually lead to 
the elucidation of the enigmatic ‘protective element’.   
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Material and methods 
Cloning and generation of transgenic lines 
The coding sequences of the Trichoderma reesei endoT and the Ostertagia ostertagi ASP1 were 
derived from those deposited at GenBank under accession number 4G2U_A and CAZ16624.1, 
respectively. The recombinant endoT and ASP1 sequences that were cloned as described below and 
used to transform various Arabidopsis lines are given in the supplemental information (SI1 and SI2). 
The sequence coding for the endoT without signal peptide was extended in silico at its 5’-end with the 
Kozak motif (CCACC) followed by a sequence encoding the first 32 amino acids that make up the 
medial-Golgi targeting signal of the Arabidopsis β1,2-xylosyltransferase (Nagels et al., 2011b; Pagny et 
al., 2003). The resulting gene was optimized to resemble the codon usage of endogenous Arabidopsis 
seed storage proteins and chemically synthesized flanked by attL1-L2 sites. A multisite gateway 
recombination reaction (all GatewayTM reactions were performed according to the manufacturer’s 
protocol) transferred the gene to a destination vector that contains a T-DNA segment carrying the bar 
gene for phosphinothricin resistance and a seed-specific expression cassette under control of the 
β-phaseolin promoter and the arcelin5-I terminator.  
The coding sequence of the ASP1 was extended in silico at its 5’-end with the Kozak motif (CCACC) plus 
a sequence encoding the ER-targeting peptide of the Arabidopsis 2S albumin seed storage protein 
(Krebbers et al., 1988). The resulting gene was codon optimized, flanked by attL1-L2 sites and 
chemically synthesized. An LR recombination reaction transferred the gene to the gateway compatible 
pPphasGW destination vector that contains a T-DNA segment carrying the nptII gene for kanamycin 
resistance and a seed-specific expression cassette under control of the β-phaseolin promoter and the 
arcelin5-I terminator (Morandini et al., 2011).  
All the genes were sequence-verified prior to transfer to the destination vectors. Heat shock then 
delivered all expression vectors to Agrobacterium strain C58C1RifR containing the pMP90 virulence 
plasmid (Koncz & Schell, 1986) and the resulting strains were used to transform Arabidopsis thaliana 
(L.) Heyhn, ecotype Columbia 0 and the allelic complex-glycan deficient 1-1 and 1-2 mutants,  by floral 
dip (De Buck et al., 2012; von Schaewen et al., 1993). The Arabidopsis thaliana cgl1-1 and 1-2 mutants, 
stock number N6192 and N16366 respectively, were obtained from the European Arabidopsis Stock 
Centre (Nottingham, UK). Transformed seeds containing the T-DNA were identified and lines 
propagated to homozygosity as detailed in (De Buck et al., 2012). In short, T1 seeds obtained after 
floral dip were grown on selective Murashige and Skoog medium for three to four weeks at 21 C° on a 
16-h light / 8-h dark cycle. Twenty transformants were then transferred to soil and grown under the 
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same conditions. These were selfed and when seed setting was complete, transferred to a room at 25 
°C and low humidity until completely dry. The dry seeds of each transformant were harvested to 
obtain twenty T2 seed stocks. These stocks were screened for the presence of recombinant protein by 
western blot analysis (for endoT) or Coomassie staining of polyacrylamide gels (for ASP1) as detailed 
below and seven stocks with high accumulation of the recombinant protein were analyzed for the 
number of integrated T-DNA loci. As the T1 transformants are per definition hemizygous, the T-DNA 
locus number can be determined by the segregation ratio in the T2 generation. To identify the single 
locus T-DNA integration lines, seeds of segregating T2 stocks were sown on selective medium and the 
observed ratio of germinated over sensitive seeds was compared to the expected 3:1 segregation ratio 
for single locus lines using a χ2 statistical test (De Buck et al., 2012). For each antigen, the T2 stock with 
the highest antigen content and the T-DNA integrated at a single locus in the genome was retained 
and propagated to homozygosity. 
 
Protein extraction, protein concentration determination, SDS-PAGE, Coomassie staining and 
western blot analysis 
To characterize the endoT accumulation in transgenic seed, TSP was extracted as described elsewhere 
(De Buck et al., 2012) with minor modifications: 1 ml of cold extraction buffer (50 mM Phosphate 
buffer, pH 7.8, 0.3 M NaCl and supplemented with an EDTA-free, proteinase inhibitor cocktail (1 tablet 
per 50 ml; Roche)) with or without the detergent n-Dodecyl β-D-maltoside (1% w/v) was added to 10 
mg of liquid nitrogen (N2) frozen, crushed seeds. Samples were vortexed for 1 minute and centrifuged 
at approximately 20,000 g and 4°C for 30 minutes. 700 µl supernatant was removed, snap-frozen in 
liquid N2 and stored at -20°C. Total protein concentration was determined by the Lowry method as 
described in De Buck et al. (2012). The ASP1 was extracted from the seed following the same protocol 
that was applied to the endoT except that an acid extraction buffer was used (0.1 M sodium acetate at 
pH 4.4 supplemented with CHAPS (0.1% w/v ) and an EDTA-free, proteinase inhibitor cocktail (1 tablet 
per 50 ml; Roche)). During the solubility assay, ASP1 was extracted from the seeds three times with 0.1 
m sodium acetate buffer at pH 4.4 and a final fourth time using the same buffer but supplemented 
with 5% v/v β-mercaptoethanol and 8 M urea. 
Seed extracts containing TSP were separated by reducing SDS-PAGE. To visualize proteins via 
Coomassie staining, the gels were submerged in InstantBlueTM (Expedeon) solution for an hour and 
then washed three times for 20 minutes with double distilled water (ddH2O). Stained gels were 
photographed with the Molecular Imager® ChemiDocTM XRS+ Imaging System (Biorad) and 
densitometric analysis of the visualized proteins was performed with the Image Lab 3.0 software 
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(Biorad). For western blot analysis the proteins were transferred electrophoretically from a 
polyacrylamide gel onto Immobilon-P polyvinylidene fluoride membrane (Millipore, Billerica, MA). 
Blots were blocked in 4% (w/v) skimmed milk and 0.1% (v/v) Tween 20 in PBS. Polyclonal rabbit 
α-endoT and α-ASP1 sera, diluted 1:10.000 and 1:5000 in blocking buffer, respectively, were used to 
detect the recombinant proteins in combination with an anti-rabbit IgG HRP-linked whole antibody 
diluted 1:5000 in blocking buffer (from sheep, GE healthcare). Western blotting was further performed 
as described in De Buck et al. (2012) and the released chemiluminescent signal measured with the 
abovementioned imaging system. Quantification of signal intensities was performed with the Image 
Lab 3.0 software (Biorad). To identify high-mannose bearing glycoproteins western blots were 
developed using ConA coupled to HRP: after transfer of the SDS-PAGE separated proteins onto the 
blotting membrane, remaining free sites were blocked with 3% BSA and 0.05% (v/v) Tween 20 in PBS 
and the membrane incubated with ConA-HRP (1 mg/ml in blockbuffer) with or without the ligand 
methyl-α-D-mannopyranoside (100 mM, in blockbuffer). Western blotting was further performed as 
described above. 
 
PNGaseF digestion of recombinant endoT 
Seed extracts containing TSP were treated with peptide N-glycosidase F (PNGaseF, New England 
Biolabs) to analyze the endoT glycosylation status. Glycosidase reactions were performed according to 
the manufacturer’s protocol. In short, to 9 µl of extract, 1 µl of 10x denaturing buffer was added and 
the sample was incubated at 100°C for 10 minutes. Then, 2 µl G7-buffer, 2 µl 10% NP-40 and 2 µl 
PNGaseF was added to the sample. Sample volume was adjusted to 20 µl with ddH2O, after which the 
sample was incubated at 37°C for one hour and analyzed by western blotting. 
 
ELISA to determine endoT accumulation level 
The endoT content of specific seed stocks was analyzed by ELISA. Seed extract were prepared in 
binding buffer with detergent as detailed above, dilution series were made in duplicate with sodium 
carbonate as the buffer (50mM NaHCO3, pH 9.6), loaded onto Maxisorp 96-well plates (Nunc, Sigma 
Aldrich) and coated overnight at 4°C. Plates were washed three times with Tween (0.1% v/v) in PBS 
between all following steps unless stated differently. PBS with BSA (1% w/v) and Tween (0.1% v/v) was 
used to block the wells after which 100 µl polyclonal rabbit α-endoT was added (diluted 1:2.500 in 
blocking buffer). Subsequently 100 µl donkey α-rabbit IgG-HRP (Sigma Aldrich) was added as 
secondary antibody (diluted 1:5000 in blocking buffer) and the wells were washed five times. 
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Incubation with 100 µl TMB (Sigma Aldrich) allowed color development that was stopped after 30 
minutes by addition of 100 µl 1M HCl after which the plates were read at 450 nm in a VERSAmax 
tunable microplate reader. Measured OD values were plotted against a standard curve derived from 
duplicate dilution series of purified endoT and used to calculate the endoT content of the different 
stocks.  
 
Recombinant ASP1 purification 
The acid extraction of the recombinant ASP1s from the seeds was coupled to a three-step purification 
protocol consisting of cation and anion exchange chromatography followed by gel filtration. Seed 
extracts were prepared in binding buffer (40mM sodium acetate, pH 4.4, supplemented with an EDTA 
free proteinase inhibitor cocktail (1 tablet per 50 ml; Roche)) by adding frozen and pulverized seeds to 
cold buffer at a fixed w/v of 1 g seeds per 70 ml buffer. The extract was vortexed and centrifuged for 
30 minutes at 4°C and 40,000 g to remove cell debris. The supernatant was removed, passed through a 
GF-prefilter (Sartorius) and a Millex®-HP filter unit (Millipore) and then flowed over the cation 
exchange column (Hitrap SP HP 1 ml; GE Healthcare) fitted onto an Äkta Explorer® purification system. 
Bound ASP1 was eluted by passing a gradient of elution buffer (40 mM sodium acetate, pH 4.4, 1M 
NaCl) over the column. Subsequently the eluted fractions containing the majority of the ASP1  were 
pooled, diluted in 20mM TrisHCl to lower the conductivity, adjusted to pH 8.0 and flowed over the 
anion exchange column (Hitrap Q HP 1 ml; GE healthcare) fitted onto the same purification system. 
Bound ASP1 was released from the column by a gradient of elution buffer (20 mM TrisHCl, pH 8.0, 1 M 
NaCl). Again, the eluted fractions containing most ASP1 were retained, pooled and subjected to a final 
gel filtration step by passage over a HiLoad Superdex 200 pg column (GE healthcare), with LPS-free PBS 
as the mobile phase, fitted onto the same purification system. Removal of impurities and/or 
degradation products was assayed by Coomassie staining of polyacrylamide gels and whenever 
necessary, pure, gel filtrated ASP1 was concentrated using Amicon® Ultra centrifugal filters (Millipore, 
3 kDa molecular weight cutoff). The ASP1 concentration was derived from the sample optical density 
at 280 nm measured by a NanoDrop® ND-1000 spectrophotometer. Samples were snap-frozen in 
liquid N2 and stocked at -20°C. 
 
Recombinant ASP1 glycan analysis by endoT digest 
To check the susceptibility of the glycan structures carried by wild type and cgl ASP1 to digestion with 
endoT, purified ASP1 (in PBS) was incubated overnight at room temperature with serial dilutions of 
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active, purified endoT produced in the yeast Pichia pastoris. Sample glycosylation status was 
subsequently checked by a mobility shift assay on Coomassie stained polyacrylamide gels.  
 
Recombinant ASP1 glycan analysis by glycosidase treatment and DSA-FACE 
To identify the glycan structures present on wild type and cgl ASP1, purified recombinant ASP1 was 
digested with the endoglycosidases PNGaseA and PNGaseF  to release its glycan structures that were 
then fluorescently labeled and analyzed by DSA-FACE via the plate method as described in (Laroy et al., 
2006). In short, reduced and denatured, and for PNGaseA digest also trypsinized, ASP1 was bound on 
polyvynilidene fluoride membranes in a 96-well plate. The washed, carboxymethylated, protein was 
digested with PNGaseF or PNGaseA, the supernatans transferred to a reaction tube and evaporated. 
Glycans were fluorescently labeled with 8-amino-1,3,6-pyrenetrisulfonic acid (APTS) and gel filtrated 
by passage over G10 Sephadex in 96-well plates to desalt and remove excess label. After evaporation 
and resuspension in nanopure water, the glycans were eventually analyzed on a DNA-sequencer. 
Sequential treatment and analysis of the released glycans with different exoglycosidases allowed 
elucidation of the glycan structures present on the wild type and cgl ASP1.  
 
Recombinant ASP1 glycan analysis by MALDI-TOF spectrometry 
The truncation of the glycans on the ASP1 produced in the GlycoDelete Arabidopsis was analyzed by 
MALDI-TOF mass spectrometry. Trypsinization of the GlycoDelete ASP1 prior to mass spectrometry 
occurred in-solution or in-gel according to the protocols described in the following paragraphs.  
For in-solution trypsinization, a reducing and denaturing buffer (50 mM TrisHCl, 10 mM DTT, 8 M urea) 
was added to 5 µg of purified GlycoDelete ASP1 in PBS, samples were incubated at 37°C for 45 
minutes, a 10x concentrated iodoacetic acid solution (200 mM in nanopure H2O) was added and 
samples incubated in the dark for another 30 minutes after which samples were concentrated via 0.5 
ml spin columns (10 kDa molecular weight cutoff, VS0102; Sartorius) to 50 µl. To ensure maximal 
digestion the samples were treated with a mixture of trypsin and the endoproteinase Lys-C (200 ng, 
1:25 ratio of protease to target protein, Trypsin/Lys-C mix Mass Spec Grade; Promega). Samples were 
incubated 4 hours at 37°C to allow digestion by the Lys-C which is functional under highly denaturing 
conditions. Subsequently, the samples were diluted (450 µl 50 mM TrisHCl, pH 8), lowering the ureum 
concentration to activate the trypsin, incubated overnight at 37°C and dried in a speedvac. Samples 
were finally reconstituted with 10 µL of 0.2% trifluoroacetic acid (TFA) (Sigma-Aldrich) and cleaned up 
with C18 ZipTip® pipette tips (Millipore, Billerica, MA, USA) according to the manufacturer’s 
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instructions. Samples were analyzed with α-cyano-4-hydroxycinnamic acid (CHCA) matrix saturated in 
50% acetonitrile containing 0.1% TFA, on a 4800 MALDI TOF/TOFTM Analyzer (Applied Biosystems by 
Life Technologies) in the positive ion mode. The reported m/z values were observed in several 
iterations of technical optimization of these experiments and the results of the fully optimized 
experiments are shown. The m/z values observed in the mass spectra were compared to the 
theoretical m/z values of ASP1 tryptic peptides that were calculated using the PeptideMass software8. 
Values for different glycoforms of the tryptic glycopeptides were generated by the addition of glycan 
mass increments to those of the naked glycopeptides and values for ASP1 peptides resulting from 
nonspecific cleavage were calculated using the FindPept software9.  
For in-gel tryptic digest, 8 µg purified GlycoDelete ASP1 was mixed with 5x concentrated SDS-PAGE 
sample buffer (De Buck et al., 2012) and incubated for 8 minutes at 98°C. After the denaturation, an 
excess of iodoacetamide was added (3 µl of 0.5 M iodoacetamide in nanopure H2O), samples were 
incubated for one hour in the dark at room temperature, run on polyacrylamide gels and visualized via 
Coomassie staining. An area containing the GlycoDelete ASP1 carrying trunctated glycans and possible 
larger glycoforms was excised, destained and dried in a speed vac. Subsequent tryptic digest was 
performed by reswelling  the gel fragments with 500 ng trypsin / cLys-r mix resuspended in 25 mM 
ammonium hydrogen carbonate (NH4HCO3) and incubating overnight at 37°C. The tryptic peptides 
were extracted from the gel, dried in a speed vac, reconstituted with 10 µL of 0.2% trifluoroacetic acid 
(TFA) (Sigma-Aldrich), cleaned up with C18 ZipTip® pipette tips and further analyzed as described 
above.  
 
Immunization of rabbits  
Two groups of five rabbits were immunized subcutaneously with purified GlycoDelete or wild type 
ASP1 (in LPS-free PBS) following a prime-boost protocol. Rabbits received a first injection of 35 µg 
recombinant ASP1 mixed with complete Freund’s adjuvant in a 1:1 ratio at day one, followed by three 
booster shots of 35 µg ASP1 mixed with incomplete Freund’s adjuvant in a 1:1 ratio at days 14, 28 and 
56. Blood samples were taken on day zero (preimmune) and at days 28, 36 and 80 when the rabbits 
were euthanized. Serum samples were incubated for 30 minutes at 56°C prior to freezing. The trial was 
performed by the Health Department of the CER groupe (Marloie, Belgium).  
 
                                                            
8
 http://web.expasy.org/peptide_mass/ 
9
 http://web.expasy.org/findpept/ 
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Characterization of the antibody response in rabbits 
ELISAs were performed to study the antibodies induced by immunization of rabbits with the wild type 
and GlycoDelete ASP1. To measure the presence of IgG antibodies specific for the ASP1 peptide 
backbone, high-mannose bearing cgl ASP1 was reduced, denatured and deglycosylated with PNGaseF, 
and used as antigen in ELISA. To achieve the latter, PNGaseF buffer (50 mM Phosphate buffer, pH 7, 
0.5% w/v SDS, 0.4 M β-mercapthoethanol) was added to purified cgl ASP1, samples were heated for 10 
minutes at 98°C, Igepal was added (final concentration 1% w/v) together with in-house produced 
PNGaseF and samples were incubated overnight at 37°C.  Complete ASP1 deglycosylation was 
monitored by mobility shift assay on Coomassie-stained polyacrylamide gels. A final 10 minute heating 
step at 98°C inactivated the PNGaseF. Reduced, denatured and deglycosylated ASP1 was then diluted 
in sodium carbonate buffer (50 mM, pH 9.6) and used to coat Maxisorp 96-well plates (Nunc, Sigma 
Aldrich) overnight at 4°C (10 ng per well). Wells were washed three times with washing buffer (PBS, 
0.1% v/v Tween 20) and this step was repeated between all following steps unless stated differently. 
Wells were blocked for two hours (PBS, 250 mM glycine, 1% w/v BSA), emptied and allowed to dry 
overnight at room temperature. Serial dilution of sera were made (in PBS, 0.1% v/v Tween 20, 0.1% 
goat serum), 100 µl was added to each well and plates were incubated for two hours. Donkey α-rabbit 
IgG-HRP (Sigma-Aldrich) was used as secondary antibody (diluted 1:5000 in PBS with 1% w/v BSA), 100 
µl was added and plates incubated for one hour. Plates were washed five times and 100 µl TMB was 
added to allow color development that was stopped after 30 minutes by addition of 100 µl 1M HCl 
after which plates were read at 450 nm in a VERSAmax tunable microplate reader. The background 
signal was subtracted from the measured values and an OD value of 0.3 was taken to calculate 
antibody titers. 
A similar strategy was followed to probe for the presence of plant-glycan specific IgG antibodies in the 
sera of the immunized rabbits. Here, different glycoforms of GBP-Fc, a synthetic antibody, were used 
as antigen in ELISA to identify sugar specific total IgG. High-mannose and complex plant-glycan bearing 
glycoforms of the GBP-Fc had previously been purified from Pichia pastoris and wild type Arabidopsis 
thaliana, respectively, and had been extensively characterized (Dr. T. De Meyer T, PhD dissertation 
2013). The naked GBP-Fc peptide backbone was obtained by reduction, denaturation and 
deglycosylation of the high-mannose GBP-Fc glycoform as described above for the cgl ASP1 and the 
peptide backbone was used together with the high-mannose and complex-glycan bearing glycoforms 
as antigen in ELISA. To avoid experimental variation due to differential antigen preparation, the 
high-mannose and complex glycoform were also treated as described above with the exception that 
heat-inactivated PNGaseF was added to the samples and this was checked by mobility shift assay on 
Coomassie-stained polyacrylamide gels. ELISA was further performed as described in the previous 
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paragraph with the exception that 50 ng of GBP-Fc was coated per well. The background signal, 
determined by coating the GBP-Fc peptide backbone as antigen, was subtracted from the measured 
values and an OD value of 0.3 was taken to calculate antibody titers. 
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Supplemental information 
 
 
 
Figure S1. T2 analysis and inter-transformant variation in accumulation level of the seed-produced ASP1s. 
The wild type ASP1 was propagated to homozygousity by Dr. A. De Paepe and provided as such. 
Information on inter-transformant variation was not at hand for these lines. 20 GlycoDelete ASP1 and 19 
cgl ASP1 T2 transformed seed stocks were screened for antigen content via Coomassie stained 
polyacrylamide gels. After visual inspection, seven lines showing high antigen accumulation were selected 
and analyzed for single locus T-DNA integration. Subsequently, the line with the highest antigen content 
and the ASP1 T-DNA integrated at a single locus in the genome, was retained (indicated with a hollow 
arrowhead) and propagated to homozygousity. Seed extracts were prepared at a fixed w/v ratio, 10 µl was 
loaded onto the gels that were run under reducing conditions. (A) The 20 screened GlycoDelete ASP1 T2 
seed stocks. (B) The 19 screened cgl ASP1 T2 seed stocks.  
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Figure S2. Recombinant ASP1 purification. Wild type ASP1 was extracted from one gram of a homozygous 
seed stock and purified by three consecutive chromatography steps. ASP1 purity and integrity was 
monitored by SDS-PAGE and Coomassie staining under reducing (left panels) and non-reducing conditions 
(middel panels). 10 µl was loaded onto the gels. Right panels represent the corresponding chromatograms 
showing the OD280. (A) Cation exchange chromatography step. Fractions pooled, diluted and subjected to 
further purification are indicated with a black circle. (B) Anion exchange chromatography step. Eluted 
fractions were separated into ASP1 dimers (green circle) and multimers (red circle) and independently gel 
filtrated, (C) and (D), respectively. Abbreviations used: DC, Dual Color ladder; kDa, kilodalton; S, sample; FT, 
flow through. 
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Figure S3. DSA-FACE analysis of recombinant ASP1 glycan structures and α1,2-mannosidase (α1,2man) 
digests. Glycans were released from purified recombinant ASP1 and treated with α1,2-mannosidase. (A) 
Oligomaltose standard, the number of glucose units is indicated. (B) Glycans released from wild type ASP1 
by PNGaseF and (C) digested with α1,2man. (D) Glycans released from cgl ASP1 by PNGaseA and (E) 
digested with α1,2man. (F) EndoT released wild type ASP1 glycans and (G) digested with α1,2man. (H) 
RNAseB high-mannose glycan standard. Abbreviations used: α1,2man, α1,2-mannosidase.  
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Figure S4. Overview of the α-ASP1 peptide backbone ELISAs. Sera obtained from the final bleeding of 
GlycoDelete (left panel) and wild type ASP1 immunized rabbits (right panel) were subjected to ELISA with 
reduced, denatured and deglycosylated ASP1 coated as the antigen. Values are the average of three 
independent experiments, error bars represent the standard deviation. Background indicates the signal 
detected when a pooled sample was loaded onto wells coated with inactivated PNGaseF only. Are given, 
the serum dilution and the corresponding signal measured at 450 nm.  
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Figure S5. Overview of the α-GBP-Fc ELISAs. Sera obtained from the final bleeding of GlycoDelete (left 
panels) and wild type ASP1 immunized rabbits (right panels) were subjected to ELISA with the GBP-Fc 
peptide backbone, the high-mannose (Hm) GBP-Fc and the xylose/fucose (X/F)  bearing GBP-Fc coated as 
antigens. The GBP-Fc peptide backbone was coated to determine the background signal. Are given, the 
serum dilution (X-axis) and the corresponding signal measured at 450 nm (Y-axis). Dilution series were 
made in triplicate and the average values are shown. No glycan-specific IgG could be detected in the sera of 
the GlycoDelete ASP1 immunized rabbits, whereas three out of five wild type ASP1 immunized rabbits had 
generated IgG specific for fucose and xylose.   
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Table S1. Matching peptides for unspecific cleavage of GlycoDelete ASP1 
 
Observed m/z Predicted m/z Δmass peptide position 
     
1.975.020 1.974.967 -0.053 (L)RNLQPDTEANIYNWQI(R) 116-131 
1.975.020 1.974.967 -0.053 (R)NLQPDTEANIYNWQIR(P) 117-132 
1.975.020 1.974.967 -0.053 (S)LRNLQPDTEANIYNWQ(I) 115-130 
1.975.020 1.974.992 -0.028 (I)DTSIPQNLAQWLLFQNS(Q) 81-97 
1.975.020 1.975.083 0.063 (F)HNQVRRDIAGASPLLNLT(G) 22-39 
     
2.185.150 2.185.067 -0.082 (T)PWSWVTASLRNLQPDTEAN(I) 107-125 
2.185.150 2.185.104 -0.046 (R)NLQPDTEANIYNWQIRPL(S) 117-134 
2.185.150 2.185.129 -0.021 (L)PIDTSIPQNLAQWLLFQNS(Q) 79-97 
     
2.386.220 2.386.179 -0.041 (R)NLQPDTEANIYNWQIRPLSN(I) 117-136 
     
 
Supplemental table 1. In silico prediction of internal glycoDelete ASP1 peptides derived from nonspecific 
cleavage that match the m/z values of unidentified peaks in the MALDI-TOF spectrum of in-gel trypsinized 
GlycoDelete ASP1. 
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       1 ATGAGTAAAC GGAATCCGAA GATTCTGAAG ATTTTTCTGT ATATGTTACT 
TCTCAACTCT CTCTTTCTCA TCATCTACTT CGTTTTTCAC TCATCGGTAC 
     101 CCGTTAAAGA ACTGCAGCTC AGAGCTGAAC CAACCGATCT CCCTAGGCTT 
ATCGTCTACT TCCAGACTAC CCACGACTCT AGCAACCGTC CCATAAGCAT 
     201 GTTGCCACTC ATCACTGAGA AGGGTATAGC CTTGACACAC CTTATCGTTT 
GCTCCTTCCA CATTAACCAG GGCGGAGTGG TTCACCTAAA CGACTTTCCA 
     301 CCCGATGATC CACACTTCTA CACCCTCTGG AACGAGACTA TCACTATGAA 
GCAGGCTGGG GTCAAGGTTA TGGGAATGGT CGGTGGCGCA GCTCCTGGTT 
     401 CATTCAACAC GCAGACTCTT GACTCTCCGG ACTCAGCCAC CTTCGAACAT 
TACTACGGCC AACTCCGCGA TGCTATAGTT AACTTCCAGT TGGAGGGAAT 
     501 GGATCTCGAC GTGGAGCAAC CAATGAGCCA ACAAGGTATC GACAGACTCA 
TCGCGCGACT AAGAGCTGAT TTCGGACCCG ACTTCTTGAT TACCCTCGCC 
     601 CCTGTTGCTT CAGCATTGGA GGACTCCTCA AACCTTTCTG GTTTTAGCTA 
TACAGCCCTC CAACAGACCC AGGGAAACGA CATTGACTGG TACAACACTC 
     701 AGTTCTACTC TGGTTTCGGC TCAATGGCAG ACACCTCCGA CTACGACCGC 
ATCGTCGCTA ACGGCTTCGC CCCAGCTAAA GTTGTCGCCG GACAGCTCAC 
     801 GACTCCTGAA GGTGCAGGAT GGATTCCAAC CAGCTCCCTA AACAACACTA 
TCGTTAGCCT CGTATCCGAG TATGGCCAAA TAGGTGGGGT TATGGGATGG 
     901 GAGTACTTTA ATAGCCTCCC GGGTGGAACC GCCGAACCAT GGGAGTGGGC 
GCAAATCGTC ACAGAAATCC TTAGACCCGG ATTGGTTCCA GAGCTCAAGA 
    1001 TTACCGAGGA TGACGCCGCT CGTTTGACCG GTGCATACGA AGAAAGCGTG 
AAAGCTGCCG CTGCAGATAA CAAGTCCTTC GTTAAGAGGC CTAGCATCAA 
    1101 CTACTACGCT ATGGTCAACG CGTAA 
 
         1   MSKRNPKILK IFLYMLLLNS LFLIIYFVFH SS  VPVKELQL RAEPTDLPRL IVYFQTTHDS  
       61   SNRPISMLPL ITEKGIALTH LIVCSFHINQ GGVVHLNDFP PDDPHFYTLW NETITMKQAG  
      121   VKVMGMVGGA APGSFNTQTL DSPDSATFEH YYGQLRDAIV NFQLEGMDLD VEQPMSQQGI  
      181   DRLIARLRAD FGPDFLITLA PVASALEDSS NLSGFSYTAL QQTQGNDIDW YNTQFYSGFG  
      241   SMADTSDYDR IVANGFAPAK VVAGQLTTPE GAGWIPTSSL NNTIVSLVSE YGQIGGVMGW  
      301   EYFNSLPGGT AEPWEWAQIV TEILRPGLVP ELKITEDDAA RLTGAYEESV KAAAADNKSF  
      361   VKRPSINYYA MVNA* 
 
Supplemental Information 1. EndoT sequences. The EndoT open reading frame (ORF) from 5’ to 3’ end as it 
was cloned into the expression vector (upper sequence) and the translation thereof (lower sequence, the 
β1,2-xylosyltransferase medial-Golgi targeting signal is underlined).  
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       1 ATGGCAAACA AGCTTTTCCT CGTCTGCGCA ACTTTCGCCC TCTGCTTCCT 
CCTCACCAAC GCCGGTTTTT GCTGCCCAGC CGATCTCAAC CAGACTGATG 
     101 AGGCAAGAAA GATCTTCCTC GATTTTCACA ACCAAGTTCG CCGTGATATC 
GCAGGTGCCA GCCCGTTGCT CAACCTCACC GGAGCTGTTC AGATGCGAAA 
     201 CGTTCTCGGT CCAGCTAAGA ACATGTACAG AATGGACTGG GACTGCAACC 
TCGAAGCCAA AGCAAAGGCC ATGATCTGGC CATGCACTAC CCCTCTCCCA 
     301 ATCGACACGA GCATTCCACA GAACCTCGCT CAGTGGCTAC TTTTCCAAAA 
CAGCCAGGAA AACGAGGTCT TGACCCAAAC GCCCTGGTCT TGGGTCACCG 
     401 CATCACTAAG AAATCTTCAA CCTGATACAG AGGCTAACAT CTACAACTGG 
CAGATTAGAC CACTATCCAA CATCGCTAAC TGGCAGAACC TAAAAGTTGG 
     501 ATGTGCTCAC AAGGTTTGCA AATTCCCCAC CGGGACAAAC ATGGTTGTGT 
CTTGCGCTTA CGGCGGCGAG GTCCTCCAGG ATAACGAAGT TGTCTGGGAC 
     601 AAGGGACCAA CTTGCATGTG CAACGCTTAC CCCAACAGCT TCTGCTGCAA 
CAATCTCTGT GACACAATCG CTGCTGCAAC ACTTCGCAAC CAGCCTTGCA 
     701 AGAGCACTTG A 
 
1   MANKLFLVCA TFALCFLLTN A GFCCPADLN QTDEARKIFL DFHNQVRRDI AGASPLLNLT  
       61   GAVQMRNVLG PAKNMYRMDW DCNLEAKAKA MIWPCTTPLP IDTSIPQNLA QWLLFQNSQE  
      121   NEVLTQTPWS WVTASLRNLQ PDTEANIYNW QIRPLSNIAN WQNLKVGCAH KVCKFPTGTN  
      181   MVVSCAYGGE VLQDNEVVWD KGPTCMCNAY PNSFCCNNLC DTIAAATLRN QPCKST* 
 
Supplemental information 2. Recombinant ASP1 sequences. The ASP1 ORF from 5’ to 3’ end as it was 
cloned into the expression vector (upper sequence) and the translation thereof (lower sequence, the 2S 
ER-signal peptide is underlined). 
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Vaccine production in Arabidopsis seeds 
Since its discovery the PRRSV has spread rapidly, becoming endemic in almost all pig-rearing countries 
around the world, and is nowadays considered to be the most important pathogen of swine. Whereas 
older strains would mainly be problematic for pregnant sows and piglets, the situation is nowadays 
further aggravated by the fact that lately also highly pathogenic strains have been appearing that 
cause severe symptoms among pigs of all ages and have a high incidence of mortality. Vaccines are 
being used to minimize the clinical impact of an infection but because of the genetic drift of the virus, 
these constantly loose their power and it has been proposed that a whole battery of complementary, 
adaptable vaccines will be needed to effectively combat the virus. A subunit vaccine, that is safe and 
contains epitopes important in protective immunity, would be of good use in combination with the 
exisiting attenuated vaccines.  
We wanted to evaluate the capacity of the Arabidopsis seed-platform, previously used to obtain high 
seed specific expression of a range of heterologous proteins, for vaccine production. To this goal we 
selected the GP3, GP4 and GP5 of the PRRSV to be expressed in our system and included in a subunit 
vaccine against the PRRSV. Viral antigens are complex, often difficult to express proteins and plants 
could occupy a niche among the current platforms by producing these. However, antigens are 
frequently plagued by low expressing levels that in their turn can obstruct further vaccine 
development.  Indeed, when PRRSV antigens were expressed in different plant species they showed 
very low accumulation levels that did not even reach the 1% of TSP threshold.  We set out to tackle 
this issue by the rational design of antigen formats and fusions that were aimed at augmenting the 
accumulation of the antigens in the seed.   
Several strategies were tested and these included removal of transmembrane domains and/or 
coupling the antigens to stabilizing protein domains such as the GFP and IgG Fc-domains. We showed 
that the antigens as such do not accumulate very well in our system, hereby confirming their difficult 
to produce nature, but that by select optimization their accumulation could be boosted by multiple 
factors resulting in several antigens with yields that exceeded the 1% of TSP threshold, a feature that 
hasn’t been attained by any previous study generating PRRSV antigens in planta. The results further 
show that the viral antigens can correctly be produced in the ER, with the additional benefit that 
high-mannose glycans are present on the antigens that might direct these to antigen presenting cells, 
and that the added Fc-domains have a double role and also effectively serve as affinity handle besides 
increasing accumulation.  
We delivered proof-of-principle of the immunogenicity of purified seed-produced antigens by showing 
that virus-neutralizing antibodies are generated in mice after injection of a GP4 derived antigen, which 
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is similar to the in vivo situation were GP4 is also an important target for neutralizing antibodies. Alas, 
this could not be reproduced during a preliminary trial in piglets that had received an antigen cocktail. 
An in-depth experiment with challenge is required to shed light on this matter and to dissect the role 
of each antigen in more detail and evaluate if the antigens have, for example, a priming effect that 
stimulates a faster immune reponse after challenge. Perhaps the presence of an immunodominant, 
non-neutralizing B-cell epitope in the antigen cocktail skewed the induction of antibodies towards 
non-neutralizing epitopes. Indeed, for the GP5 such a decoy epitope has been identified (Ostrowski et 
al., 2002) and this might have affected the antibody response when it was administered together with 
the GP3 and GP4 derived antigens. Again, a challenge experiment could assess the role of each antigen 
alone and determine which antigens offer good protective immunity.  
Another interesting venue is offered by the Fc-domain that is carried by the antigens that were 
administered to the piglets and that is derived from the porcine IgG3. In silico prediction hints at a 
good binding of the Fc-domain to the neonatal Fc receptor (FcRn) and experimental evidence seems to 
support this statement (Butler et al., 2009; Virdi et al., 2013). An alternative route of antigen 
administration could thus be envisaged where the antigens would be delivered intranasally and 
associate with the FcRns present in the mucosa via binding of their IgG3 Fc-domain, resulting in their 
effective uptake. The feasibility of this approach to mucosal vaccination was shown in mice by Ye et al. 
(2011) who could generate both a mucosal as a systemic B and T-cell response against a model antigen 
fused to an IgG Fc-domain when this was administered intranasally together with the adjuvant CpG. As 
the PRRSV is primarily transmitted via the respiratory route, a mucosal immune response would be a 
great first line of defence, which is a feature desirable for all PRRSV vaccines, and this merits further 
investigation. 
All in all, our results confirm that the PRRSV antigens are poor accumulators in planta, and show that 
by mimicking the structures that do produce well in our system, i.e. antibodies, via fusion of the 
antigens to Fc-domains (and the GFP) their accumulation could be considerably increased. For some, 
but not all antigens, yields exceeded the 1% of TSP deemed necessary for economic viability of a PMP. 
The results also show that no general optimization rule fits all antigens, however, most antigens do 
have the tendency to accumulate better after fusion to stabilizing domains. Antigens could be 
efficiently purified and were immunogenic, at least in mice, but their protective capacity in pigs 
remains to be elucidated.  
To formulate a straightforward conclusion concerning the suitability of the seed-platform for the 
production of antigens with the final intention of generation a functional vaccine, is a more complex 
matter. The obtained results show that, with respect to accumulation and purification, antigens can 
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indeed be produced in the seeds. The optimized antigens could be purified via a straightforward 
protocol and taking into consideration that downstream processing represents the bulk cost 
associated with therapeutic protein production, this turns out favourable. However, the protective 
capacity of the seed-produced antigens remains to be elucidated and this is as crucial as high yield and 
efficient purification. It determines factors such as the dose that is required per immunization and this 
in its turn directly influences the amount of antigen that needs to be produced and hence, the price 
tag associated with the final vaccine. To conclude, antigen production in the seed and purification 
from the latter is feasible, as shown by our results, but this not necessarily translates into an 
efficacious and affordable vaccine and the suitability of the seed platform for the production of such a 
vaccine must thus be evaluated on a case-by-case basis and will be determined by the outcome of the 
interplay between the factors antigen immunogenicity, accumulation and downstream processing. 
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Glycoengineering Arabidopsis seeds 
Plants have distinct advantages over other systems for the production of recombinant proteins: they 
are capable of complex protein synthesis, they do not harbor animal and human pathogens, 
production is easily scalable for most systems and possibly, also cheap. One major drawback however, 
is that the plant and human N-glycosylation pathways diverge during the later stages of glycan 
maturation in the Golgi apparatus and this results in the introduction of specific structures on complex 
plant glycans that are not encountered on human glycans and hence, are possibly immunogenic. 
Indeed, a large part of the human population has antibodies against the plant specific glycans 
β1,2-xylose and core α1,3-fucose (Bardor et al., 2003; Mari, 2002) and this can prove problematic 
when a therapeutic protein bearing these glycans is delivered into the blood stream. Binding of these 
glycan specific antibodies can result in rapid clearance of the therapeutic, but in the worst case 
scenario, this immunogenicity might provoke a life threatening anaphylactic shock.  
Given the importance of these immunogenic glycans, a plethora of strategies have been employed to 
‘humanize’ plant glycans, i.e. to avoid the synthesis of immunogenic glycans and to convert plant 
glycosylation pathways to human-like synthesis. These glycoengineering techniques range from 
relatively straightforward retention of a recombinant protein in the ER, to the more elaborate 
inactivation of endogenous plant glycosyltransferases, which has often been coupled to the 
concomitant introduction of heterologous transferases into the plant glycosylation machinery. 
Needless to say, these are tedious strategies that require the coordinated expression of several genes 
at the same time and at the right place. These endeavours are further complicated by the polyploidy of 
many crop species, requiring decade long breeding strategies to obtain homozygous lines for all 
knock-outs and transgenes. We, on the other hand, have developed a straightforward system that 
bypasses extensive manipulations of the glycosylation pathway by seed-specific expression of a single 
fungal gene in a selected Arabidopsis thaliana mutant lacking just one endogenous glycosyltransferase. 
The resulting so-called ‘GlycoDelete’ seed-platform permits the production of any therapeutic 
glycoprotein and delivers the latter as one glycoform, bearing N-glycans that are trimmed down to a 
single GlcNAc, completely devoid of immunogenic β1,2-xylose and core α1,3-fucose.  
To create such a platform, we selected the endoT, based on previous successes in mammalian cells, 
which is an endoglycosidase from the fungus Trichoderma reesei that cleaves high-mannose and 
hybrid-type N-glycans between the two protein-proximal β1,4-linked GlcNAc residues. We fused it to a 
plant Golgi glycosyltransferase targeting signal and introduced it in the Arabidopsis cgl mutant whose 
proteins carry high-mannose glycans only, which are an excellent substrate for the endoT. We show 
that upon seed-specific expression, active endoT is produced that can digest the glycans of both 
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endogenous seed proteins and those of a reporter protein that was also introduced in the cgl seeds 
under control of the same regulary elements used to drive endoT expression. Although the endoT 
content of the seeds was rather low, it was sufficient to entirely process a ten-fold excess of the 
reporter protein ASP1. The yield of the recombinant ASP1, an immunogenic protein from the helminth 
Ostertagia ostertagi, produced in the GlycoDelete seeds, was considerably lower than that of the ASP1 
produced in seeds lacking endoT but the exact cause of this observation requires further in-depth 
studies. It should be noted that the ASP1 expression cassette was introduced independently in the cgl 
mutant and the Glycodelete background (cgl mutant plus endoT). Consequently, the lower expression 
might well be due to a clonal variation. The ASP1 has a high vaccine potential to protect cattle from O. 
ostertagi and because of difficulties in isolating large quantities of ASP1 from Ostertagia itself, there is 
a great interest to produce recombinant ASP1. However, recombinant versions of the ASP1 seem to 
lack some essential structural element, rendering them non-protective. Indications are at hand that 
also the seed-produced ASP1s are structurally divergent from the native ASP1 (neutralizing antibodies 
induced by the native ASP1 do not recognize recombinant ASP1 from wild type seeds). Further 
investigation is needed to elucidate the precise nature of this critical element and to determine if the 
seed-produced ASP1s also lack this element. One way to easily obtain additional information on this 
topic would be to check if the antibodies present in the sera of the rabbits that have been immunized 
with the wild type and the GlycoDelete ASP1 and bind to the peptide backbone of the seed-produced 
ASP1, are also capable of recognizing the native ASP1, e.g. by competitive ELISA. In case that protective 
capacity could be demonstrated for the seed-produced ASP1s, a recombinant vaccine against 
Ostertagia ostertagi based on the seed-produced ASP1s can surely be envisaged, given that the high 
accumulation of the ASP1s in the seed, combined with the optimized purification protocol would much 
facilitate ASP1 production. 
In-depth study of the glycans present on the different seed-produced ASP1s revealed that the glycan 
profiles of the recombinant ASP1s are in complete accordance with the expected profiles: complex, 
immunogenic plant glycans for the wild type ASP1, high-mannose glycans for the cgl ASP1 and 
trimmed glycans consisting of a single GlcNAc on the GlycoDelete ASP1. Rabbits were injected with 
wild type and GlycoDelete ASP1 to investigate the immunogenicity of the glycans present on the 
ASP1s. Indeed, the majority, but not all of the rabbits immunized with wild type ASP1 had generated 
plant glycan specific antibodies that were completely absent in the sera of the GlycoDelete ASP1 
immunized group. These results confirm the immunogenic potential of the plant specific β1,2-xylose 
and core α1,3-fucose so acclaimed in literature and validate the efforts dedicated to ‘humanizing’ 
plant glycans. It also, at least in rabbits, points to genetic predisposition as an important factor in 
determining the outcome of exposure to these potentially immunogenic glycans. Last but not least, it 
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convincingly demonstrates that the GlycoDelete seed-platform can be used for the in planta 
production of therapeutic proteins with a homogeneous glycan profile lacking immunogenic plant 
glycans.  
The GlycoDelete seed platform has several unique advantages. The seed specific expression of the 
endoT (and the target protein) avoids interference with normal plant development and bestows the 
platform with the additional benefits associated with seed production of PMPs, such as accumulation 
of the PMP in a small volume and stable environment and the possibility to store the unprocessed 
seeds for prolonged periods of time, which allows decoupling of PMP production and processing. The 
platform is simple and only requires supertransformation of the GlycoDelete line with a gene of 
interest under control of the same regulatory elements used to drive the endoT gene. The system is 
robust and was shown to completely digest a recombinant protein present in ten-fold excess over the 
endoT, which translates into a minimal processing capacity of 7 mg recombinant protein per gram dry 
seed weight (3.5% of TSP) and possibly much more. The final and perhaps most important advantage is 
that it fully accomplishes the goals that were set during its conception, namely that it produces a 
therapeutic protein bearing short glycans, important to maintain its native conformation, that are 
homogeneous and at the same time also completely lack the immunogenic β1,2-xylose and 
α1,3-fucose. 
The GlycoDelete seed-platform could be used as such for the commercial production of PMPs. The 
small stature of the Arabidopsis host facilitates cultivation in greenhouses were it can be densely 
packed and contained. Methods for the automatic harvesting and sowing of Arabidopsis seeds are 
under investigation and it has been estimated that Arabidopsis grown in a greenhouse facility could 
generate somewhere from 180 to 240 grams of dry seeds per square meter each year (He et al., 2013; 
Loos et al., 2011a). Using its minimal capacity as a conservative estimate, this would correspond to 1.2 
to 1.6 grams of endoT digested PMP produced in the GlycoDelete seed platform per square meter on a 
yearly basis. Alternatively, the GlycoDelete technology could be transferred to another crop, such as 
pea, whose seeds have an even higher protein content that can account for up to 40% of seed weight. 
Work is underway in our lab to establish if expression patterns of synthetic IgAs produced in 
Arabidopsis seeds using the seed-specific expression cassette can be translated to pea (Dr. V. Virdi, 
personal communication). If the expression cassette functions similarly in pea then it would be feasible 
to transfer the GlycoDelete technology as such to pea and although a mutant lacking GnTI activity is 
not available, such a mutant could be created via meganuclease (or similar) technology.  
Another interesting venue would be to check if the endoT could be transiently expressed in, for 
example, Nicotiana benthamiana leaves, as has been tested for the bacterial PNGaseF that was able to 
Conclusions & perspectives 
143 
 
completely deglycosylate co-expressed reporter proteins (Mamedov et al., 2012; Mamedov & Yusibov, 
2013). PNGaseF has a broader substrate specificity than endoT, but it will nevertheless be interesting 
to determine if the endoT can also function as an integral part of a transient expression system. The 
latter represents another potential application of the endoT, especially because of the current 
industrial interest in platforms based on transient production of PMPs. As becomes clear from this 
discussion, there are several valid options available to continue with the application of the GlycoDelete 
technology in planta. 
In conclusion, we have designed and engineered a platform for the seed-specific production of 
therapeutic proteins in planta that carry minimal glycans which are necessary to maintain the overall 
protein fold but that at the same time are homogeneous and completely devoid of the immunogenic 
plant specific structures β1,2-xylose and α1,3-fucose. We demonstrate the full functionality of the 
system and prove that a minimally glycosylated version of a recombinant helminth antigen produced 
in the platform does not provoke an anti-glycan response upon immunization of rabbits whereas its 
recombinant counterpart produced in non-engineered, wild type seeds does, hereby confirming the 
immunogenicity of these plant glycan structure and validating the potential of the GlycoDelete 
seed-platform. The system has several advantages over other glycoengineered solutions to ‘humanize’ 
plant glycans and can be used as such for industrial applications. Alternatively, the GlycoDelete 
technology can be tailored to meet specific needs and there are several options for further application 
of the technology in planta.  
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